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ABSTRACT
The complete primary structure of a thioltransferase isolated from human erythrocytes
was determined using a combination of matrix-assisted laser desorption ionization time-of-
flight mass spectrometry (MALDI-TOF-MS) and fast atom bombardment (FAB) high
performance tandem MS. The amino acid sequence of this human glutaredoxin (hErGrx) was
assembled from tryptic and chymotryptic peptides whose sequences were deduced from
collision-induced-dissociation (CID) mass spectra.
An adhesive protein, mefp-3, isolated from the foot of the marine mussel M edulis,
presented unique challenges to the determination of the amino acid sequence due to its
unusual composition. The complete amino acid sequence of mefp-3 was finally determined
by the application of mass spectrometry to this problem. Specifically, mefp-3 peptides were
digested with carboxypeptidase P and analyzed by MALDI-TOF-MS to obtain the C-terminal
sequences. The combined approach of Edman degradation and MALDI-TOF-MS serves as
an example of the complementarity of mass spectrometry with more traditional sequencing
methods. In addition, mefp-3 contains a basic amino acid which was determined to be 4-
hydroxyarginine by FAB tandem mass spectrometry.
E. coli inosine monophosphate dehydrogenase (IMPDH) inactivated with 5-ethynyl-
1-p-D-ribofuranosylimidazole-4-carboxamide monophosphate (EICARMP) forms a covalent
adduct with Cys-305 as determined by MALDI-TOF-MS. Sequence corrections, identified
and confirmed by MALDI-TOF-MS, showed that the native protein consists of 488 amino
acids, has 5 Cys, and that Arg is at position 206.
A method for specific, partial cleavage of proteins at locations occupied by Cys was
developed. Reaction with cyanide ion and 4-vinylpyridine generates overlapping sequences
from proteins containing disulfide bonds. The addition of 4-vinylpyridine was shown to
drive the reaction by trapping the free sulfhydryl groups formed by cyanide attack of the
disulfide bond.
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Section I
Introduction
I. 1 A Brief History of Mass Spectrometry of Peptides and Proteins
Ionization of a given analyte, whether it be a small organic molecule or a large
protein such as serum albumin, is a prerequisite to mass spectrometric analysis. This basic
property of mass spectrometry, independent of the type of instrument, confined early
protein sequencing efforts to the analysis of small peptides.' Electron ionization mass
spectrometry (EIMS), probably the most common method of ionization in the earlier days
of mass spectrometry, worked extremely well for the analysis of small non-polar and
generally more volatile organic compounds. On the other hand, EIMS of even the smallest
peptides was a challenge because of the polar (and hence, non-volatile) nature of the peptide
structure. One of the first successful strategies for enhancing peptide ionization involved
increasing peptide volatility through chemical derivatization.2 Another innovation was the
use of gas chromatography to separate the derivatized peptides and deliver them into a mass
spectrometer to determine the mass to charge ratio (m/z) of the molecular and fragment
ions.3 ,4 The amino acid sequence of these small peptides could then be deduced by analysis
of the fragments generated.
The discovery and development of new ionization methods played a crucial role in
the maturation of mass spectrometry as a technique for the analysis of proteins and
peptides. With EI, a so-called "hard" ionization method, high energy deposition allowed
the detection of only the most stable molecular ions. New desorption ionization techniques
such as 2 52Cf plasma desorption 5 and field desorption, 6 enjoyed early success due to the
"softer" ionization processes that produced predominantly protonated molecules, (M+H)',
which are very stable even when the molecules are large. In addition, the derivatization
necessary to increase peptide volatility for EIMS was no longer required. While field
desorption is rarely employed today, 252Cf plasma desorption instruments still enjoy routine
use in many biochemistry laboratories to this day largely due to the fact that they were the
first instruments capable of the generation and detection of very high mass molecular ions.
In 1981, a new ion source and ionization method were described by Barber et al.
which allowed for the first time the facile ionization of very polar, thermally labile, and
nonvolatile molecules without any prior derivatization.7 The procedure involved
dissolution of the analyte in a liquid matrix that was then bombarded with energetic (fast)
atoms giving rise to protonated molecular ions with little or no fragmentation. The
discovery of fast atom bombardment (FAB)a ionization ushered in a new era in the mass
aThe terms liquid secondary ionization mass spectrometry (LSIMS) and FAB mass
spectrometry (FABMS) are both found in the literature and may cause some confusion for the
uninitiated reader. The latter term simply refers to the ionization achieved by bombardment with
neutral atoms while ions (usually metal cations) are used in LSIMS. The fast atoms or ions are
accelerated to achieve a translational energy on the order of eV to several keV. Whether analyte
ionization is achieved by neutral atoms or ions, the mechanism of ionization is almost certainly
the same. Furthermore, the mass spectra arising from use of either method are essentially
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spectrometry of peptides and proteins (as well as other biomaterials and involatile
molecules). Large peptides and even small proteins such as insulin were now capable of
being ionized without derivatization and with little or no fragmentation.8 " FAB ionization
also allowed the development of protein sequencing methodology through the use of
collisionally activated dissociation (discussed further in Section 11.2) using different types
of mass spectrometers. The success of FAB as an ionization technique is demonstrated by
its widespread implementation since the early 1980s and the resultant unprecedented
growth in the volume of biological research using mass spectrometry for peptides and
proteins that still continues to this day.
Although FAB is still widely used, the more recent development of two additional
"soft" ionization techniques has revolutionized the field of biological mass spectrometry
even further. Electrospray as an ionization method for mass spectrometry was first
described in 1984 by Fenn and Yamashita. 12 No doubt the most interesting characteristic of
electrospray ionization (ESI) is its ability to generate numerous multiply charged ions. Due
to the complexities involved with interfacing a liquid spray to a high vacuum system, the
first mass spectrometers to be used with ESI were the simpler quadrupole instruments that
have only a limited mass range. 13 ,14 Fortuitously, with ESI the ion signal due to large
species (such as proteins) is divided over multiple (M+nH) n" ions, most of which are
identical. It is thus the practice of this laboratory to refer to both techniques simply as FAB for
simplicity and in deference to the original discoverers.
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observed at m/z values under 2000 (which is within the mass range of quadrupole mass
spectrometers). ESI has also been successfully coupled with high performance magnetic
sector instruments to increase the resolution and mass range. 5"-' However, the design of
ion sources to interface ESI with the high vacuum systems and high accelerating voltages
such as those found in magnetic sector instruments is quite a challenge and consequently,
still in the process of refinement. This is demonstrated by the fact that most of the work
with ESI and magnetic sector instruments to date has dealt with fundamental studies using
known compounds.
The remaining "soft" ionization method, matrix-assisted-laser-desorption-ionization
(MALDI), was somewhat serendipidously discovered by Karas and Hillenkamp in 1987.~9
While experimenting with simple laser desorption, these workers made the crucial
observation that very large molecules could be ionized without fragmentation using
ultraviolet (UV) laser desorption by introducing a small UV absorbing molecule as a
matrix. MALDI differs from ESI in that the MALDI experiment is generally performed
with a crystalline sample preparation (rather than a liquid spray at atmospheric pressure)
which facilitates operation at high vacuum. Furthermore, the best results are obtained with
pulsed lasers, the nature of which is particularly amenable to the use of time-of-flight mass
spectrometers which (in principle) have an unlimited mass range. MALDI is also capable
of generating multiply charged ions but not to the extent that ESI does. Finally and most
importantly, ESI and MALDI have in common an increase of several orders of magnitude
for both detectable mass range and sensitivity as compared to FAB ionization. This large
increase in sensitivity and mass range has rapidly placed MALDI and ESI methods in the
forefront of mass spectrometric research with proteins and peptides.
1.2 Fast Atom Bombardment Mass Spectrometry
Ionization of peptides or proteins by FAB involves dissolution of the analyte in a
non-volatile liquid matrix such as glycerol and bombarding the liquid with a beam of
neutral or charged molecules (see footnote on page 17). 7,20,2 1 Figure 1.1 is a schematic
drawing illustrating the FAB ionization process using a beam of Cs' ions (which have been
determined to increase the sensitivity as compared to bombardment with neutral atoms such
as those from gaseous Xe).22,23 As shown in Figure I. 1, both positively and negatively
charged analyte and matrix ions as well as uncharged neutral molecules are desorbed from
the liquid as a result of the bombardment. The precise mechanism by which an analyte is
ionized by FAB is not thoroughly understood; the liquid matrix apparently absorbs most of
the energy imparted by the fast atoms and only a portion of the introduced energy is
absorbed by the analyte molecules. The result is the production of intact molecular ions
GO
Mass Analyzer
SG
Cs+ ion gun St
Oo O Matrix with analyte
@@co@ @ •
I I
FAB Target Plate
Figure I. 1. Schematic of a FAB ion source illustrating the FAB ionization process. Ion slits
and focussing lenses are not shown for clarity and the drawing is not to scale. The fast
atom (Cs') ion beam is represented by the dark circles. The desorbed secondary ion beam
consists of positive, negative, and matrix ions denoted by "+", "-", and "M", respectively.
Neutrals are also produced and are indicated by "N".
I
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(with the addition or removal of a proton)a with almost no fragmentation. In positive ion
mode FAB, only the positively charged analyte (and matrix) ions are accelerated out of the
ion source and into the mass analyzer. Although matrix ions are detected along with the
peptide ions, they rarely interfere with the peptide analysis since the signals due to the
matrix ions are strongest only at the lower m/z values.
The effect of the liquid matrix has been investigated by a number of laboratories. 24 -27
For peptides, glycerol with the addition of an acid such as acetic acid or trifluoroacetic acid
(TFA) is usually the first choice of matrix because of its high viscosity and low volatility.
Thioglycerol alone or mixed with glycerol also tends to work slightly better with increasing
size and hydrophobic character of the peptide. Although seldom used in this laboratory, a
eutectic mixture of dithiothreitol and dithioerythritol 5:1 (a.k.a. "magic bullet") has also
been shown to increase the ion yield of larger peptides.28 The drawback to using the thiol
matrices is that they are more volatile and thus evaporate from the ion source more readily
which reduces the time available for acquiring a mass spectrum. This can be particularly
problematic with tandem mass spectrometry where the signal to noise (S/N) is routinely
enhanced through the summation of several individual scans. The instrument used for
FABMS as well as protein sequencing using FAB and tandem mass spectrometry is
aBoth positive and negative FABMS, [with detection of (M+H)÷ and (M-H)- ions,
respectively], have been shown to successfully generate peptide molecular ions. However,
positive ion FAB is more sensitive for peptide ions (probably because peptides contain many
sites that are easily protonated) by at least an order of magnitude and consequently, the
overwhelming majority of work in this area has been done using positive ion mode FAB.
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discussed further in Section 11.2.
The best FABMS results are obtained with purified peptides since contaminants,
particularly inorganic salt cations, can severely reduce the ion yield. Metal cations, for
example sodium and potassium, also decrease ion yield in part by distributing the total ion
current among several ions, e.g., (M+H)+, (M+Na)+, and (M+K)+, rather than just the
protonated species. For this reason, peptides destined for FABMS analysis are almost
always purified with reversed phase high performance liquid chromatography (RP-HPLC)
to remove the bulk of the contaminants. HPLC is also useful for the partial fractionation of
peptide mixtures, (e.g., a protein digest), especially for the separation of hydrophilic from
hydrophobic peptides. Since peptides containing hydrophobic groups tend to stay closer to
the surface of the liquid matrix, they are more easily ionized by the FAB ion beam. In some
cases, this may result in the suppression of the ion signal of more hydrophilic peptides. 29 A
partial fractionation of a protein digest followed by FABMS analysis of the resultant
fractions alleviates this problem.
1.3 Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry
The use of laser desorption in mass spectrometry dates back to the early 1960s and
is very similar conceptually to FAB ionization (Figure I. 1) except that the analyte is
bombarded directly (no matrix was used initially) with photons instead of fast atoms from
an ion gun.303 2 Similar to FAB ionization, an advantage of laser desorption lies in its ability
to ionize non-volatile, polar compounds. 33,34 However, the upper limit to the size of
biopolymer molecules that can be ionized directly as intact molecular ions is only about 1
kDa. Analyte ionization with laser desorption occurs by the energy transfer from the laser
photons to the analyte via resonant absorption of the analyte molecule at the laser light
wavelength. However, in the case of larger molecules, for example, proteins, the increase
in degrees of freedom (which provides additional pathways for energy dissipation) requires
higher laser power to achieve enough resonant absorption for ionization. Unfortunately, the
higher laser power also causes photodissociation and sometimes thermal decomposition of
the analyte. A major breakthrough occurred when Hillenkamp and Karas et al. from the
Miinster group decided to mix the analyte with a large amount of a small organic molecule
("matrix") resulting in the technique known today as matrix-assisted-laser-desorption
ionization (MALDI).' 9 The incorporation of a matrix with the analyte was found to permit
laser desorption ionization of very large (> 100 kDa) protonated molecular ions with little
or no fragmentation.35 The first successful MALDI mass spectrum of a protein was
acquired using nicotinic acid as the matrix compound, which was selected on the basis of its
high molar absorptivity at the wavelength (266 nm) of the frequency-quadrupled Nd:YAG
laser.36
To minimize thermal decomposition, the energy transfer from laser to analyte must
be executed as rapidly as possible. For this reason, pulsed lasers with short pulse widths of
10 nsec or less are utilized for MALDI. The pulsed nature of the lasers makes them ideally
suited for use with time-of-flight (TOF) mass spectrometers" which have a very high mass
range.a The optimal matrix to analyte molar ratio has been empirically determined for a
broad range of sample types and is normally somewhere between 100:1 and 50,000:131 (the
observation of this laboratory is that the optimum ratio for the analysis of proteins and
peptides is closer to the latter values). It has been proposed that the presence of the MALDI
matrix serves at least three functions.39,40 The first is to absorb the energy of the laser
photons through resonant absorption. Secondly, the large molar excess of the matrix
evidently isolates the analyte molecules and reduces the strong intermolecular forces
between analyte molecules thereby allowing ionization of individual molecules and
preventing excessive formation of large cluster ions. Finally, the matrix effects ionization
of the analyte molecule through partial transfer of the energy gained by resonant absorption
without causing fragmention or decomposition of the analyte molecular ion. The ionization
of the analyte is believed to proceed through proton transfer from the matrix.
The structures of the MALDI matrices used in the experimental work described in
the following sections are shown in Figure 1.2. These are the most commonly used
aln theory, the mass range of a time-of-flight mass spectrometer is limited only by the
laser pulse frequency. Thus, mass range increases with lower frequency. In practice, this is not
the only limitation. For example, high mass ions sometimes do not have sufficient kinetic
energy to be efficiently detected especially when lower accelerating voltages are employed.38
This particular problem can be alleviated through the use of post-acceleration at the detector.
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matrices, especially for protein and peptide analysis. All successful matrices have in
common a relatively low mass (M, < 250 u) and the ability to resonantly absorb energy at
the wavelength of the laser light. However, not all compounds with these characteristics are
necessarily good matrices. Analyte incorporation into the crystalline matrix has been found
to be essential for successful ionization of the analyte.3 9,4 ' The first step in MALDI sample
preparation is to mix solutions containing analyte and matrix and then apply a small drop
(0.5 - 1 ptL) of the resultant solution to the MALDI target plate (usually polished stainless
steel). As the liquid dries, (prior to insertion into the mass spectrometer), a circular
crystalline film forms. Matrices such as 2,5-dihydroxybenzoic acid (DHB) and 3-
hydroxypicolinic acid (HPA) successfully co-crystallize with the analyte to form long
needle-like crystals about 100-150 pm in length.41 ,42 Although both DHB and HPA both
provide satisfactory sample preparations, the spots are heterogenous due to the crystal size
and the tendency of the matrix/analyte crystals to form closer to the edges of the sample
preparation (i.e., near the rim of the sample spot). This surface heterogeneity can
sometimes make it more difficult to find so-called "hot spots" (positions on the sample
preparation surface from which the sample ions are easily generated). On the other hand,
sinapinic acid (SA)43 and m-cyano-4-hydroxycinnamic acid (ACCA)44 co-crystallize with
the analyte to generate much smaller crystals (about 5-30 pm) and thus provide a much
more homogeneous surface.45 Furthermore, the analyte concentration gradient from center
to edge found with DHB and HPA is not observed when SA and ACCA are used as the
matrix compounds. The more uniform surface allows the acquisition of good quality mass
:CH-COOH
CH30
)H
OCH 3
OH
3,5-Dimethoxy-4-hydroxycinnamic acid
Sinapinic acid (SA)
HO
2,5-Dihydroxybenzoic acid (DHB)
COOH
CH=C-C--N
OH
a -Cyano-4-hydroxycinnamic acid (ACCA)
COOH
/N=N- OH
Q N
HO COOH
2-(4-Hydroxyphenylazo)benzoic acid (HABA) 3-Hydroxypicolinic acid (HPA)
Figure 1.2. Structures of some common MALDI matrix compounds used for the analysis of
proteins and peptides.
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spectra from virtually every position on the sample spot. In addition, more homogeneous
sample preparations also tend to increase the sensitivity thereby requiring less laser power
for analyte ionization which enhances resolution (vide infra). The exploration of different
methods for preparing more homogeneous and thinner films of matrix and analyte mixtures
in an effort to improve sensitivity, resolution, mass accuracy, and reproducibility is
currently a very active area of MALDI research.46-49
Although a number of compounds have been evaluated as matrices for MALDI,S in
practice, only a handful of these are routinely used for the analysis of proteins and peptides.
Different matrix properties such as molar absorptivity, size and type of crystal formation,
solubility, etc., provide for unique matrix behaviors. The results with mixtures such as
peptide digests, can be quite different when using different matrices." In general, it has
been observed that smaller peptides are more easily ionized using either ACCA or DHB
matrices. On the other hand, larger peptides and proteins that are poorly ionized with
ACCA or DHB can often be ionized very easily simply by switching to the SA matrix. In
the experimental work related in the following sections, MALDI-TOF-MS analysis of
proteins and peptides was performed almost exclusively with either the SA or the ACCA
matrix because of the resulting more homogeneous sample surface. Although these
matrices usually provide the best results, occasionally it is still necessary to use another
matrix, (e.g., one of the other three shown in Figure 1.2) to obtain the optimal result.
Another potential problem is the tendency of certain matrices to form adduct ions that can
broaden peaks at high mass where the protonated molecular ion is not resolved from the
adducted species.43' 52 Although the use of SA generally does produce a small adduct ion at
m/z = (M+H+206) ÷ [where M is the molecular weight of the analyte], ACCA has the
advantage of not generating any analyte adduct ions. Some matrices are very sensitive to
the analyte concentration while others may tolerate a much wider range. For example,
while HABA is known to work optimally at analyte concentrations of 1 pmol/JpL or less,
other matrices tend to be less sensitive and can still work quite well at analyte
concentrations above 10 pmol/pLL. Thus, selection of the MALDI matrix is largely
dependent on the type of application and necessitates a familiarity with a variety of different
types (and behaviors) of matrix compounds. Finally, it is highly unlikely that a "super"
matrix will ever be discovered that can provide a superior result for every analyte type.
The energy deposition as a result of the photon bombardment of the MALDI matrix
leads to heating and expansion of the crystal surface generating a plume of particles in the
ion source containing both ionized and neutral matrix and analyte molecules." A jet
expansion model has been proposed to explain this ejection of matrix and analyte
molecules.""4, Higher laser irradiance increases the size and density of the plume, leading
to greater energy dispersion and also raises the potential for collisional activation of the
analyte.54,56 Therefore, maximal resolution and minimal fragmentation is obtained by
maintaining the laser beam at the minimum irradiance required for detection of the analyte
ion.
A schematic diagram of the first MALDI-TOF instrument acquired by this
laboratory (in 1990) is shown in Figure 1.3. This instrument, the VT 2000 (Vestec Corp.,
Houston, TX), was the first commercially available instrument designed exclusively for
MALDI-TOF-MS. Initial experiments with this instrument were carried out using the
nicotinic acid matrix with the frequency-quadrupled Nd:YAG (which has a 9 nsec pulse
width) at 266 nm. However, the introduction of cinnamic acid derivatives by Beavis and
Chait43 and DHB by Karas and co-workers4' were found to work as well or better at the
higher wavelength, 355 nm, achievable with the third harmonic of the Nd:YAG laser.57
This quickly led to the use of the much simpler and less expensive N, laser which emits
light of wavelength 337 nm. Furthermore, the pulse width of the N2 laser is much narrower
(3 nsec) and the shot-to-shot reproducibility superior to that of the Nd:YAG laser which
rendered the latter laser essentially obsolete for this application. Consequently, all of the
MALDI experiments that are described in the following sections were carried out using the
N2 laser.
Referring to Figure 1.3, the N2 laser (generally operated at a repetition rate of 5 Hz
for the analysis of peptides and proteins) emits a photon beam that is guided through a UV
transparent aperture into the instrument and focused onto the sample target in the ion
source. The laser beam is manually attenuated using a variable beam attenuator to achieve
the "threshold" value, (i.e., the minimum laser irradiance required to produce a signal due to
the analyte) which is facilitated by a real-time display of the ion signal throughout the entire
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mass range on the ocilliscope. On the VT 2000, the laser trigger for the N2 laser is the same
one originally used for the Pockels cell for the Q-switch on the Nd:YAG laser. The trigger
signal is simultaneously sent to the laser and to the fast transient digitizing oscilloscope
(LeCroy 9450A) to begin acquisition of data. The ion source of the TOF mass spectrometer
consists of the sample target and a dual set of acceleration plates to enhance field
homogeneity. The ions are accelerated into the field free flight tube (2 m in length) and
allowed to drift toward the detector.a The VT 2000 uses high acceleration voltages
(typically 30 or 35 kV) to obtain good resolution since the initial energy distribution of the
ions in the ion source (a principal source of peak broadening) 54' 56 as a percentage of the
kinetic energy decreases with increasing acceleration voltage. The detection of the
accelerated ions is achieved with a hybrid detector consisting of a single microchannel plate
(MCP) followed by a 20-stage secondary electron multiplier with focusing mesh Cu/Be
dynodes. A potential of -3.4 kV is applied to the first (MCP) detector plate which results in
a gain of approximately 108. This amplified ion signal is then directed to the digitizing
oscilloscope. The analog signal is digitized at 200 MHz (5 nsec time slices) using an 80
MHz bandwidth filter. Typically 30 shots (at 5 Hz) are signal averaged by the digitizer for
each acquired mass spectrum. The digitized information is then downloaded to a PC and
the mass spectra are further processed by software developed in-house on a MicroVAX
system.58
aSince most proteins and peptides are easily protonated, the best sensitivity is usually
achieved with positive ion acceleration.
Since the accelerated ions all have the same initial kinetic energy, different masses
will have different velocities and the mass of a detected ion can thus be related to time with
calibration standards using the following equation:
(m/z) /2 = At + B
(where m/z is the mass to charge ratio, t is the time, and A and B are calibration constants
that are dependent on the acceleration voltage and ion drift length).5 9
The original VT 2000 instrument came equipped with a set of pulsed deflection
plates between the ion source and the detector which were installed for deflection of lower
mass (matrix) ions to prevent saturation of the detector. The deflection plates were later
replaced with a system utilizing a guide wire which was installed in the center of the flight
tube. The guide wire voltage is synchronized with the trigger signal to allow deflection of
the matrix ions. The guide wire is at + 100 V potential at the start of acquisition which
deflects the majority of the low mass ions away from the detector. Shortly after the known
arrival time of the matrix ions at the detector, the guide wire potential is switched to -100 V
where it remains until the next trigger signal is received. Use of the guide wire for
deflection of matrix ions was found to greatly increase the sensitivity of this instrument for
detection of higher mass ions. For the analysis of smaller molecules such as peptides,
(where saturation of the detector is not usually problematic), the voltage on the guide wire
was usually kept constant at - 100 V throughout the mass range.
The VT 2000 is also capable of generating IR MALDI spectra using the Er-YAG
laser (X = 2.94 glm). The use of lR lasers with MALDI was first explored due to the
potential of greatly expanding the range of available matrix compounds. 60 ,61 In contrast to
UV-MALDI where ionization occurs via electronic transitions, IR-MALDI ionization is due
to vibrational transitions. Some of these transitions, e.g., the O-H and N-H stretching
modes can be quite energetic at -3 gtm wavelength. Liquids such as water and glycerol are
thus potential matrices using IR lasers. The drawback to IR lasers is that they tend to be
difficult to use and usually have very long pulse widths (the Er-YAG laser pulse width is
120 nsec). The primary application of IR lasers to date has been in the MALDI analysis of
blotted proteins on membranes such as polyvinylidene difluoride (PVDF).6 2'6 3
Section II
Amino Acid Sequencing by Mass Spectrometry
II.1 Introduction
The most common strategy for sequencing proteins involves specific cleavage of the
unknown protein with an endoproteinase followed by HPLC fractionation of the digest in
order to individually separate the peptides for sequencing by the Edman degradation.
Alignment of the peptides in the proper order necessitates a second digest with an
endoproteinase of a different specificity. The second digest generates peptides which, after
purification and sequencing, provide overlapping sequence information which then allows
the complete primary structure of the protein to be deduced. When sequencing proteins by
mass spectrometry, this general strategy remains the same except that the sequencing is
performed using a different principle of analysis.64 A major advantage of mass
spectrometry is the capability of sequencing individual components of a mixture without
the prior separation into single peptides required for the Edman method. Nevertheless,
protein sequencing by mass spectrometry is most properly viewed not as a replacement of
traditional methods such as Edman sequencing, but rather as a powerful complementary
technique (especially in those cases where the traditional methods have failed).
For a successful digest, the protein to be sequenced is denatured and any disulfide
bond linkages are reduced and the resulting sulfhydryl groups S-alkylated. Typically only a
handful of endoproteinases such as Endo-Lys-C, Endo-Asp-N, and trypsin are used because
of their high degree of specificity. 65 In addition to the enzymatic methods, there are also a
number of chemical cleavage reagents that have also been employed for the purpose of
generating peptides for sequence analysis. A variety of enzymes as well as chemical
reagents for protein cleavage are commonly available and their use has been described in
the literature. 65' 66 In addition, a method for the specific chemical cleavage of proteins at
cysteine with concomitant generation of peptides with overlapping sequences is described
in Section VI.
Section 11.2 FAB Tandem Mass Spectrometry
A schematic diagram of the JEOL HX 11 O/HX 110 high performance tandem mass
spectrometer6 7 used for the FAB tandem mass spectrometry (MS/MS) experiments is shown
in Figure II. 1. Both HX 110 mass spectrometers are identical magnetic sector instruments
of EB configuration that can be operated together or independently. The first sector (E) is
an energy filter that utilizes a radial electric field to reduce the energy dispersion of the ions
generated in the ion source. The energy focused ions leaving the electric sector are then
focused according to their momentum by the magnetic (B) sector. Thus, much higher
resolution is achieved than is possible with a simpler one sector magnetic instrument due to
the double focusing by both energy and momentum. For protein sequencing, the first step
is to determine the molecular weight of peptides generated by the digests. After partial
HPLC fractionation, the peptides are ionized by FAB and the m/z values for the protonated
peptides [(M+H)÷] are determined using the first mass spectrometer (MS-1). For this type
of experiment the electric field of the first E sector is held constant while the magnetic field
of the B sector is scanned in order to successively focus the ions on Detector 1 according to
their m/z values. At the 10 kV maximum acceleration voltage of this instrument, ions up to
m/z 14,500 can be detected. Although the width of the main slit of MS-1 can be narrowed
(at the expense of sensitivity), to achieve very high mass resolution the much lower
resolution of 1:3000 is sufficient for the separation of an isotopic multiplet and allows
selection of the 12C-only species for the majority of the peptides.a Peptide (M+H) ÷ ions
generated by FAB ionization are generally very stable although fragmentation for sequence
information can be increased somewhat by introducing higher peptide concentrations into
the mass spectrometer. However, tandem mass spectrometry (MS/MS) offers a much better
solution.68' 69 One of the major advantages of MS/MS is that it precludes the need for careful
fractionation by HPLC because MS-i is now used as a mass filter (illustrated in Figure 11.2)
to introduce specific ions into the second mass spectrometer (MS-2). Furthermore, the high
aOperation of the magnetic sector instrument under these conditions allows the isotopic
mutiplets of peptides with m/z of at least 3000 to be easily resolved. Thus, the italicized m/z
values in the following text and tables denote monoisotopic mass, i.e., the sum of 12C, 1H, 14N,
160, etc., isotopes only. This distinguishes these measurements from polyisotopic m/z
measurements (for example, the m/z values determined by linear, continuous [non-DE] MALDI-
TOF-MS) indicated in normal type.
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resolution (the mass resolution of MS-1 is doubled when B is kept constant) of MS-1 allows
the selection of only the '2C component of the peptide ion without sacrificing any
sensitivity. For the MS/MS experiment, the ion source of MS-2 is replaced with a collision
cell that is filled with an inert gas with a high ionization potential (such as He) and usually
floated to some potential above ground. The 12C-only molecular ions from MS-1 with
several keV translational energy encounter the He atoms in the collision cell and become
collisionally activated." The molecular ions fragment via collisionally induced dissociation
(CID) and the resultant ions are detected by MS-2. Since the velocities of the precursor
(molecular) ions and fragment ions are the same, the separation can be achieved by simply
scanning the electric sector of MS-2. A well resolved fragment ion spectrum is obtained by
the simultaneous scanning of MS-2 in such a manner that E2 and B2 always have the proper
values for optimal transmission of fragment ions (i.e., a linked scan).68
The type of fragment ions (the structures and nomenclature appear in Appendices I -
III) produced by CID of peptide molecular ions is now well established. 71' 72 The majority of
the fragments arise from cleavage of the peptide backbone. Those ions containing the
amino terminus are designated an, bn, and cn, while x,, Yn, and z, are those ions that contain
the C-terminus.a In addition, some of these ions (also resulting from cleavage of the peptide
backbone) contain neither the N-terminus nor the C-terminus in which case they are termed
aThe subscript "n" refers to the position of the amino acid in the peptide from the N-
terminus and C-terminus for N-terminal and C-terminal ion types, respectively.
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internal fragment ions. Due to the high acceleration voltage capability of the JEOL
HX110/HX1 10 instrument, the peptide fragmentation is usually performed using high
energy CID (so called because the collisions occur at kilovolt energies). The principal
advantage of using high energy CID (as opposed to low energy CID 73) for peptide
sequencing is that the higher energy of the collisionally activated species results in
additional fragmentation of the amino acid side chain; these ion types are termed dn for the
N-terminal containing and v, and wn for the C-terminal containing ions, respectively. For
example, the fragments produced due to the different side chain structures of the isomeric
Leu and Ile now allows these two amino acids to be distinguished. 74' 75 Since the side chain
cleavage occurs between the p-y carbons, residues with p-branched side chains can
generate more than one product. For example, the two possible dn ions from the side chain
cleavage of Ile (at position n) are shown below:
CH 3
H+ CH H +  CH
- 1-0 Rn.. CH
Rn-1 QCH-CH3 RnI I H-(NH-CH-CO)n-1-NH-CHH-(NH-CH-CO)n- 1-NH-CH -
an + 1 dna
CH3
H + CH 3  H+ H2,..- ,.-- • :, H 2
Rn-1  CH-CH2H 3  Rn-. CH
H-(NH-CH -CO)n.I--NH-CH - H-(NH-CH-CO)n.--NH-CH
an + 1 dnb
By convention, the fragment of lower m/z is designated as dna and the higher one dnb. The
C-terminal w, ions are designated similarly. Finally, the presence of these additional ions
in high energy CID mass spectra provides supplementary information and thereby increases
the confidence of the sequence assignment.
Both low and high energy CID mass spectra contain immonium ions (Appendix I)
which serve to confirm the presence (or absence) of individual amino acids. With high
energy CID, the additional fragmention of the side chains leads to high mass ions
(Appendix IV) whose mass differences from the precursor ion are specific for individual
amino acids. These ions are labeled as "-X" in the high energy CID mass spectra in the
following sections and indicate loss of the side chain of amino acid X.
For any given peptide, not all of the possible fragment ions types are generated.
However, this is not a problem and in fact aids in the interpretation of the spectrum since
the fragmentation mechanisms are known to arise mainly from charge-remote processes.
Thus, the presence and location of basic amino acids, which are easily protonated and thus
positively charged, strongly affects the type of fragmentation that is observed. For
example, N-terminal basic sites lead to the formation of the N-terminal ion types while the
C-terminal ion types occur when the basic site is localized on the C-terminal portion of the
fragment. Fragmentation can also be influenced by other (non-basic) amino acids. For
example, the side chain specific formation of "d" ions, (an N-terminal ion type with the
charge therefore localized on the N-terminal portion of the fragment), tends to be most
prominent when the side chain of the amino acid is not aromatic and contains at least two
carbons." Similarly, proline has been observed to form abundant Yn and yn-2 ions7' and
residues preceding threonine tend to form more abundant c, ions.76 The understanding of
the observed fragmentation in relation to a specific peptide sequence is continually being
refined. For example, the two species an - 46 and z, - 46 have recently been discovered to
occur (due to loss of -CH 3S') when Met is at position n - 1 relative to the N-terminus and C-
terminus, respectively.7 7
II.3 Reflectron and Post-Source-Decay Mass Spectrometry
The existence of an initial kinetic energy distribution for the ions produced in the
MALDI ion source thereby contributing to peak broadening and poorer resolution5 4 ,56 has
already been mentioned in Section 1.3. Although increasing the acceleration voltage
reduces this effect, the resultant higher electric fields in the ion source can also lead to more
prompt fragmentation (i.e., in the ion source) of the molecular ions. A much better
alternative is to construct a secondary acceleration field after the drift region to arrest the
ions and re-accelerate (reflect) them back toward the ion source. This reflection corrects for
the time dependent dispersion caused by the initial kinetic energy distribution. Figure 11.3
is a schematic diagram of the Voyager Elite MALDI-TOF reflectron mass spectrometer
(PerSeptive Biosystems, Framingham, MA). This instrument can be operated both in the
linear and reflector mode and thus has two (circular) MCP detectors. The ions generated in
the ion source reach both detectors by passing through an orifice in the center of the
reflector detector. In the reflector mode, the ions are prevented from reaching the linear
detector by the electrostatic mirror (reflector) which reverses the peak broadening due to the
initial kinetic energy distribution. The result is an improvement in resolution by at least an
order of magnitude which allows isotopic species to be easily resolved for peptides up to
about 3 kDa. A drawback of using the instrument in the reflectron mode is the decrease in
sensitivity in comparison to an identical experiment performed in linear mode. This is due
to the fact that both the intact molecular ions as well as any resultant fragment ions
contribute to the ion signal in the linear mode since both species have essentially the same
flight time.a Conversely, only intact molecular ions retain sufficient kinetic energy to be
well focused onto the reflector detector in reflector mode. Fragment (metastable) ion
species that formerly contributed to the signal in the linear mode no longer have the same
flight time as the molecular ion and are not well resolved. This feature of reflectron mass
spectra is exploited in post-source-decay (PSD) mass spectrometry (vide infra).
The decrease in the signal to noise ratio (S/N) observed in reflector mass spectra has
aThe dissociation of molecular ions in the drift tube region is another source of peak
broadening and contributes to the lower resolution in linear mass spectra.
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led to a reexamination of the factors leading to lower resolution in linear mode and some
solutions. MALDI ions have been successfully cooled by storage in an ion trap prior to
extraction into a TOF mass spectrometer.78 More recently, several groups have explored the
application of a pulsed extraction field in the MALDI ion source in an effort to reduce the
initial kinetic energy distribution.79-81 Assuming that production of gas-phase ions occurs
instantaneously in MALDI and that the primary source of poor resolution is due to energy
dispersion in the ion source, the initial kinetic energy distribution of the ions can be
decreased by applying the extraction field after ionization has occurred (delayed extraction).
The Voyager instrument has recently been modified to allow the acquisition of mass spectra
by delayed extraction.82 The exact time delay is empirically determined and is normally
between 50-500 nsec. This modification now allows routine MALDI analysis of a peptide
such as angiotensin I (M, 1295.7) with mass resolution of at least 1:3000 in the linear mode.
Furthermore, sensitivity remains excellent and peptide isotope peaks can easily be resolved
using delayed extraction in the linear mode.82
In early 1991, Spengler et al. identified fragment ions in reflector mass spectra of
peptides and proteins due to metastable decay of molecular ions and suggested that these
fragment ions could provide structural information.8 3 Further work by the same laboratory
demonstrated that it was indeed possible to obtain sequence information from peptides by
PSD using a reflectron mass spectrometer.8 4,85 The Voyager data acquisition software is
equipped with an option for instrument control in the PSD mode. The concept behind PSD
mass spectrum acquisition is illustrated in Figure 11.4. In this hypothetical case, a precursor
peptide ion having (M+H) ÷ of m/z 1000 undergoes dissociation to form two fragment ions,
A+ and B':
B÷  <---------- (M+H) ---------- > A+
m/z 300 m/z 700
All three ions have different kinetic energies and will therefore penetrate the electrostatic
mirror to different depths. At a mirror ratio (Vref / Vacc) of 1.00, maximal penetration (and
therefore maximal resolution in time) is achieved only for the precursor ion. Although both
A' and B÷ are detected at this mirror ratio, the reflector penetration of these ions is very
shallow and results in broad or unfocused peaks. Focusing of the fragment ions is
accomplished by reducing the reflector voltage to increase the flight time (and hence the
penetration depth) of a fragment ion such that it follows the trajectory of the precursor ion
(i.e., it has the same flight time and penetration depth) at mirror ratio 1.00. By stepwise
reduction of the reflector voltage, metastable fragment ions of differing energy can
successively be brought into focus. Thus, in this example, fragments A+ [m/z 700] and B÷
[m/z 300] are optimally focused when the PSD mirror ratios are adjusted to 0.70 and 0.30,
respectively. The individual PSD mass spectra are concatenated into a composite mass
spectrum using the same software. The m/z scale of the PSD spectrum of an unknown is
calibrated using the fragment ions in the PSD mass spectra of authentic peptides of known
I I I I I I I I I I
Ions from
Ion Source
I I I I I I I I I I
Mirror Ratio = 1.00
Ions from
Ion Source
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Mirror Ratio = 0.70
I I+ I
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Ion Source ... . .
n+c
1-111111111
Mirror Ratio = 0.30
Figure 11.4. Principle of MALDI-PSD mass spectrum acquisition. The shape of the
reflected ion trajectories is conical. The circular reflector detector (cutaway view shown)
has an opening in the center to allow ions to pass through into the electrostatic reflector
region. Only molecular ions, (M+H)÷, are correctly focused (solid lines) when the mirror
ratio equals 1.00. Fragment ions A' and B' are brought into focus (solid lines) by
successive lowering of the mirror ratio. In this example the m/z of (M+H)÷, A', and B' is
1000, 700, and 300, respectively.
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fragmentation according to the following equation:
m/zfragment = m/Zprecursor ( (tfragment / tprecursor- C) / (1 -C1)) ((MR- C3) (1- MR)C4 )
(where MR is the mirror ratio, t is the flight time, and Ci, C3, and C4 are the calibration
constants). The calibration constants are calculated with the aid of another computer
program. An example of a calibrated composite PSD mass spectrum is shown in Figure
11.5. The molecular ion (M+H) ÷ = m/z 1296.7 is due to human angiotensin I which has the
amino acid sequence DRVYIHPFHL. MALDI-PSD mass spectra are very similar to the
CID mass spectra acquired using tandem mass spectrometers (Section 11.2) and a
comparison has already been reported.8 6 The nomenclature in Figure 11.5 is the same used
for identification of fragments derived from CID mass spectra.87 The structures of these
fragment ions are shown in Appendix I. MALDI-PSD mass spectra generally contain ak, bn,
and Yn type as well as immonium and internal fragment ions. Some additional ions
(Appendix II) encountered in MALDI-PSD mass spectra include the an -17, bn - 17, bn +
H20, and [internal fragment - 28] ions.
The PSD spectra are similar in many respects to the MS/MS spectra obtained from
CID experiments.86 Furthermore, the use of MALDI-PSD for protein sequencing is very
attractive since very little sample is required (the complete mass spectrum in Figure 11.5
was acquired from only one pmol of the peptide) and mixtures such as the protein digests
do not present a problem due to the introduction of timed deflection gates that allow
individual selection of molecular ions as long as they differ in mass by at least + 0.2 %.
The Voyager instrument is equipped with a timed ion selector (Figure 11.3) that consists of a
pair of deflection plates near the entrance of the reflector region. The timed ion selector
deflects all but the desired molecular ions-- since this deflection occurs prior to ion
reflection, some of these ions are also metastable fragments-- allowing MALDI-PSD to be
performed even with mixtures (such as peptide digests). Although it is possible in principle
to determine the complete sequence of an unknown peptide by analysis of the fragments
that result from PSD, the strength of this technique (at the present time) lies in providing
confirmatory rather than complete sequence information. While the molecular ions of some
peptides fragment easily producing many ions, others exhibit fewer cleavages and some
molecular ions appear to not fragment at all. Due to its infancy as a method for protein
sequencing, PSD is still in the process of refinement.
Ion detection on the Voyager instrument is accomplished by dual microchannel
plates. Similar to the VT 2000, the Voyager also has a guide wire to enhance sensitivity. In
addition, saturation of the detectors by matrix ions is prevented by a low mass gate which
consists simply of a time delay before application of the detector voltage. On the Voyager
instrument, the ion source acceleration voltage is generally between 20 and 25 kV. The
analog detector signal is digitized with a 300 MHZ Tektronics scope in the same manner as
with the VT 2000 instrument except that data processing is performed using the PerSeptive
Biosystems GRAMS software. Between 64 and 256 scans are summed for each mass
spectrum.
11.4 MALDI-TOF-MS and "Ladder" Sequencing
Conventional SDS-PAGE for obtaining protein molecular weight information is a
crude technique compared to MALDI-TOF-MS and is sometimes an unreliable indicator of
Mr. A principle advantage of MALDI-TOF-MS is its ability to provide accurate molecular
weight information of very high molecular weight species (such as proteins) with very low
sample consumption (typically 1 pmol or less). In the course of protein structure
determination, the extremely accurate Mr information (ascertained by measurement of the
m/z value for the protonated molecular ion, [(M+H)÷]) provided by MALDI-TOF-MS is
very useful by confirming or ruling out certain sequences. Protein sequencing by MALDI-
TOF-MS is similar to the other methods (e.g., Edman degradation, FAB MS/MS) in that
cleavage of the protein to generate peptides for individual sequence analysis is still
required. Unlike FAB, the relative insensitivity of MALDI to buffers and salts allows
aliquots from proteolytic digest solutions to be analyzed directly without any prior
purification. Thus, MALDI-TOF-MS provides a method for rapid and accurate molecular
weight determination of peptides derived from protein digests. As with the protein Mr
determination, MALDI analysis of several digests using enzymes of different specificity
can either confirm or rule out specific sequences.
Following protein cleavage, the resultant peptides can be sequenced by MALDI-
TOF-MS in several ways. Although it has been known for some time that molecular ions
generated by MALDI are prone to fragmentation while in the field free drift regions of a
TOF mass spectrometer, it is only very recently8 4,8 5 that experiments have been designed
and carried out expressly to exploit this aspect of MALDI-TOF-MS. This type of MALDI
reflectron experiment, (PSD), has already been discussed (Section 11.3). Another promising
development is the application of CID to MALDI-TOF-MS of peptides and it has been
demonstrated that some of the resultant fragments are the d, and wn types which occur only
in high energy CID experiments."8 These types of fragments facilitate interpretation of the
mass spectrum by providing additional information and also allow the isomeric Ile and Leu
residues to be distinguished.74
MALDI-PSD on most reflectron instrumentsa requires the acquisition of individual
reflectron spectra obtained using different mirror ratio voltages which are then concatenated
into a single composite mass spectrum. On the other hand, MALDI-TOF experiments
performed in the linear mode are much faster, simpler and provide increased sensitivity (for
the molecular ions) since the molecular and resultant fragment ions are detected
aAcquisition of MALDI-PSD mass spectra of peptide standards has been demonstrated on
a TOF instrument utilizing a coaxial curved field reflectron which obviates the need to scan the
reflectron or step the voltage.8 9
simultaneously. For these reasons, it would be desirable to have a method for protein
sequencing using a simpler linear TOF instrument. Exopeptidase digestion,
(carboxypeptidase Y90,91), has been used to obtain the C-terminal sequence of peptides by
analysis of the resulting systematically degraded peptides by FABMS. 92 More recently,
carboxypeptidases Y and B (CpY and CpB93, respectively) were used together with linear
MALDI-TOF-MS to obtain C-terminal sequence information of a peptide from synthetic
human parathyroid hormone.94 The much lower sample consumption of MALDI-TOF-MS
compared to FABMS makes the former the method of choice for these types of
experiments. For example, the MALDI-TOF mass spectrum of 1 pmol of human renin
substrate, a tetradecapeptide with sequence DRVYIHPFHLLVYS, is shown in Figure 11.6
after incubation with CpY for 15 min. The six peaks below the molecular ion of renin
substrate, [(M+H) ÷ = m/z 1760.0] correspond to losses in mass consistent with the
sequential removal of S, Y, V, L, L, and H, respectively. The mass accuracy of MALDI-
TOF-MS, (± 0.0 1% with an internal standard59), is sufficient to unambiguously distinguish
residues whose masses differ by 1 Da (e.g., Asp and Asn; see Appendix IV). An additional
advantage of using carboxypeptidases is that the resulting C-terminal sequence information
is complementary to the N-terminal sequence data provided by traditional Edman
degradation.
A number of exopeptidases have been isolated and characterized but only a few of
these are commercially available. 95'96 Among the carboxypeptidases, CpA93, CpB, CpY and
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CpP9 7 are easily obtainable, however, only CpY and CpP are non-specific in that they are
capable of catalyzing the hydrolysis of all of the commonly known amino acids. With
CpY, optimal peptide cleavage occurs near neutral pH while CpP digests are generally
carried out at lower pH values (pH 4-6). Both CpY and CpP release hydrophobic amino
acids rapidly and charged residues somewhat less rapidly while Gly, especially in the
penultimate position, slows the release of the terminal amino acid. Although Pro is cleaved
by both CpP and CpY, the reaction rate is very slow. It is the experience of this author that
although CpY and CpP behave similarly, CpP exhibits higher enzymatic activity. In
addition, peptides can also be cleaved sequentially from the N-terminus using
aminopeptidases. Aminopeptidase M (AmM) isolated from hog kidney is commercially
available and like CpY and CpP is also non-specific. 98'99 The complete sequence of a
peptide can thus be determined by separate carboxypeptidase and aminopeptidase
experiments using MALDI-TOF-MS to analyze digest aliquots removed at timed intervals.
In the ideal case, exopeptidases sequentially cleave each amino acid and the
resultant degraded peptides are detected by MALDI-TOF-MS which then allows deduction
of the sequence. Unfortunately, different amino acids are released at different rates which
can lead to gaps in the sequence. In addition, the reaction often appears to stop at certain
residues (especially Pro) without yielding any further information. The hydrolysis rate of
the terminal amino acid is also affected by neighboring residues and especially by the
penultimate one. Although chemical reagents for the C-terminal sequential degradation of
peptides exist, (e.g., thiocyanate ion to form C-terminal thiohydantoins' 00-102 ), these
chemical degradation methods suffer from their own unique problems.
Undoubtably the most successful sequential cleavage method is the one used for
Edman degradation sequencing where phenylisothiocyanate (PITC) reacts with the peptide
N-terminus to form (after addition of TFA) the phenylthiohydantoin (PTH) derivative. A
"ladder" sequencing technique'0 3, based on the Edman degradation reaction, has been
developed in conjunction with MALDI-TOF-MS analysis using PITC with a small amount
(5 %) of phenylisocyanate (PIC). The latter functions as a terminating agent by generating
peptides having phenylcarbamyl (PC) N-termini (these are stable in TFA and do not lead to
cleavage of the next peptide bond). Each Edman cycle is performed in the same reaction
vessel, the contents of which, are then analyzed by MALDI-TOF-MS. Sequence
interpretation is straightforward since the resulting "ladder" mass spectrum (in this case for
six cycles) is conceptually similar to the one shown in Figure 11.6. A drawback of this
method is that with each successive cycle, PIC consumes a portion of the starting peptide
which ultimately limits the number of cycles. This problem has been overcome by a
technique (also based on the Edman degradation reaction) developed recently by Pappin et
al. utilizing trifluoroethylisothiocyanate (TFETC) rather than PITC to form the
thiohydantoin derivative (TFETH).10 4 The use of volatile reagents eliminates the need for
HPLC since the reagents (TFETH and TFA [or HFBA]) can be removed by evaporation.
Instead of the terminating reagent, a fresh aliquot of starting peptide is introduced at the
beginning of each Edman cycle. Like the PITC/PIC reaction, all of the cycles are
performed in the same reaction vessel. After completion of the final cycle, the "ladder"
mass spectrum of the vessel contents is generated by MALDI-TOF-MS.
The modified Edman degradation methods described above are too tedious to
perform manually and are well suited to automation. On the other hand, exopeptidase
digestion of peptides coupled with MALDI-TOF-MS can, in principle, be carried out very
rapidly and with much less effort. As already noted, the major disadvantage to
exopeptidase digestion is due to the variability of amino acid cleavage rates. This problem
has been addressed quite recently by attachment of quasi-terminating groups to the C-
terminus of peptide standards in the course of carboxypeptidase digestion.'0 5 By
introducing high concentrations of lysinamide to CpY digests, the former functions as a
nucleophilic reagent that competes with H20 in the hydrolysis reaction. Since the
hydrolysis rate of the amino acid amide is very slow, a "ladder" MALDI mass spectrum can
be generated that contains a set of ions due to sequentially degraded, lysinamide terminated
peptides.
II.5 Summary of Applications Discussed in Sections III - VI.
This section has provided an overview of the different methods used for the mass
spectrometric analysis of proteins and peptides presented in the following sections. The
complete primary structure of a protein (glutaredoxin isolated from human erythrocytes)
solely determined using FAB ionization and high performance tandem mass spectrometry is
described in Section III. FAB tandem mass spectrometry was also used to deduce the
structure of a novel amino acid (Section IV) isolated from a mussel protein. The amino
acid sequence of the latter, isolated from M. edulis, was finally determined (after
incomplete results by Edman degradation) using MALDI-TOF-MS in combination with
exopeptidase digestion (Section IV). The active site of the E. coli inosine monophosphate
dehydrogenase enzyme has been determined and the amino acid sequence of the protein
was corrected using MALDI-TOF-MS (Section V). Finally, the reaction of cyanide with
disulfide bond containing proteins was optimized using MALDI-TOF-MS analysis of the
reaction mixtures (Section VI).
Section III
Determination by Mass Spectrometry of the Primary Structure
of the Glutaredoxin Isolated from Human Erythrocytes
III.1 Introduction
Glutaredoxins (Grx), also known as thioltransferases,' 06 are essential for the
glutathione (GSH) dependent synthesis of deoxyribonucleotides.'0 7o,0 8 Ribonucleoside
diphosphates are known to be reduced to deoxyribonucleoside diphosphates via an electron
transport chain with NAPDH, FAD, thioredoxin (Trx) and Trx reductase.' 09 However, an
alternate electron transport system involving Grx and Grx reductase was discovered
following the observation that mutant E. coli not expressing Trx was still capable of
producing deoxyribonucleotides. 1°0-l 2 The Grx and Trx electron transport systems are very
similar although the former system differs from the latter in having glutathione as a
prosthetic group in Grx reductase. Glutaredoxins are distinguished from thioredoxins in
their ability to be reduced by GSH. Although not homologous, the similar function of Trxs
and Grxs has been supported by X-ray data which show these two proteins to have similar
conformations."0 Thioredoxins and glutaredoxins are also thought to play a role in cellular
sulfhydryl homeostasis.' 06,108 1 13 A Grx has been isolated from human red blood cells or
erythrocytes (hErGrx) that has been shown to play a role in the maintenance of reduced
sulfhydryl groups in these cells. 114
Circulating red blood cells respond in a number of ways to oxidative stresses. For
example, the conformation of hemoglobin (Hb) can change and affect 02 and heme binding
due to the presence of a reactive sulfhydryl group on each p-subunit of the protein. 115,116
Similarly, energy production in erythrocytes is affected by inactivation of
phosphofructokinase due to oxidation of the sulfhydryl groups.1 7 The hErGrx protein was
identified as a thioltransferase due to its ability to catalyze the GSH-dependent reduction of
Hb-S-S-glutathione mixed disulfides and reactivate oxidized phosphofructokinase in
vitro.' 14.118 In addition, the same protein was found to catalyze the regeneration of red blood
cell membrane sulfhydryl groups modified by oxidation.119 In this section, the application
of FAB in conjunction with high performance tandem mass spectrometry (as well as
MALDI-TOF-MS) for the complete primary structure determination of this thioltransferase
is discussed.
All mammalian Grxs of known primary structure 12 0 -122 exhibit very close homology
and possess an acetylated amino terminus. Because of this close homology, the primary
structure of hErGrx is of interest in evolutionary studies. The hErGrx also contains a
blocked amino terminus 14 and is thus an excellent candidate for sequencing by mass
spectrometry since, unlike amino acid sequencing by Edman degradation, blocked amino
termini do not present any special problems in mass spectrometric protein sequencing. 123
The identity of this thioltransferase as a human Grx was confirmed by the high degree of
sequence homology to the mammalian Grxs, however, the human homologue is
distinguished by unique amino acid differences.
111.2 Experimental Procedures
For both the FABMS and MALDI-TOF-MS experiments, the isolated hErGrx was
first S-alkylated. S-ethylpyridylated hErGrx was prepared by dissolving approximately 60
tg (5 nmol) of lyophilized protein in denaturing buffer (8 M urea, 100 mM Tris-HC1, pH
8.4) for 30 min at 37 'C. Reduction and S-ethylpyridylation were performed concurrently
by simultaneous addition of 10 ýiL of each reagent solution (1% (v/v) solutions in n-
propanol of triethylphosphine and 4-vinylpyridine, respectively) followed by purging with
argon and incubation of the reaction mixture at 37 'C for 2.5 h.' 24 S-carbamidomethylated
glutaredoxin was prepared by dissolving about 240 [tg (20 nmol) of the protein in a
denaturing buffer (6 M guanidine-HCl, 100 mM Tris-HC1, 1 mM EDTA, pH 8.4). After 1 h
at 37 oC, 17 gL of a 0.04 tg/jtL aqueous solution of DTT were added, the solution purged
with argon, and incubated at 37 "C for an additional hour. Thirteen microliters of a 0.17
jtg/!iL aqueous solution of iodoacetamide were then added, the solution again purged with
argon, and incubated for 1 h at 37 "C. The resulting S-alkylated protein was purified using
reversed phase HPLC (RP-HPLC).
Peptides for FABMS analysis were prepared by proteolytic digestion of the S-
alkylated Grx. S-carbamidomethylated Grx was digested with trypsin (100:1
substrate:enzyme) in digestion buffer of 2 M urea, 100 mM Tris-HCI (pH 8.4) for 12 h at 37
'C. The digest was partially fractionated by RP-HPLC. Two of the S-
carbamidomethylated fractions (containing larger peptides (M+H)÷ = m/z 2404 and 3291,
respectively) were further digested with Endo-Asp-N in 100 mM ammonium acetate (pH
7.8) for 6 h followed by HPLC fractionation. S-ethylpyridylated Grx (from 5 nmol of
protein) was digested with Endo-Lys-C (200:1 substrate:enzyme) in digestion buffer (2 M
urea, 100 mM Tris-HC1, pH 9.0) at 25 'C for 22 h. S-ethylpyridylated Grx prepared from
10 nmol of protein was digested with trypsin using the same conditions as described for the
S-carbamidomethylated analogue. Finally, S-ethylpyridylated Grx (from about 20 nmol of
protein) was digested with a-chymotrypsin using the same conditions as for trypsin. In all
cases, partial fractionation was accomplished by RP-HPLC.
Peptides (i.e., protein digests) for MALDI-TOF-MS were prepared from 1 nmol or
less of the S-alkylated Grx. The S-ethylpyridylated Grx was digested with Endo-Glu-C
(100:1 substrate:enzyme) in 2 M urea, 100 mM ammonium acetate (pH 4.0) for 12 h at 37
'C. However, Endo-Glu-C was observed to be less specific than the Endo-Lys-C, tryptic,
and Endo-Asp-N digests. The S-ethylpyridylated Grx was also digested with Endo-Asp-N
in 2 M urea, 100 mM ammonium acetate (pH 7.8) for 12 h at 37 'C. Aliquots from the
reaction solutions were diluted with MALDI matrix solution and analyzed (no HPLC
fractionation) directly by MALDI-TOF-MS. The Endo-Lys-C digest described in the
previous paragraph was analyzed similarly.
The molecular weight of the proteolytic peptides was determined by MS-i of the
tandem high resolution mass spectrometer (JEOL HXl10/HX110). Single scans were
acquired at a scan speed of 2.2 min to scan the range from m/z 100 to 6000. The main
(source) slit of MS-1 was adjusted to provide approximately 1:3000 resolution. At this
resolution, the isotope multiplets resolved at least up to m/z 3000. Thus, the m/z values
correspond to the monoisotopic values. The ions were accelerated using 10 kV accelerating
voltage and the cesium gun operated at 20-25 kV. For tandem mass spectrometry, MS-1
was used to mass select individual peptides as their 12C-only protonated molecules, (M+H)'.
Fragmentation of the molecular ions occurred via CID with He in the field-free region
between MS-1 and MS-2. The resulting fragments were mass analyzed by MS-2 using
linked scans (0.8 min from m/z 50 to 2000). The collision cell was floated at 3 kV above
ground. The resolution of both instruments was set to 1:1000 (i.e., the static resolution of
MS-1 was 1:2000 and dynamic resolution of MS-2 was 1:1000). Since all CID fragments
are derived from the 12C-only precursor ion they also are monoisotopic. Both MS-1 and
CID profile scans (using 300 Hz and 100 Hz filtering, respectively) were collected using the
JEOL DA5000 data system. A more detailed description of FAB ionization and the JEOL
tandem mass spectrometer can be found in Sections 1.2 and 11.2, respectively.
Matrix solutions of either SA or ACCA were prepared in mixtures of ACN and H2O.
The ACCA matrix solution was approximately 10 g/L in 50 % ACN while SA was prepared
as a saturated solution in 30 % ACN. Sample preparation for MALDI-TOF-MS involved
dilution of the intact Grx or Grx digest with one of the matrix solutions to give a final
concentration between 1-10 pmol/ýiL. About 1 IiL of the analyte/matrix solution was
applied to the probe target and allowed to evaporate. MALDI-TOF mass spectra were
acquired using the modified Vestec VT 2000 instrument (Section 1.3). A Laser Science N2
laser (LSI, Inc. Cambridge, MA) was operated at a repetition rate of 5 Hz. Laser irradiation
of the sample produced protonated (mostly singly and doubly charged) ions which were
analyzed by the TOF mass spectrometer using 30 kV accelerating voltage. The isotope
multiplets were not resolved (the resolution is generally between 1:100 and 1:300) and the
resulting m/z values are thus derived from the polyisotopic envelope at full-width of the
peak at half-height.
RP-HPLC was carried out using Waters model 510 HPLC pumps, a 680 gradient
controller, a Rheodyne 7125 injector, and a Waters model 490 UV multiwavelength
detector monitoring at 214 nm. For fractionation of digests, a Vydac C4 column (25 cm x
4.6 mm I.D.) was used at a flow rate of 0.5 mL/min with a linear gradient of 100 %
H20/TFA (1:0.0005) to 40 % H20/TFA (1:0.0005) and 60 % ACN/TFA (1:0.00035) over
60 min. For purification after reduction and alkylation of Grx, a short Vydac C4 guard
column (2 cm x 4.6 mm I.D.) was used at a flow rate of 2 mL/min initially at 100 %
H20/TFA (1:0.0005) changing directly to 80 % ACN/TFA (1:0.00035) after the solvent
front had passed the detector.
In order to resolve the ambiguity between Gln or Lys in the final position of the C-
terminal peptide, the digest fraction containing this peptide was dried and redissolved in 40
pL glacial acetic acid and 10 gtL acetic anhydride and kept at 37 'C for 1 h. The solvent
was then removed and the peptide analyzed by FABMS.
All water used in these experiments was filtered and deionized using a Milli-QTM
system. ACN and solvents other than water were chromatographic grade and were obtained
from either Fisher or Baker. A Fisher Accumet model 15 pH meter and standard Ag/AgCl
reference combination glass electrode were used to measure the pH of mL quantities, e.g.,
buffer solutions. Otherwise "colorpHast" (EM Science) indicator strips were used to check
pH. Urea, guanidine-HC1, glycerol, and thioglycerol were purchased from Fluka, Trizma
base and EDTA from Sigma, enzymes from Boehringer Mannheim, a solution of 100 mM
ammonium acetate (pH 7.8) from Pierce, acetic anhydride from Mallinckrodt, glacial acetic
acid and concentrated HCI from Fisher, triethylphosphine, 4-vinylpyridine, iodoacetamide,
and all MALDI matrix compounds from Aldrich. The solvent from collected HPLC
fractions was removed using a Savant speed-vac concentrator.
III.3 Results and Discussion
The primary structure of hErGrx was determined solely by tandem mass
spectrometry following a strategy used previously in this laboratory to determine the amino
acid sequence of rabbit bone marrow Grx. 1'22 In addition, this work with hErGrx also
provided an opportunity to demonstrate the utility of MALDI-TOF-MS in protein
sequencing. The Grx protein, (11.3 kDa by SDS-PAGE), was isolated and purified from
human erythrocytes at Case Western Reserve University." 4 A more accurate molecular
weight determination of the native protein was performed using MALDI-TOF-MS which
typically requires only about 1 pmol of material.a Sinapinic acid (SA) was chosen as the
matrix for these MALDI-TOF experiments because it provided the best signal intensity and
resolution for the Grx protein at the 337 nm wavelength generated by the N2 laser. The
resultant protonated molecular ions, (M+H) + and (M+nH)n" , were mass analyzed by the
TOF mass spectrometer. The MALDI-TOF mass spectrum of the isolated hErGrx (shown
in Figure III.1A) exhibited singly and doubly charged protonated ions, [(M+H) ÷ and
(M+2H)2+, respectively], of the protein molecule. The structure of these peaks (in contrast
to the sharper and better resolved peaks of the horse heart myoglobin used as an internal
standard), implied that the material was not homogeneous and that the major component
aWhile FABMS can also be used to determine the molecular weight of proteins, (for
example, the M, of a similar protein, Trx (M, 11,750) isolated from Chromatium vinosum was
determined by FABMS' 25), it is a difficult experiment to perform and sample consumption
(typically several nmol) is very high due to the decrease in sensitivity with increasing mass.
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Figure III.1. MALDI-TOF mass spectra of hErGrx. A. Material isolated and purified from
RBC. B. Reduced with triethylphosphine. C. Reduced and S-ethylpyridylated. The ions
labeled "Std (M+H) ÷" and "Std (M+2H) ÷"" at m/z 16,952.5 and m/z 8476.8, respectively, are
due to the internal standard (horse heart myoglobin). The matrix was sinapinic acid and the
low intensity peaks adjacent to the major peaks are adducts of the matrix.
had a M, of 11,841. Reduction of Grx with either triethylphosphine or DTT resulted in a
decrease in the mass of the protein to 11,688 Da. The mass spectrum (shown in Figure
III.1B) exhibits a somewhat broadened peak because the reduced glutaredoxin ionizes
poorly (i.e., requires higher laser power). On the other hand, the mass spectrum of the S-
ethylpyridylated Grx (shown in Figure III.1C) produces a single sharp peak for the (M+H) +
ion at m/z 12,215. The amino acid analysis performed prior to the primary structure
determination predicted that the hErGrx protein, (consistent with the close homology of the
other mammalian Grx proteins to each other20 -122), contained only four cysteines.14
However, based on the Mr of the reduced Grx (11,688), the increase in mass for the S-
ethylpyridylated protein (525 Da) corresponded to the value calculated for alkylation by
five ethylpyridyl groups (5 x 105 = 525). Thus, the hErGrx contains five cysteine groups.
This conclusion was confirmed by reducing and alkylating hErGrx (with DTT and
iodoacetamide, respectively) to give the S-carbamidomethylated product which generated a
(M+H)÷ ion at m/z 11,974 by MALDI-TOF-MS. Once again, the increase in mass (285
Da) of the S-carbamidomethylated compared to the reduced protein agreed very well with
the calculated value for alkylation by five carbamidomethyl groups (285 Da).
The heterogeneity of the isolated Grx (Figure III.1A) is attributed to the
modification of some of the cysteines in the isolation and purification process. The fact that
the reduced Grx ionized poorly in contrast to the S-alkylated and native protein provides
additional support for this hypothesis. The reduction in mass by 153 Da corresponds to the
conversion of two -S-S-CH 2-CH 2-OH groups to -SH (calculated difference: 2 x 76 = 152
Da). However, the shape of the peak in Figure III. 1A does not exclude the possibility that
one, two, and three cysteines have reacted in a 1:2:1 ratio rather than two completely
modified cysteines. The scheme shown below provides a plausible explanation for these
observations. Treatment of the reduced Grx with hydroxyethyldisulfide (HEDS), routinely
performed at the last step of purification, could give the distribution of protein forms
shown.
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The S-carbamidomethylated Grx was digested with trypsin and the digest partially
fractionated by RP-HPLC. The molecular weight of the peptides in each HPLC fraction
was determined by FABMS and the amino acid sequence by tandem mass spectrometry.
However, three of the tryptic peptides (M+H) ÷ = m/z 2309, m/z 2854, and m/z 3292 were
too large to be unambiguously sequenced and were further digested with Endo-Asp-N. The
sequence of the resulting peptides permitted (together with overlapping sequences derived
separately from chymotryptic peptides) the assembly of the sequences of these three tryptic
peptides. Overlapping sequence information was furnished by digestion of the S-
ethylpyridylated Grx with a-chymotrypsin. In a separate experiment, larger peptides were
produced by digesting the S-ethylpyridylated protein with Endo-Lys-C. The latter digest
provided confirming information for the alignment deduced from the tryptic and
chymotryptic peptides. As with the tryptic digest, the chymotryptic and Endo-Lys-C
digests were partially fractionated and the molecular weights of the peptides were
determined by FABMS. The amino acid sequences (except for the larger Endo-Lys-C
peptides) of the peptides were also deduced from the CID mass spectra. The FABMS data
resulting from the tryptic, chymotryptic, and Endo-Lys-C digests of hErGrx is shown in
Tables III.1, 111.2, and 111.3, respectively. Figures 111.2, 111.3, and 111.4 provide examples of
CID mass spectra of Grx peptides and the interpretation of these spectra (as shown by the
annotations) leading to the sequences displayed at the top of each spectrum. The complete
amino acid sequence of hErGrx derived from the peptides generated by the various
enzymatic digests of the protein is shown in Figure 111.5.
A comparison of pig liver' 21, calf thymus120 , rabbit bone marrow122, and the human
Grx amino acid sequences is shown in Figure 111.6. Like the other mammalian Grxs,
Table III. 1. FABMS data from the tryptic digest (and further digestion with Endo-Asp-N)
of S-carbamidomethylated hErGrx.
HPLC Tryptic Tryptic/HPLC Peptidea Sequence (from CID) Asp-N' Sequence (from CID) Position b(M+H)÷  (M+H) +
1 472.1 TVPR 68-71
1 542.1 IQPGKc 9-13
6 563.4 VFIGK 72-76
7 629.4 QIGALQ 100-105
10 870.4 LKQIGALQd 98-105
10 1037.3 Ac-AQEFVNCK 1-8
13 1638.7 VVVFIKPTCPYCR 14-26
14 1395.9 RAQEILSQLPIK 27-38
15 1239.7 AQEILSQLPIK 28-38
15 1322.6 VVVFIKPTCPYe 14-24
16 2309 - --------------------- > 768.3 DCIGGCS 77-83
1559.0 DLVSLQQSGELLTR 84-97
17 2854 --------------------- > 563.2 VFIGK 72-76
768.3 DCIGGCS 77-83
1558.8 DLVSLQQSGELLTR 84-97
22 3293 --------------------- > 520.3 DITAT 46-50
805.5 QGLLEFV 39-45
856.3 DHTNEIQ 51-57
1164.7 DYLQQLTGAR 58-67
1356.7 DITATNHTNEIQ 46-57
aMonoisotopic (M+H)+ = m/z (in italics) determined by FABMS.
bAccording to the final sequence determined in this work.
cIle determined from the CID mass spectrum of chymotryptic peptide (M+H) ÷ = m/z 1535.9.
dThe N-terminal Leu was determined from the CID mass spectrum of the chymotryptic
peptide (M+H) ÷ = m/z 1127.8.
eThe Lys preceding Pro was identified from the CID spectrum of an Endo-Lys-C peptide
having this Lys at its C-terminus.
Table III.2. FABMS data for peptides resulting from the chymotryptic digestion of S-
ethylpyridylated hErGrx.
HPLC Chymotryptic
Fraction Peptide' Sequence Derived by CIDb Positione
(M + H)'
6 757.6 KQIGALQ 99-105
7 501.2 LQQLd 60-63
7 536.2 Ac-AQEF 1-4
7 573.4 AQEIL 28-32
7 629.5 QIGALQ 100-105
7 729.3 RAQEIL 27-32
7 885.7 RRAQEIL 26-32
7 926.5 IKPTCPYe 18-24
7 1093.8 CRRAQEIL 25-32
8 870.6 LKQIGALQ f  98-105
8 960.5 VSLQQSGEL9 86-94
8 1127.8 TRLKQIGALQ 96-105
9 718.5 TVPRVF 68-73
9 1103.8 TGARTVPRVF 64-73
10 1174.6 VSLQQSGELLT9 86-96
11 1073.5 VSLQQSGELL9 86-95
11 1096.8 SQLPIKQGLL 33-42
11 1535.9 VNCKIQPGKVVVF 5-17
14 1372.7 SQLPIKQGLLEF 33-44
aMonoisotopic (M+H)÷ = m/z (in italics) determined by FABMS.
bGln and Lys were differentiated based on this specificity of Endo-Lys-C (see Table 111.3).
cAccording to the final sequence determined in this work.
dThe N-terminal Leu was determined from the CID spectrum of tryptic/Asp-N peptide
(M+H)÷ = m/z 1164. 7.
elle was determined from the CID spectrum of tryptic peptide (M+H)' = m/z 1638.7.
fThe N-terminal Leu was determined from the CID spectrum of chymotryptic peptide
(M+H)÷ = 1127.8.
gThe Leu at position 88 was differentiated from Ile from the CID mass spectrum of
tryptic/Endo-Asp-N peptide (M+H) ÷ = m/z 1559.0.
Table 111.3. FABMS data for peptides resulting from the Endo-Lys-C digestion of S-
ethylpyridylated hErGrx.
Endo-Lys-C
Peptidea Sequence Derived by CID Position b(M + H)+
2 542.2 IQPGKc 9-13
3 629.3 QIGALQd 100-105
4 1085.6 Ac-AQEFVNCK 1-8
5 704.5 VVVFIK 14-19
Endo-Lys-C
Peptidea Assigned Sequencee (M+H)+ PositionbFrac. (M + (M+H)
7 2426.2 PTCPYCRRAQEILSQLPIK 2426.3 20-38
8 2645.0 DCIGGCSDLVSLQQSGELLTRLK 2645.3 77-99
8 3113.3 VVVFIKPTCPYCRRAQEILSQLPIK 3111.7 14-38
11 4289 QGLLEFVDITAT(D/N)HTNEIQD-
YLQQLTGARTVPRVFIGK f
aMonoisotopic (M+H) ÷ = m/z values are indicated in italics.
bAccording to the final sequence determined in this work.
cIle was determined from the CID spectrum of chymotryptic peptide (M+H)÷ = m/z 1535.9.
dThe C-terminal Gln was determined by N-acetylation and determination of the mass
difference by FABMS (see text).
eThe peptide sequences were assigned on the basis of molecular weight, the specificity of
the Endo-Lys-C protease, and CID derived data from the tryptic and chymotryptic digests
of hErGrx (Tables III.1 and 111.2).
fThe signal due to the (M+H) ÷ ion of this peptide was not sufficiently strong to permit
resolving the 1 Da difference between Asp and Asn at position 51.
gThe calculated (polyisotopic) value is based on Asn at position 51.
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Cya Arg We Thr Gin Glu
Cym Arg Wit Thr Gin Glu
Cya Arg LyW Thr G1n Glu
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Pig
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Figure III.6. Comparison of pig liver, calf thymus, rabbit bone marrow, and human
erythrocyte glutaredoxins amino acid sequences showing their alignment and homology.
Identification of Asn as well as Asp at position 51 in the human sequence is indicated by
the asterisk. Identical residues are framed.
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hErGrx also contains an acetylated Ala at the N-terminus which was determined from the
CID mass spectrum of the N-terminal tryptic peptide [(M+H) ÷ = m/z 1085. 7d] of S-
ethylpyridylated hErGrx (Figure III.7). The presence of the b, ion at m/z 114.0 indicated
that acetylated Ala (rather than un-acetylated Leu or Ile which have the same mass) is at the
N-terminus since b, ions in CID mass spectra of peptides with a free (basic) N-terminal
amino acid are generally not observed.'2 2 In addition, the absence of Leu or Ile in the
peptide sequence is further confirmed by the lack of a peak at m/z 86 which corresponds to
the immonium ion for these isomeric amino acids. The CID mass spectrum of the tryptic
peptide from S-carbamidomethylated Grx (top of Figure III.2) also contains a b, ion at m/z
114. 0 and served to confirm the deduced sequence.
Despite the similarities of hErGrx to the other mammalian Grx proteins, there are a
number of differences. Of particular interest is the discovery of a fifth cysteine near the N-
terminus of hErGrx. The N-terminal tryptic peptide from the S-ethylpyridylated Grx
(Figure 111.7) also contains an abundant ion at m/z 106.0 corresponding to the ethylpyridyl
group and a high mass ion at m/z 979.2 which arises from the loss of the ethylpyridyl
moiety from the (M+H)÷ precursor ion. Tryptic digestion of the S-carbamidomethylated
Grx gave an analogous (M+H) ÷ ion at m/z 1037.3 and the subsequent CID mass spectrum
(top of Figure 111.2) of this peptide provided additional confirmatory evidence for the
aThe m/z values in italic type denote monoisotopic mass as discussed previously in this
section.
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position of this fifth cysteine.
The hErGrx contains a His whose position in the sequence is not homologous with
the His-89 in the Grx proteins from pig liver and calf thymus. The CID mass spectrum of
the tryptic/Endo-Asp-N peptide (M+H)÷ = m/z 856.3 (shown in Figure 111.8) exhibits an
abundant ion at m/z 110.3, the immonium ion of His. The a2 and b2 ions, (m/z 225.4 and
m/z 253.4, respectively), correspond to a peptide with Asp and His at the amino terminus.
The Asp was identified as the N-terminus of this peptide (finally assigned to position 51)
on the basis of the specificity of Endo-Asp-N and the presence of the y6 and z6 + 1 ions,
(m/z 741.4 and m/z 725.4, respectively). Thus, His is the second residue in this peptide and
was assigned to position 52 in the final amino acid sequence. A second peptide generated
from the tryptic/Endo-Asp-N digest, (M+H)÷ = m/z 1356. 7 (bottom spectrum of Figure
111.2), provided confirmatory evidence for the position of His in hErGrx. In addition, the
presence of a strong signal at m/z 770.4 for the c7 ion provided further confirmation for Thr
after His since c, ions are generally not very abundant in CID mass spectra except at
positions preceding Thr.76 This peptide (together with the peptide of (M+H)÷ = m/z 856.3)
revealed an apparent microheterogeneity in the protein since Asn instead of Asp was
identified at position 51 for the peptide in Figure 111.2. Further confirmation of this finding
came from the fact that the measured m/z of this peptide was 0.9 Da less than that expected
from a peptide with Asp at position 51 that resisted cleavage. (The residue masses of Asp
and Asn are 115. 0 and 114. 0, respectively). The assignment of Asn rather than Asp (except
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at the N-terminus) in this peptide is consistent with the fact that Endo-Asp-N cleaves at the
peptide bond N-terminal to Asp but not Asn. Furthermore, the results of isoelectric
focusing of hErGrx in agarose indicated the presence of two pI forms whose observed pH
values corresponded to those predicted with either Asp or Asn at position 51.126 However,
subsequent cloning and sequencing of the cDNA of hErGrx'2 7,128 identified Asn as the
amino acid at position 51. Thus, a plausible explanation is that the Asp-51 is due to
deamidation of the Asn presumably occurring during the isolation and purification of the
protein. On the other hand, this was surprising in light of the fact that none of the other
eleven Asn and Gln residues (including a near neighbor at Asn-54) were similarly
affected. 126
The hErGrx protein is unique among the other Grx proteins in the absence of Met at
position 88 which is in agreement with the amino acid analysis and lack of CNBr reactivity
which indicated the absence of this amino acid."14 The CID mass spectrum of the
tryptic/Endo-Asp-N peptide (M+H)* = m/z 1559. 0 (shown in Figure III.9) has a nearly
complete wn ion series. The b5 and abundant w,0 ions (m/z 528.6 and m/z 1085.7,
respectively) together identify Leu as the amino acid at position 88. (The side chain
specific cleavage resulting in the formation of the w10 ion also serves to differentiate Leu
from Ile). The identity of all twenty-one Ile and Leu residues (which are isomeric) could be
determined based on the dn or wn ions which involve cleavage of the side chains at the p,y-
carbon bond.7 4,7 5 Further examples of CID mass spectra where Ile and Leu were
differentiated on the basis of dn or w, ions are shown in Figure III.3. The top and bottom
mass spectra also demonstrate how the presence of a basic amino acid (Arg) near the N-
terminus directs the fragmentation to produce mainly N-terminal ions of which many are d.
ions. Conversely, the middle spectrum has Arg at the C-terminus and consequently, the C-
terminal wn and vn ions predominate.
The isobaric Lys and Gln were differentiated on the basis of the specificity of Endo-
Lys-C. The only exception was the C-terminal Gin which was identified by N-acetylation
of the C-terminal tryptic peptide (M+H) ÷ = m/z 629.4. The m/z of this peptide after N-
acetylation shifted to 671.4 (i.e., monoacetylation) due to the reaction of the free N-
terminal amino group, rather than to m/z 713.4 (i.e., diacetylation), the value expected if a
Lys was part of this molecule. The proteolytic digests were typically carried out over
longer time periods (12 - 24 h) to insure complete cleavage and therefore proper
identification of internal Lys and Gin residues. A side effect of the longer incubation times
was the formation of a number of N-terminally carbamylated peptides due to the presence
of the denaturant urea. Fortunately, these peptides are easily distinguished on the basis of
their mass (the carbamylated peptides are 43 Da higher in mass) and from their CID mass
spectra. An example of a tryptic peptide and its corresponding N-terminally carbamylated
peptide is shown in Figure III.4. The m/z values for the C-terminal ions are identical in
both mass spectra while the N-terminal ions are 43 Da higher for the adducted peptide.
Furthermore, the carbamylated peptide generates an abundant b, ion (absent in the spectrum
of the unadducted peptide) at m/z 172.3 which, as already noted above, is indicative of N-
terminal modification. Thus, the unintended consequence of the presence of these
carbamylated peptides was to provide additional supporting evidence for the assigned
sequences.
The top CID mass spectrum in Figure 111.4 of the uncarbamylated peptide
(QIGALQ) is unique in containing at least four N-terminal fragment ions of the type an -17
and bn -17. The source of these ions is the particularly facile deamidation of the N-terminal
Gin to form pyroglutamic acid' 29 as shown below:
H 0
H2N-C
CH 2
H-N-CH-C--
H
O
I I
HN C
The experimentally determined M, (11,688) of the reduced hErGrx by MALDI-
TOF-MS was in close agreement with the calculated M, (11686.6) based on the mass
spectrometrically derived sequence (for Asn at position 51). Similarly, the M, (also
determined by MALDI-TOF-MS) of the S-carbamidomethylated (11,973) and of the S-
ethylpyridylated (12,214) proteins also agrees well with the calculated values of 11,971.9
and 12,212.3, respectively. These results establish the mass of the human Grx protein and
clarify the ambiguity that existed previously because of the earlier estimation of 6500 Da
for the molecular weight of human placental thioltransferase. '30 MALDI-TOF-MS was also
used to confirm the hErGrx sequence by the analysis of unfractionated proteolytic digests.
For example, the MALDI-TOF mass spectra of Endo-Lys-C and Endo-Asp-N digests of S-
ethylpyridylated hErGrx are shown in Figure III. 10. These digests generate larger peptides
which are more efficiently ionized by MALDI. The data from Figure III.10 for the Endo-
Lys-C and Endo-Asp-N digests is compiled in Tables 111.4 and I1.5. The sequences listed
were not determined by these experiments but are shown for the convenience of the reader.
Although some of the smaller peptides were not detected by the MALDI experiments,
taken together, the information from the two digests provided confirmation for the entire
hErGrx sequence.
In the course of sequencing hErGrx, a few peptides were observed whose masses
did not fit the final sequence. These peptide ions, (which tended to be weaker signals),
could have resulted from non-specific cleavage of hErGrx. Two of the tryptic peptides
happened to ionize well enough to allow acquisition of good quality CID mass spectra
(shown in Figure III.11). Clearly, the sequences of these peptides is not homologous with
any of the Grx sequences shown in Figure 111.6. The masses and sequences of these
'unidentified" peptides were searched using a protein database library. 131 The results of
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Table III.4. MALDI-TOF mass spectral data from Endo-Lys-C digestion of S-
ethylpyridylated hErGrx from Figure III. 10.a
Calc'd Obs'dPosition (M+.) (M+I)÷ Amino Acid Sequence(M+H)+ (M+H)+
1-8 1086.26 1086.26* ()Ac-AQEFVNCK
9-13 542.66 - (K) IQPGK (V)
14-19 704.93 - (K) VVVFIK (P)
14-38 3113.84 3113.8 (K) VVVFIKPTCPYCRRAQEILSQLPIK (Q)
20-38 2427.94 2427.6 (K) PTCPYCRRAQEILSQLPIK (Q)
39-76 4288.85 4288.85* (K) QGLLEFVDIT...QLTGARTVPRVFIGK (D)
77-99 2647.09 2646.5 (K) DCIGGCSDLVSLQQSGELLTRLK (Q)
100-105 629.73 - (K) QIGALQ()
aShown are the expected Endo-Lys-C cleavage products and the peptides detected. The m/z
values marked with an asterisk were used as internal standards. The smaller peptides
(ionized by FABMS) are more difficult to ionize by MALDI-TOF-MS and were not
detected.
Table III.5. MALDI-TOF mass spectral data from Endo-Asp-N digestion of S-
ethylpyridylated hErGrx from Figure III.10.a
Calc'd Obs'dPosition (M+H)÷ (M+H) Amino Acid Sequence(M+H)+ (M+H)+
1-45 5491.65 5491.7 () Ac-AQEFVNCKIQPG...QGLLEFV (D)
46-57 1357.42 - (V) DITATNHTNEIQ (D)
58-76 2163.53 2164.6 (Q) DYLQQLTGARTVPRVFIGK (D)
77-83 865.02 865.02* (K) DCIGGCS (D)
84-105 2411.81 2412.1 (S) DLVSLQQSGELLTRLKQIGALQ ()
93-105 1483.80 1484.2 (G) ELLTRLKQIGALQ ()
aShown are the expected Endo-Asp-N cleavage products and the peptides detected.
Although the cleavage rate is generally much faster at the N-terminus of Asp, one N-
terminal cleavage at Glu (93-105) was observed. Porcine insulin, [(M+H) ÷ = m/z 5778.60],
and peptide 77-83 (denoted by the asterisk) were used to internally calibrate the spectrum.
The presence of Asp rather than Asn at position 51 would explain the absence of peptide
46-57.
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this search identified the sequence, GIPTLLLFK, [(M+H) ÷ = m/z 1167.6] as a tryptic
peptide from E. coli thioredoxin while three other peptides (M+H) + = m/z 765.5, m/z 1422.3
(VHVGDEDFVHLR as deduced by CID-MS) and m/z 2457.4 (whose ion signal was too
weak to allow unambiguous sequence determination) corresponded to tryptic peptides from
human cystatin-B. Therefore, the preparation used for the mass spectrometric sequence
determination of hErGrx contained fragments from at least two other proteins, (human
cystatin-B and E. coli thioredoxin.a), although the concentration of these contaminants was
probably quite low in comparison to hErGrx. In retrospect, it is not at all surprising that
only the E. coli peptide GIPTLLLFK was found, because it is easily ionized since it
consists primarily of hydrophobic amino acids (and has Lys at the C-terminus) and
therefore would be expected to ionize well by FAB even at lower levels. 29 The peptide
VHVGDEDFVHLR produced a strong signal for the same reasons. The CID mass spectra
in Figure III. 11 also serve as additional examples of ion types known to arise from specific
amino acids or sequences. Thus, in the CID spectrum of peptide GIPTLLLFK, the y, - 2
ion provides further evidence for Pro at that position and the relatively higher abundance of
the c3 ion confirms that the Pro precedes Thr. This peptide is also somewhat unusual in
generating abundant internal fragment ions indicated by the "PT" and "IPT/PTL"
annotations. In addition, both of these internal fragment ions also undergo loss of H20 (18
Da) presumably from the Thr side chain. The lower CID mass spectrum consists
aThese particular proteins were used as molecular weight markers for SDS-PAGE of
hErGrx in the same laboratory where the isolation of hErGrx was performed.
93
predominantly of C-terminal ions due to the basic Arg at the C-terminus. The abundant ion
at m/z 110.2 in the immonium ion region of the spectrum indicates that His is in the
sequence. It is interesting to note that in both of the His containing mass spectra (Figures
111.8 and III.11 [bottom]), His is in the second position and that a secondary ion,75 d2D and
d2V, respectively, is formed. A secondary dx ion results from the fragmentation of the n - 1
side chain (where X stands for the single letter code for the n - 1 residue).
III.4 Conclusion
The complete amino acid sequence of a human thioltransferase (Grx) isolated from
erythrocytes was determined solely by high performance tandem mass spectrometry. In
addition, molecular weight determination of the native and S-alkylated hErGrx was
accomplished by MALDI-TOF-MS which established that hErGrx has five instead of four
cysteines. The MALDI molecular weight determination of hErGrx (M, 11,688) also served
to clarify the ambiguity caused by the previous estimate (M, 6500 Da) for the molecular
weight of a human thioltransferase.'3 0 The final primary structure of hErGrx was
assembled from tryptic and chymotryptic peptides whose sequences were deduced by CID
mass spectrometry. Finally, unfractionated protein digests of hErGrx were also analyzed
by MALDI-TOF-MS. The resultant mass spectra provided additional confirmatory
evidence for the assigned primary structure.
The hErGrx protein was found to be quite homologous to the other mammalian Grx
proteins of known structure and also contains an acetylated N-terminus and lacks Trp. Like
the pig liver and calf thymus Grx proteins hErGrx contains a His residue, however, its
location is at position 52 rather than 89. In contrast to the other Grx proteins, hErGrx does
not contain any Met. Of particular interest is the discovery of a fifth cysteine near the N-
terminus of hErGrx which could be due to a silent mutation or a functionally significant
change. It is noteworthy that the human thioredoxin (Trx) also has an "extra" fifth Cys
residue 132 compared to other mammalian Trx proteins. It has been hypothesized that this
Cys could serve to anchor the hErGrx to the red blood cell membrane while retaining
catalytic activity at its active cite (Cys-22/Cys-25). 2"6
Section IV
Determination of the Primary Structure of a Mussel Adhesive Protein
from Mytilus edulis and Identification of a Novel Amino Acid
IV. 1 Introduction
The marine mussel, Mytilus edulis, is particularly adept at attaching its foot to
underwater surfaces through the byssus, a thread-like structure ending in adhesive pads or
plaques.' 33 The process of this surface bonding is of considerable technological and
scientific interest since it is quite strong, rugged, and persists in spite of prolonged
immersion in seawater. Furthermore, the mussel foot proteins involved in this adhesion
process are naturally occurring and presumably environmentally benign. Mature byssal
adhesive plaques exhibit extensive protein cross-linking which renders isolation of
individual protein components from these plaques difficult or impossible. However, the
cross-linking of freshly secreted plaque precursor proteins can be prevented by lowering the
temperature (cold shock)134 which then allows their isolation. At least four distinct families
of polymorphic proteins named mefp (for Mytilus edulis foot protein) have previously been
isolated in this manner from the foot and byssal adhesive plaques of Mytilus edulis.'34
The first mefp protein to be characterized (mefp-1)' 35 was found to have a mass of
ca. 120 kDa, contain 3 ,4-dihydroxyphenylalanine (or Dopa), and consist of tandemly
repeated decapeptides each containing at least one residue of Lys, Dopa, as well as 4-
hydroxyproline, and 3,4-dihydroxyproline.' 36-138 The second foot protein (mefp-2), another
Dopa containing constituent of the mussel foot plaques of mass ca. 46 kDa, has also been
previously characterized. 139 The remaining two proteins, mefp-3 and mefp-4 are also major
components of the cold-shocked plaques, however, until recently there was no detailed
information concerning these proteins.
The mefp-3 protein is synthesized and stockpiled in the mussel foot of M. edulis and
then specifically deposited into the adhesive plaques of the byssus. 140 Like the other plaque
precursor proteins, mefp-3 also has a high Dopa content but is distinguished from the others
by high levels of a new post-translational modification of arginine. The structure of this
modified arginine was determined to be 4-hydroxyarginine by FAB tandem mass
spectrometry (Section IV.2). Although the conversion of Tyr to Dopa in mefp-3 was
essentially complete, the modification of arginine to the hydroxylated analogue varies
between 40 and 80 %. The initial primary structure determination of mefp-3 was carried
out using Edman degradation sequencing, however, complete sequence analysis of the
protein was hampered by the coelution of related peptides (since every position containing
Arg also contained Arg-OH) and the presence of Dopa. Consequently, only the N-terminal
portion of these mefp-3 derived peptides were clearly defined by the Edman method.
Another factor contributing to the failure of initial sequencing attempts was the notorious
difficulty in sample handling presented by the unique structural characteristics of these
proteins (a high content of Arg-OH and Dopa with the latter known to form reactive
quinones'41). The complete primary structure of mefp-3 was finally determined by the
application of exopeptidase digestion in combination with MALDI-TOF-MS. The
sequence determination of the mefp-3 protein described in this section serves to illustrate
the utility of mass spectrometry in providing solutions to problems that are difficult or
impossible to solve using traditional methods alone.
IV.2 Experimental Procedures
The mefp-3 protein was isolated from the feet of fresh exsanguinated mussels by
Waite et al. at the University of Delaware (the procedure is described elsewherel40 ). Like
the other mefp proteins, mefp-3 represents a family of adhesive proteins with similar
structure and is thus a heterogeneous mixture. Isolation of the different polymorphs (at
least nine variants were observed) of the crude mefp-3 was accomplished at the University
of Delaware using C8 RP-HPLC and the resultant peaks analyzed by acid-urea-
polyacrylamide gel electrophoresis (Figure IV.1). Fractions 37-39 appeared to be the most
electrophoretically homogeneous and were initially pooled for sequence analysis. The
mefp-3 variant in these three fractions (37-39) was designated mefp-3F and the sequence
determination of mefp-3 described in this section is based on this variant.
The mefp-3 protein is extremely prone to oxidation and very reactive in large part
due to the presence of Dopa. Oxidation of mefp-3 was minimized by performing the
protein digests in a solution containing ascorbic acid as an anti-oxidant. For each digest, a
fresh buffer solution was prepared by adding crystalline ascorbic acid to a 1 M solution of
Tris base with constant stirring until the pH, (measured using a Fisher Accumet Model 15
pH meter), was 9.0. Prior to digestion, the mefp-3 protein was denatured by dissolution in
8 M urea for 30 min at 37 'C. Endo-Lys-C digestion of mefp-3F (1:100 enzyme:substrate
by weight) was carried out in 2 M urea, 250 mM Tris-Ascorbate at pH 9.0 under Ar for 4 h
at 25 'C. The progress of the digest was monitored by analyzing aliquots from the Endo-
Lys-C digests by MALDI-TOF-MS.
Peptides from the Endo-Lys-C digest were fractionated by RP-HPLC (Figure IV.2)
for the exopeptidase digests. Surprisingly, the chromatography of the mefp-3 peptides
using longer (25 cm x 4.6 mm I.D.) C4 and C1 8 RP-HPLC columns yielded unsatisfactory
results. The best separation of the peptides was achieved using a shorter, 5 cm x 4.6 mm
I.D. Vydac C4 column, with gradient elution of 100 % A to 25 % B in 30 min (where A and
B were the HPLC mobile phases, 0.005% aqueous TFA and 0.0035% TFA/ACN,
respectively) on a HP-1050 chromatograph using a Waters 490 multiwavelength UV
detector with the detector output captured with GRAMS/386 chromatography software.
Approximately 500 pmol of the mefp-3F protein digested with Endo-Lys-C was injected
onto the HPLC chromatograph after four hours (Figure IV.2). The peptides in the collected
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fractions were lyophilized using a centrifugal evaporator and later redissolved in distilled
water for analysis. Further chymotryptic digestion of the largest Endo-Lys-C peptide
(approximately 1:100 enzyme:substrate by weight) was performed in 1.5 M urea, 50 mM
Tris-ascorbate buffer (pH 8.5) at 25 'C for 30 min (and then analyzed by MALDI-TOF-
MS).
MALDI-TOF-MS analysis of the mefp-3F protein or peptides derived thereof were
dissolved in ACCA matrix solution to give a final concentration between 1-10 pmol/[iL.
About 1 CpL of this solution was applied to the target plate and allowed to evaporate. The
MALDI-TOF-MS experiments were carried out using the Vestec VT-2000 mass
spectrometer (Section 1.3) using the N2 laser (337 nm) at a repetition rate of 5 Hz. The
resulting protonated molecular ions were accelerated to 30 or 35 keV kinetic energy.
For exopeptidase digestion, the mefp-3F protein or peptides generated from
enzymatic digestion of mefp-3f were dissolved in either 100 mM ammonium acetate (pH
4.0) or 100 mM ammonium citrate (pH 5.5) and digested with CpP. Alternatively, AmM in
50 mM sodium phosphate (pH 7.0) buffer was used to obtain N-terminal sequence
information. The reactions with CpP were performed at room temperature and those with
AmM at 37 'C. The enzyme to substrate ratio was between 1:10 and 1:100 by weight,
respectively. Aliquots from the reaction solutions were taken at timed intervals and
dissolved in ACCA matrix solution before being analyzed by MALDI-TOF-MS.
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FAB-CID mass spectra of Arg, Arg uniformly labelled with '5N ("5N-Arg for short),
and Arg-NG-OH were measured to determine the structure of the CID fragment ions from
Arg. N-acetylation of these compounds was accomplished by dissolving several ýIg in 80
jiL glacial acetic acid and 20 ýiL acetic anhydride at 37 'C for 1 hr. Butyl esters of Arg,
15N-Arg, and Arg-NG-OH were prepared separately by incubation in 200 pL of 3 N HCl/n-
butanol at 90 oC for 30 min. The reagents were removed using a Savant speed-vac
concentrator prior to mass spectrometric analysis. Arg, the modified and unmodified Arg
standards, the unknown Arg-OH from mefp-3, (and later, the authentic 4-hydroxyarginine)
were dissolved in distilled H20 and ionized by FAB using glycerol as the matrix in the
JEOL high performance tandem mass spectrometer (Section 1I.2). Similarly, the peptide in
HPLC fraction 1 (Figure IV.2) was analyzed by FABMS. Both two sector and four sector
mass spectra were acquired using the JEOL Complement data acquisition software. The
operating conditions were identical to those used for FABMS analysis of the Grx peptides
(Sections 11.2).
The sources for many of the reagents used for the work in this section have been
described previously in Section 111.2. In addition, ascorbic acid, citric acid, and sodium
phosphate were obtained from Mallinckrodt, 100 mM ammonium acetate (pH 4.0) buffer
and CpY from Pierce, Arg and the dipeptide YW from Sigma, 3 N HCl/n-butanol reagent
from Supelco, and 15N-Arg from Schwartz Chemical Co. Both the endopeptidases (Endo-
Lys-C and a-chymotrypsin) and exopeptidases (AmM and CpP) used for structure
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determination of mefp-3F were purchased from Boehringer Mannheim. Finally, the Arg-
NG-OH and authentic 4-hydroxyarginine were kindly supplied by P.L. Feldman (Glaxo
Research Institute, Research Triangle Park, NC) and E.A. Bell (King's College, London),
respectively.
IV.3 Structure Determination of a Modified Arginine
An unidentified basic amino acid from mefp-3 hydrosylates was isolated using ion
exchange chromatography. This amino acid gave an intensely scarlet color after exposure
to Sakaguchi spray which indicated the presence of a guanidino group.'4 0 The amino acid
was ionized by FAB and produced an abundant (M+H)÷ ion of m/z 191.2 indicating a
molecular weight of 190.2. This is 16 Da higher than that of Arg and, together with the
Sakaguchi reaction, suggested that the unknown amino acid was a hydroxyarginine. In
order to elucidate the structure of the Arg-OH, Arg and 'SN-Arg were first analyzed by
FAB-CID-MS (mass spectra shown in Figure IV.3). Comparison of these two CID spectra
allowed deduction of the structures of the fragments (Figure IV.4) due to Arg since each
nitrogen atom increased the m/z value of the corresponding 'SN-Arg fragment by 1 Da. The
m/z values in Figure IV.4 are due to the Arg fragments while those in parentheses are from
the 'IN-Arg derivative. In addition, a CID mass spectrum of NG-hydroxyarginine was also
obtained. The structure assignments in Figure IV.4 were confirmed by CID mass spectral
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analysis of N-acetylated and butyl esters of Arg, "N-Arg and Arg-NG-OH. The CID mass
spectrum of the unknown amino acid from mefp-3 is shown in Figure IV.5A and its
similarity to the Arg and "5N-Arg CID mass spectra in Figure IV.3 provided further
confirmation for its identity as a hydroxylated Arg. Two abundant ions (m/z 70 and 87) in
the CID mass spectrum of Arg are not present to any appreciable extent in the CID mass
spectrum of Arg-OH whereas the latter spectrum exhibits two new peaks at m/z 86 and 103
which correspond to a mass shift of 16 Da, respectively. On the other hand, both spectra
contain an ion at m/z 73. From the structures of these ions (Figure IV.6) one can deduce
that the unmodified Arg must be 4-hydroxyarginine. This assignment was later confirmed
by obtaining a CID mass spectrum of authentic 4-hydroxyarginine (Figure IV.5B) which is
identical to the CID mass spectrum of the Arg-OH from mefp-3 (Figure IV.5A).
IV.4 Amino Acid Sequence of Mefp-3F
The mefp-3 protein isolated from the mussel foot of M. edulis was fractionated by
C, RP-HPLC and the fractions analyzed by acid-urea-polyacrylamide gel electrophoresis
(Figure IV. 1) by Waite et al. at the University of Delaware.'14 The mefp-3 protein family
consists of at least nine variants of which the sixth, mefp-3F (fractions 37-39), appeared to
be the most electrophoretically homogeneous. The mefp-3 primary structure reported in
this section is based on this mefp-3F variant (for sequence analysis fractions 37-39 were
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Figure IV.4. Structures of the fragment ions from the FAB-CID mass spectra of Arg and
"
5N-Arg. The m/z values in parenthesis are of the fragments from 15N-Arg. All m/z values
are monoisotopic and are from the mass spectra in Figure IV.3.
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The initial molecular weight determination of mefp-3F (11 kDa) was performed by
Waite et al. using discontinuous SDS-PAGE.140 Prior to the application of mass
spectrometry to this problem, the electrophoretically determined Mr of mefp-3F caused
considerable confusion in the attempt to reconcile the data obtained by Edman sequencing.
The MALDI-TOF mass spectrum of the major component of the intact mefp-3F is shown in
Figure IV.7. Bovine ubiquitin, (M+H) ÷ = m/z 8565.9 and (M+2H) ÷" = m/z 4283.4 for the
singly and doubly charged protonated molecular ions, respectively, was used as an internal
standard. The singly charged region of mefp-3F is expanded in the inset and shows that
mefp-3F produces a cluster of peaks that differ from the most highly hydroxylated form,
(M+H)÷ = m/z 6135.2, of the protein in multiples of-16 mass units. The mefp-3F protein
and peptides derived thereof are unique in forming these ion clusters due to the presence of
both Arg and Arg-OH.
The unusual amino acid composition of mefp-3 complicated conventional
approaches to sequencing this protein. For example, the incomplete post-translational
hydroxylation of mefp-3 coupled with numerous short sporadic sequence repeats introduced
uncertainties into the Edman degradation derived sequence data. In addition,
endoproteinase digestion of mefp-3 was complicated by the tendency of this protein to
oxidize, polymerize, and degrade while in solution, especially at alkaline pH. Tryptic
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digestion in particular resulted in an inordinate amount of peptides making analysis very
difficult. On the other hand, Endo-Lys-C retained its specificity producing a very simple
digest containing apparently only two peptides, based on the MALDI-TOF mass spectrum
of this digest (Figure IV.8). It contains two major ion clusters with (M+H) ÷ = m/z 1606.1
and m/z 4182.9 for the most highly hydroxylated component in each cluster, respectively.
The digest was then fractionated by RP-HPLC to separate the peptides. Fractions 2 and 3
(Figure IV.2) corresponded to these two peptides, respectively. Although no peptide ion
signal was detected from MALDI analysis of HPLC fraction 1, FABMS analysis of the
same fraction produced an (M+H) ÷ ion of m/z 384.1 (which is 16 Da higher than the
(M+H)÷ ion of the dipeptide YW). This provided an explanation for the absence of a third
peptide in the MALDI mass spectrum of the digest (Figure IV.8) since small peptides are
not efficiently ionized by MALDI and the low mass region is often obscured by peaks due
to the matrix. The FAB-CID mass spectra of the (M+H)÷ = m/z 384.1 ion and the dipeptide
YW (Figure IV.9) are clearly very similar. The ions annotated with "Y" and "W" in Figure
IV.9B are fragment ions of Tyr and Trp, respectively. In addition, the two C-terminal ions
(z, and yl) indicated in this mass spectrum establish that W is at the C-terminus (and that Y
is at the N-terminus). While the peaks labeled with "W" have the same m/z values in both
spectra, the peaks labeled with "Y" are all 16 mass units higher in Figure IV.9A. Thus, the
(M+H)÷ ion of m/z 384.1 is due to the dipeptide YW where the Y indicates Dopa.
(Similarly, a bold "R" was later used to identify Arg-OH found in mefp-3).
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The high content of Arg, Arg-OH, and Dopa in mefp-3 contributed to the
hydrophilic nature of this protein and rendered FABMS analysis difficult. Only one peptide
(isolated from a tryptic digest by Waite et al.) was sufficiently hydrophobic to be ionized by
FAB. The sequence of this peptide, GWNNGWNR, was deduced from the CID mass
spectrum (shown in Figure IV. 10). Fortuitously, the mefp-3 protein and peptides ionized
well by MALDI-TOF-MS without requiring any chemical modifications.
The C-terminal sequences of the two larger Endo-Lys-C peptides were
unambiguously determined by digesting each peptide with CpP and directly analyzing
aliquots at different time points by MALDI-TOF-MS. In addition, the peptide in HPLC
fraction 2 was digested with AmM which together with the CpP data, allowed its complete
sequence to be determined. The MALDI-TOF mass spectra of the AmM digest of this
peptide at various timepoints are shown in Figure IV. 11 while those of the CpP digest are
shown in Figure IV. 12. The partial peptide sequence determined from the resulting data
(Tables IV. 1 and IV.2) was GWNNGWN-GRRGK. The missing residue was determined
to be R from the difference between the molecular weight of the above sequence and the
measured (M+H) ÷ of the undigested peptide. Thus, the full sequence of this peptide must
be GWNNGWNRGRRGK. Further support for this conclusion was provided by the
sequence of the tryptic peptide deduced by FAB-CID (Figure IV. 10) and discussed
previously.
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Figure IV. 11. MALDI-TOF mass spectra of mefp-3F peptide (M+H) + = m/z 1606.7
incubated with AmM at various timepoints. The data is summarized in Table IV. 1.
117
1606.7
1 , i
I ,
0 min
"~ ' ~Y'it~'~ij~*\,~ir~,ZlnhWIL.~u n~ ,,O,,o I
0 mmin
30 sec
-F
-RRGK -GK
., J! :; I
kN .V. t~4·% ___N,~& ,,,KL-L·-h·_Y·.%..12·-·LI _~*_~g~!! tNJV11:~
1 min -RRG]
- A,
5 min 
-RRGK
-GRRGK
n'z 900 1100 1300 1500 1700
Figure IV. 12. MALDI-TOF mass spectra of mefp-3F peptide (M+H)+ = m/z 1606.7
incubated with CpP at various timepoints. The data is summarized in Table IV.2.
118
Y*Cm~II~WU~U CII*V ~Cll~rr-rV-~·W~CI~·IVIYlrr*~C~DU**~ U~W* IC
0 min
-
i i I r I
-
Table IV. 1. Peptides from AmM digestion of Endo-Lys-C peptide (M+H)' = m/z 1606.7.
Peptide (M+H) ÷  Mass Difference Mass Difference Partial
Observeda Observedb Calculated Sequencec
1606.7
1549.7 57.0 57.05 G...
1363.3 186.4 186.21 GW...
1249.1 114.2 114.10 GWN...
1135.0 114.1 114.10 GWNN...
1077.8 57.2 57.05 GWNNG...
891.7 186.1 186.21 GWNNGW...
777.7 114.0 114.10 GWNNGWN...
Table IV.2. Peptides from CpP digestion of Endo-Lys-C peptide (M+H) ÷ = m/z 1606.7.
Peptide (M+H) ÷  Mass Difference Mass Difference Partial
Observeda Observedb Calculated Sequencec
1606.7
1478.6 128.1 128.17 ...K
1421.4 57.2 57.05 ...GK
1249.3 172.1 172.18 ...RGK
1077.1 172.2 172.18 ...RRGK
1019.9 57.2 57.05 ...GRRGK
aThe (M+H)+ = m/z 1606.7 peptide and the ACCA matrix dimer [(M+H) ÷ = m/z 379.1]
were used as internal calibrants.
bMass difference from the peptide in the row above.
cResidues in this row have been cleaved. The bold Arg (R) represents Arg-OH.
119
The remaining ambiguity, the C-terminal sequence of the peptide in HPLC fraction
3, was resolved by CpP digestion with the resultant MALDI-TOF mass spectra (at different
time points) shown in Figures IV. 13 and IV. 14. The data from this exopeptidase digest
(Table IV.3) provided the following C-terminal sequence for this peptide:
...GNYNRYNRYGRRYGGYK. The same peptide was also digested with chymotrypsin
and analyzed by MALDI-TOF-MS (Figure IV.15). The resulting data (Table IV.4)
confirmed the peptide sequence assigned by the combination of Edman degradation and
MALDI-TOF-MS. Two peptides from this chymotryptic digest, (M+H) ÷ = m/z 1786.1 and
m/z 1486.1, were isolated by RP-HPLC and each separately digested with AmM and CpP.
The results of these four exopeptidase experiments provided further confirmation of the
deduced sequence. Most significant was the AmM digestion of the (M+H) ÷ = m/z 1786.1
peptide which resulted in the consecutive loss of A, D, Y, and Y, but did not proceed
further due to the GP residues which follow, and the CpP digestion of the peptide (M+H) ÷
= m/z 1486.8 indicating the consecutive loss of K, Y, and G from the C-terminus.
The data from analysis of the Endo-Lys-C peptides is summarized in Table IV.5.
The calculated (M+H) ÷ values expected from an Endo-Lys-C digest of mefp-3F agree well
with the actual measured values. Final sequence alignment of the Endo-Lys-C peptides was
accomplished by MALDI-TOF-MS by CpP treatment of intact mefp-3F protein which
established the C-terminus as ...RRGKYW. In addition, it was discovered serendipidously
that addition of guanidine hydrochloride reduced the activity of Endo-Lys-C sufficiently to
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Table IV.3. Peptides from CpP digestion of Endo-Lys-C peptide (M+H) ÷ = m/z 4182.9.
Peptide (M+H)÷  Mass Difference Mass Difference Partial
Observeda Observedb Calculated Sequencec
4183.25*
4055.1 128.2 128.17 ...K
3875.89* 179.2 179.18 ...YK
3761.7 114.2 114.10 ...GGYK
3410.4 351.3 351.36 ...RYGGYK
3238.2 172.2 172.18 ...RRYGGYK
3180.8 57.4 57.05 ...GRRYGGYK
3002.0 178.8 179.18 ...YGRRYGGYK
2829.4 172.6 172.18 ...RYGRRYGGYK
2715.72* 113.7 114.10 ...NRYGRRYGGYK
2536.3 179.4 179.18 ...YNRYGRRYGGYK
2364.2 172.1 172.18 ...RYNRYGRRYGGYK
2250.1 114.1 114.10 ...NRYNRYGRRYGGYK
2071.2 178.9 179.18 ...YNRYNRYGRRYGGYK
1957.2 114.0 114.10 ...NYNRYNRYGRRYGGYK
1900.2 57.0 57.05 ...GNYNRYNRYGRRYGGYK
1434.3 14 34 .46 d ADYYGPNYGPPRd
aThe peptides marked with an asterisk were used as internal calibrants in some of the
spectra.
bMass difference from the peptide in the row above.
cResidues in this column (except for the last row) have been cleaved. The bold Arg (R)
and Tyr (Y) represent Arg-OH and Dopa, respectively.
dN-terminal peptide sequence determined by Edman degradation.
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Table IV.4. Peptides from further chymotryptic digestion (Figure IV. 15) of the Endo-Lys-
C peptide of HPLC fraction 3 (Figure IV.2).
(M+H)÷  (M+H)÷  Sequence b  Positionc
Obsvda Calcd
949.9 949.96 (Y) NRYNRY (G) 20-25
1021.08* - (Y) GRRYGGYK() 26-33
1486.8 1486.54 (Y) NRYGRRYGGYK( )d 23-33
1786.1 1785.82 ()ADYYGPNYGPPRRY (G) e  1-14
1952.7 1952.01 (Y) NRYNRYGRRYGGYK () 20-33
2250.7 2250.26 () ADYYGPNYGPPRRYGGGNY (N) 1-19
2416.4 2416.45 (Y) GGGNYNRYNRYGRRYGGYK () 15-33
2716.1 2715.73 () ADYYGPNYGPPRRYGGGNYNRY (N) 1-22
3181.2 3181.19 () ADYYGPNYGPPRRYGGGNYNRYNRY (G) 1-25
4183.25* - ( ) ADYYGPNYGPPRRYGGGNY- 1-33
NRYNRYGRRYGGYK ()
aPeptides marked with asterisks in the first column were used as internal standards.
bThe bold Arg (R) and Tyr (Y) represent Arg-OH and Dopa, respectively. The sequences
shown are those corresponding to the measured molecular weights and the final sequence of
mefp-3F.
cPosition in the final sequence.
dResults of CpP digestion underlined.
eResults of AmM digestion underlined.
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avoid cleavage at Lys-46 resulting in a peptide of (M+H) + = m/z 1972.3 (calculated m/z
1972.09) using bovine insulin as an internal calibrant. Thus, the mass spectrometric data
together with the data from Edman degradation give the following sequence for mefp-3F:
ADYYGPNYGPPRRYGGGNYNRYNRYGRRYGGYKGWNNGWNRGRRGKYW
The experimentally determined (M+H)+ value for the most highly oxidized form of mefp-
3F, m/z 6135.2, agrees well with the (M+H) ÷ value 6136.31 calculated for this sequence.
IV.5 Conclusion
An adhesive protein, mefp-3, isolated from the foot of the marine mussel M. edulis,
presented unique challenges to the determination of the amino acid sequence due to its
unusual composition. Mefp-3 represents a family of similar polymorphic proteins that vary
in the extent of post-translational modification and are composed almost exclusively of
Dopa, Gly, Asn, Trp, Arg, and a previously unknown basic amino acid. (The latter was
determined to be 4-hydroxyarginine by FAB tandem mass spectrometry). Although at least
nine variants of mefp-3 were discovered, only one variant (mefp-3F) appeared
electrophoretically homogeneous. The primary structure determination of mefp-3 discussed
in this section is based on this variant.
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In contrast to the essentially complete conversion of Tyr to Dopa, the post-
translational modification of Arg was incomplete resulting in multiple hydroxylation states.
This complicated the initial attempts to sequence mefp-3 using conventional Edman
degradation. The complete sequence of the variant mefp-3F was finally determined by
using a combined approach of Edman degradation sequencing and mass spectrometry with
the C-terminal sequences of Endo-Lys-C peptides ultimately determined by MALDI-TOF-
MS analysis of CpP digests. This work serves as an additional example of the
complementarity of mass spectrometry with more traditional sequencing methods.
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Section V
The Determination of the Active Site of Inosine Monophosphate Dehydrogenase
of Escherichia coli and Correction of the Amino Acid Sequence of this Enzyme
V.1 Introduction
The oxidation of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate
(XMP) is catalyzed by the enzyme inosine-5'-monophosphate dehydrogenase (IMPDH) and
is the rate limiting step in the synthesis of guanine nucleotides.' 42 XMP is first converted to
guanosine 5'-monophosphate (GMP) by GMP synthetase and ultimately yields the
guanosine 5'-triphosphate (GTP) necessary for nucleic acid synthesis. The reaction
involving IMPDH is of particular interest due to the discovery that IMPDH is highly
expressed in tumor cells and in rapidly growing tissues.' 43 For example, northern blot
analysis of steady-state mRNAs indicated that IMPDH was up to 5-fold more active
transcriptionally in leukemic cells than in normal cells.' 44 Inhibitors of IMPDH have been
shown to reduce intracellular GTP levels and to suppress biological processes that depend
on cellular proliferation.' 45 In addition, IMPDH inhibitors have been found to have
anticancer, antiviral, and immunosuppressive activity. 46-150 Early studies with the broad-
spectrum antiviral drug Virazole (I), [a synthetic nucleotide having the structure 1-p-D-
ribofuranosyl-1,2,4-triazole-3-carboxamide-- also known as Ribavirin], suggested that its
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antiviral activity may be due to the inhibition of GMP synthesis at the step involving
conversion of IMP to XMP.'S' More recently, 5-ethynyl-l- p-D-ribofuranosylimidazole-4-
carboxamide [EICAR (II)] 152,153, an analogue of Virazole, was shown to be an extremely
potent antiviral agent. 154 Adenosine kinase converts EICAR to the active 5'-monophosphate
metabolite EICARMP' 55 (III) which has been shown to inhibit IMPDH in murine leukemia
L1210 and human lymphocyte CEM cells.156 The in vitro experiments with EICARMP and
IMPDH isolated from E. coli were carried out to directly assess the role of IMPDH as a
target enzyme for EICARMP.' 157
o o o
N CNC N NC N" N// 2
N N C CH O N C CHHO O HO--P O O
HO OH HO OH HO OH
Virazole (I) EICAR (II) EICARMP (III)
At least two mechanisms (Figure V.1) have been proposed for the IMPDH mediated
conversion of IMP to XMP. 145,158 The first involves IMPDH as a catalytic base to add
hydroxide (by deprotonation of water) directly at position 2 (C2) of IMP. Hydride transfer
to NAD then yields XMP. In the alternative mechanism, attack at C2 occurs due to base
activation of a nucleophilic residue (Nuc) from IMPDH. The resultant intermediate
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contains an oxyanion that is stabilized by an acidic residue of the enzyme. Collapse of the
oxyanion occurs with concomitant reduction of NAD÷ to NADH. Finally, a hydrolysis step
regenerates the nucleophilic residue and yields XMP. The E. coli IMPDH was observed to
be irreversibly inactivated by EICARMP' 57 which suggested that EICARMP forms a
covalent adduct with IMPDH at the active site. In this section, this hypothesis was
investigated by using MALDI-TOF-MS to analyze both the native and the EICARMP
inactivated E. coli IMPDH enzymes. In addition, in the course of these experiments, the
resulting mass spectral data indicated that the original IMPDH primary structure predicted
from the DNA sequencel 59 was in error. Corrections to the IMPDH amino acid sequence
were ultimately confirmed using MALDI-PSD mass spectrometry.
V.2 Experimental Procedures
The E. coli IMPDH enzyme was expressed, isolated and incubated with the
EICARMP reagent by Wang and Hedstrom at Brandeis University (the procedure is
described elsewhere).' 7 Approximately 30 pmol of aqueous IMPDH was mixed with an
equal volume of denaturing buffer (8 M guanidine hydrochloride, 0.025 M Tris-HCl pH
8.3, 0.002 M EDTA). Enough DTT (14 Ctg/&iL) was added to provide a 2000-fold molar
excess compared to the enzyme and the solution incubated at 37 'C for 3 h. The S-
alkylation reagent, 4-vinylpyridine, was then added (5-fold molar excess over DTT) and the
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reaction mixture kept at 37 "C overnight. Desalting was accomplished by injecting the
reaction mixture onto a 2 cm Vydac C4 reversed phase guard column and washing with
0.05% aqueous TFA. The protein was eluted from the column with 0.035% TFA/ACN.
The fraction containing the eluted protein was dried using a centrifugal evaporator.
About 15 Cpg of S-ethylpyridylated IMPDH (both native and EICARMP inactivated)
were dissolved in 2 M urea and 50 mM Tris-HCI (pH 9.0) for Endo-Lys-C digestion.
About 0.2 ptg of Endo-Lys-C was added and the digest solution kept at room temperature
for 3 h. Similarly, the S-ethylpyridylated EICARMP inactivated IMPDH was digested with
trypsin in 2 M urea and 100 mM Tris-HCI (pH 8.5) for 12 h. The tryptic digests were
partially fractionated using a 25 cm x 4.6 mm I.D. Vydac C4 RP-HPLC column. The
peptides were eluted using a 99 % A to 60 % B gradient in 60 min (where A and B are the
0.05 % TFA/H 20 and 0.035 % TFA/ACN mobile phases, respectively) using the HP-1050
chromatograph. The peptides were collected in fractions and dried using a centrifugal
evaporator.
A saturated solution of SA matrix in 30 % ACN was used for MALDI-TOF-MS
analysis of the intact IMPDH protein. The enzyme was dissolved in this matrix solution to
give a final protein concentration between 1-10 pmol/jiL. For the digests and fractionated
peptides, ACCA prepared in 50 % ACN was used as the matrix. About 1 giL of the
analyte/matrix solution was applied to the target plate and allowed to evaporate. The
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Voyager Elite (Section 11.3) MALDI-TOF-MS mass spectrometer was used to obtain linear,
reflectron, and PSD mass spectra. The sample spots were irradiated using the N2 laser at a
repetition rate of about 4 Hz. The resulting ions were accelerated to 30 kV kinetic energy
(20 kV for reflectron and PSD mass spectra). To increase mass accuracy, BSA was added
as an internal standard to the IMPDH/matrix solution. At least six separate mass spectra
(sum of 128 laser shots) were obtained for each experiment with the undigested enzyme to
ensure good measurement precision (• 0.1 %). The reported m/z values for the IMPDH
(M+H) ÷ ions in this section are the averaged results.
Aliquots from the endoproteinase digests were taken directly and diluted with the
ACCA matrix solution. The initial calibration was performed using bovine insulin as an
external standard. At least 64 (up to a maximum of 256) laser shots were summed for each
mass spectrum. PSD mass spectra of Endo-Lys-C peptides were obtained from the
unfractionated digest using the timed ion selector (Section 11.3) to deflect all but the desired
molecular and fragment ions. However, the relatively lower ion current due to the tryptic
peptide containing Cys-305 (the residue modified by EICARMP) required HPLC
fractionation prior to the PSD analysis. A more detailed description of MALDI-PSD can be
found in Section 11.3. The final PSD spectra were generated using the Perceptive
Biosystems GRAMS computer program to concatenate at least twelve separate reflector
mass spectra each acquired at different mirror ratios in order to optimally focus fragment
ions with differing kinetic energies.
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The sources for the enzymes and reagents used in this work have already been
described in Sections 111.2 and IV.2.
V.3 Identification of the Active Site Modification
The IMPDH enzyme is known to be inactivated by sulfhydryl reagents such as
iodoacetamide and methanethiosulphonate, however, the presence of IMP protects the
enzyme from inactivation.'16 0,16' This suggested that the active site near C2 of IMP (Figure
V. 1) may contain a cysteine residue. The observed irreversible inactivation of IMPDH with
the EICARMP reagent'5 7 may thus be due to a covalent modification of the E. coli protein.
The hypothetical reaction between IMPDH and one molecule of EICARMP is shown
below:
O N ' \ NH2
HO-P-OH I
O o • "CH
HO -IMPD
HO OH
O) N C./ NH2oo
NH2 II N
-- HO-P-OH CH=CH-X-IMPDH
C O
H CH-X-IMPDH
HO OH
EICARMP
(M r = 347.2)
IMPDH (M+H) + + 347.2
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Covalent modification of IMPDH by addition of EICARMP (M, 347.2) would result in a
shift to higher mass for the protein by 347.2 Da. The MALDI-TOF mass spectra of the
native and EICARMP inactivated E. coli IMPDH are shown in Figures V.2A and V.2B,
respectively. The difference (306 Da) between the measured values for the native and
EICARMP inactivated enzyme, (m/z 52,016 and m/z 52,322, respectively), corresponds to
the modification of IMPDH with one EICARMP molecule (within MALDI-TOF-MS
experimental error 59 of A 0.1%). Both the native and EICARMP inhibited IMPDH were
reduced, S-ethylpyridylated and digested with Endo-Lys-C in separate experiments. The
MALDI-TOF mass spectra of these two digests are shown in Figure V.3. The measured
and calculated masses as well as the sequences of the IMPDH peptides resulting from these
two digests are listed in Table V. 1. Although the mass spectra of the digests are similar,
they are not identical. The major qualitative difference is the shift in mass by the ion of m/z
5227.0 in Figure V.3A to m/z 5470.3 in Figure V.3B. The former corresponds to peptide
297-349 (Table V.1) in which the Cys-305 is S-ethylpyridylated. On the other hand, the
peptide ion at m/z 5470.3 in Figure V.3B is consistent only with the addition of one
molecule of EICARMP (M, 347.2) instead of vinylpyridine (M, 105.1). Consequently, the
EICARMP modification must be at position 305, the only cysteine in this peptide. The
EICARMP modified peptide, (M+H)+ = m/z 5470 peptide was too large for efficient
fragmentation by MALDI-PSD. Therefore, a shorter peptide was generated by tryptic
digestion of the S-ethylpyridylated EICARMP inactivated protein. The peptides resulting
from this digest (MALDI-TOF mass spectrum shown in Figure V.4) provided additional
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confirmation for the EICARMP modification site and IMPDH primary structure (Section
V.4). The data from the tryptic digest is summarized in Table V.2. The S-ethylpyridylated
tryptic peptide 297-308, VGIGPGSICTTR [calculated m/z 1266.51], was not observed.
However, the ion at m/z 1509.0 corresponds to this peptide with an EICARMP modified
cysteine [calculated m/z 1508.57] rather than S-ethylpyridylated. The MALDI-PSD mass
spectrum of this tryptic peptide (Figure V.5) contains three abundant fragment ions at m/z
1427.8, m/z 1295.9, and m/z 1126.9. These ions correspond to the loss of phosphate,
ribose-5'-phosphate, and S-EICARMP, respectively, indicating that EICARMP is indeed a
component of this peptide. The latter fragment ion provided further evidence for cysteine
as the modified residue. Although the facile cleavage of the phosphate and ribose groups
prevented the acquisition of a PSD spectrum with complete sequence information, the lower
mass region provided enough confirmatory data for confident sequence assignment of this
peptide and of the site of EICARMP adduction.
V.4 Correction of the Amino Acid Sequence
Based on the amino acid sequence deduced from the DNA sequence' 5 9 , E. coli
IMPDH contains six cysteines and has a calculated M, of 54,575.7. However, MALDI-
TOF-MS analysis of the native E. coli protein produced an (M+H) ÷ ion at m/z 52,016
(Figure V.2A) rather than the expected value (54,576.7). Furthermore, the (M+H)÷ ion of
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Table V.1.
EICARMP
Peptides resulting from Endo-Lys-C digestion of E. coli native and
inactivated IMPDH. (Footnotes are on the following page).
Native"a Modifieda Calc.
Position (M+HN (M+H) ÷  (M+H) +  Amino acid sequenceb(M+H)+ (M+H)+ (M+H)*
1-6 731.4 - 731.98 ()MLRIAK (E)
7-36 3213.0 3213.0 3211.64 (K) EALTFDDVLLVPAHSTVL-PNTADLSTQLTK (T)
37-72 3825.0 3824.8 3824.55 (K) TIRLNIPMLSAAMDTVTE-ARLAIALAQEGGIGFIHK(N)
73-87 1846.12* 1846.12* 1846.12 (K) NMSIERQAEEVRRVK (K)
88-110 2537.3 2537.0 2536.90 (K) KHESGVVTDPQTVLPTTT-LREVK (E)
89-110 2408.5 - 2408.72 (K) HESGVVTDPQTVLPTTTL-
REVK (E)
(K) ELTERNGFAGYPVVTEE-
111-156 5157.7 5157.3 5156.83 NELVGIITGRDVRFVTDLNQ-
PVSVYMTPK (E)
157-174 2055.4 2055.5 2055.39 (K)ERLVTVREGEAREV-VLAK (M)
183-199 1900.9 1901.9 1901.28 (K) ALVVDDEFHLIGMITVK (D)
204-212 1121.9 1122.3 1122.34 (K) AERKPNACK (D)
(K) DEQGRLRVGAAVGAGA-
213-267 5708.33* 5708.33* 5708.33 GNEERVDALVAAGVDVLLI-
DSSHGHSEGVLQRIRETRAK (Y)
268-296 2894.7 2894.3 2894.3 (K) YPDLQIIGGNVATAAGAR-ALAEAGCSAVK (V)
(K) VGIGPGSICTTRIVTGVGV-
297-349 5227.0 5470.3c 5227.05 PQITAVADAVEALEGTGIPVI-
ADGGIRFSGDIAK (A)
350-383 3446.6 3446.5 3445.90 (K) AIAAGASAVMVGSMLAG-TEESPGEIELYQGRSYK (S)
384-396 1345.4 1345.1 1345.59 (K) SYRGMGSLGAMSK (G)
397-411 1661.6 - 1661.68 (K) GSSDRYFQSDNAADK (L)
412-424 1431.5 1431.4 1431.68 (K) LVPEGIEGRVAYK (G)
429-456 3260.3 3259.9 3259.87 (K) EIIHQQMGGLRSCMGLT-GCGTIDELRTK (A)(K) AEFVRISGAGIQESHVHD-457-479 2496.1 2496.0 2495.80 (K) AEFVRVTITK (E)
480-488 1022.8 - 1023.09 (K) ESPNYRLGS ()
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Footnotes for Table V.1.
a(M+H)+ ions marked with asterisks were used as internal standards for mass
calibration.
bAmino acids in parenthesis refer to those preceding and following the Endo-Lys-C
cleavage sites.
cCalculated 5469.14 for the addition of EICARMP (M, 347.22) to Cys-305 instead
of 4-vinylpyridine (M, 105.14).
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Table V.2. Peptides resulting from tryptic digestion of EICARMP inactivated E. coli
IMPDH. (Footnotes are on the following page).
S Obs.b  Calc.Pepa  Position (MH) (MH) Amino acid sequencec(M+H)+ (M+H)'
1 7-36 3212.4 3211.64
40-56
57-72
79-85
88-107
89-107
111-137
116-137
141-156
183-199
1834.4
1639.1
887.9
2180.8
2052.7
2965.7
2337.4
1840.7
1901.5
1351.6
1834.17
1638.95
887.97
2180.47
2052.29
2965.29
2336.61
1840.15
1901.28
1351.53
(K) EALTFDDVLLVPAHSTVLPNT-
ADLSTQLTK (T)
(R) LNIPMLSAAMDTVTEAR (L)
(R) LAIALAQEGGIGFIHK (N)
(R) QAEEVRR (V)
(K) KHESGVVTDPQTVLPTTTLR (E)
(K) HESGVVTDPQTVLPTTTLR (E)
(K) ELTERNGFAGYPVVTEENELVGIITGR (D)
(R) NGFAGYPVVTEENELVGIITGR (D)
(R) FVTDLNQPVSVYMTPK (E)
(K) ALVVDDEFHLIGMITVK (D)
(R) KPNACKDEQGR (L)
12 220-260 3998.40* 3998.40 (R) VGAAVGAGAGNEERVDALVA-AGVDVLLIDSSHGHSEGVLQR (I)
13 234-260 2759.3 2759.09 (R) VDALVAAGVDVLLIDSSHGHSEGVLQR (I)
14 266-285 1987.6 1987.27 (R) AKYPDLQIIGGNVATAAGAR (A)
15 286-296 1125.33* 1125.33 (R) ALAEAGCSAVK (V)
16 297-308 1509.0 1508.57e (K) VGIGPGSICTTR (I)
17 309-342 3261.1 3260.76 (R) IVTGVGVPQITAVADAVEALEGTGIP-
VIADGGIR (F)
18 350-380 3067.5 3067.47 (K) AIAAGASAVMVGSMLAG-
TEESPGEIELYQGR (S)
19 397-420 2613.0 2612.77 (K) GSSDRYFQSDNAADKLVPEGIEGR (V)
20 402-420 2110.7 2110.29 (R) YFQSDNAADKLVPEGIEGR (V)
21 427-439 1523.9 1523.84 (R) LKEIIHQQMGGLR (S)
22 429-439 1282.6 1282.51 (K) EIIHQQMGGLR (S)
23 440-454 1767.2 1767.10 (R) SCMGLTGCGTIDELR (T)
24 455-461 851.0 850.99 (R) TKAEFVR (I)
25 462-479 1893.5 1893.11 (R) ISGAGIQESHVHDVTITK (E)
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207-217 d
I
Footnotes for Table V.2
aPeptide annotations as in Figure V.4.
b (M+H)+ ions marked with asterisks were used as internal standards for mass
calibration.
cAmino acids in parenthesis refer to those preceding and following the tryptic
cleavage sites.
dTryptic peptide (11) providing supporting evidence for Arg at position 206 rather
than Ala (see Section V.4).
eThe calculated mass for peptide 16 is for the addition of EICARMP (M, 347.22) at
Cys-305 instead of 4-vinylpyridine (M, 105.14).
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m/z 52,241 due to reduced and S-ethylpyridylated E. coli IMPDH corresponded to the
addition of vinylpyridine to five rather than six cysteine residues. These discrepancies were
resolved by incubating the S-ethylpyridylated protein with Endo-Lys-C and analyzing the
resulting digest using MALDI-TOF-MS (Figure V.3A). The N-terminal peptide
MQSVTLCIMPRQYLLTTLVEILPMLRIAK (calculated (M+H) + = m/z 3482.41) expected
from the DNA sequence was not observed in this mass spectrum. Instead, an ion at m/z
731.4, whose mass did not correspond to any predicted Lys-C peptides was in agreement
with the calculated m/z value (731.98) for the protonated molecular ion of peptide
MLRIAK. The MALDI-PSD mass spectrum of the (M+H) ÷ = m/z 731.4 ion is shown in
Figure V.6 and confirms that amino acid sequence. Edman degradation sequencing (5
cycles) of intact IMPDH provided supporting evidence that the N-terminal sequence of
native E. coli IMPDH begins with MLRIA' 57 and thus, protein synthesis must begin at the
third methionine of the original DNA-derived sequence.'" Finally, the measured m/z
values due to the (M+H) + ions of native E. coli IMPDH (52,016) and the reduced and S-
ethylpyridylated protein (52,541) are consistent with the calculated values 52,023.6 and
52,549.3, respectively. Consequently, the E. coli IMPDH gene product is only 488 amino
acids long and contains five rather than six cysteines.
The MALDI mass spectra of the Endo-Lys-C digests in Figure V.3 both contained
an initially unidentified ion at m/z 1121.9 and m/z 1122.3 (Figures V.3A and V.3B,
respectively). The MALDI-PSD mass spectrum (Figure V.7) of the (M+H) ÷ion of m/z
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1121.9 allowed the complete sequence (AERKPNACK) of this peptide to be deduced. The
calculated m/z for the protonated (M+H)÷ ion of AERKPNACK (1122.3) agrees well with
the measured values (1121.9 and 1122.3) and corresponds to peptide 204-212 with Arg
instead of Ala at position 206. Furthermore, the tryptic peptide 207-217 (Table V.2) also
provided further evidence for Arg rather than Ala at this position. The mass spectrometric
data thus confirmed another error in the published DNA sequence that was discovered upon
re-sequencing the E. coli IMPDH gene. 1"7
V.5 Conclusion
The E. coli IMPDH was shown to be irreversibly inactivated by EICARMP.' 57
MALDI-TOF-MS analysis of the native and inactivated enzymes confirmed that EICARMP
forms a covalent adduct with IMPDH. Endoproteinase digestion of the proteins in
combination with MALDI-TOF-MS analysis allowed identification of the site of
modification. Furthermore, the mass spectrometric results indicated that the deduced
IMPDH primary structure from the DNA sequence' 59 was in error. The sequence
corrections, which were identified and confirmed by MALDI-PSD, showed that the native
E. coli protein consists of 488 amino acids, has five cysteines, and the amino acid in
position 206 is Arg, not Ala.
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The site of covalent modification of E. coli IMPDH with EICARMP is at Cys-305
and strongly suggests that this residue is near C2 of IMP in the IMP/IMPDH complex. This
result is consistent with earlier work with human type II IMPDH where 6-chloropurine
riboside 5'-monophosphate (6-Cl-IMP-- another IMP derivative that inhibits IMPDH) was
shown to form a covalent adduct with Cys-33 1.162 In E. coli IMPDH, Cys-305 (305 in E.
coli is homologous to 331 in the human enzyme) apparently acts as a catalytic nucleophile
in the IMPDH mediated conversion of IMP to XMP. However, other roles for Cys-305
cannot be eliminated.
Finally, this work with the E. coli IMPDH enzyme demonstrates the applicability of
MALDI-TOF-MS and especially MALDI-PSD to important biological research. It is
particularly noteworthy that all of the mass spectrometric work was performed with less
than 500 pmol of total material and of this amount, only a small fraction (a few pmol) was
actually used in the course of MALDI analysis. In conclusion, the experimental work
related in this section provides yet another example of the complementarity of mass
spectrometry with traditional biochemical methods for protein structure analysis.
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Section VI
Generation of Peptides with Overlapping Sequences using
Cyanide Ion in Combination with 4-Vinylpyridine
VI.1 Introduction
Chemical reagents for protein cleavage are infrequently used in large part due to the
exquisite specificity of enzymes. Strategies involving most chemical cleavage reagents can
be regarded as "brute force" methods that, in addition to the desired cleavages, often
generate unwanted side products which can further complicate the sequence determination
of an unknown protein. A notable exception is cyanogen bromide which specifically
cleaves at the C-terminus of methionine and is often used in situations where larger peptides
are desired.'6 Commonly used proteases such as trypsin, chymotrypsin, and
endoproteinase-Lys-C cleave at sites that are abundant in most proteins resulting in
numerous smaller peptides. This is advantageous for Edman degradation and FAB mass
spectrometry methodologies where peptide sequencing becomes increasingly more difficult
with larger peptides. While smaller peptides are generally more difficult to ionize by
MALDI the opposite is almost always true for larger peptides. Specific cleavage of proteins
at cysteine in most cases will result in a smaller number of larger peptides since cysteine is
one of the less abundant amino acids in proteins. Consequently, MALDI-TOF mass
spectrometry is especially well suited to the analysis of the larger peptide products that
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would result from a cleavage reaction of this specificity.
It has been known for some time now that disulfide bond containing proteins can be
cleaved with cyanide ion at cysteine residues. Yet, unlike cyanogen bromide, cyanide ion is
seldom used as a cleavage agent in modem laboratories interested in protein
characterization. Protein biochemists generally rely on only a handful of sequencing "tools"
such as trypsin or cyanogen bromide to cut proteins into smaller, more manageable
peptides. For this reason, additional methods for the specific cleavage of proteins are
highly desirable since they would provide more flexibility especially when dealing with
difficult sequencing problems. The potential of cyanide to specifically generate larger
peptides with overlapping sequences was a compelling reason to examine this reaction more
closely. For a quick and accurate measure of the molecular weights of the products,
MALDI-TOF mass spectrometry turned out to be an ideal method.
VI.2 Specific Cleavage of Proteins by S-Cyanylation
Almost exactly a century ago, Lang reported that mammals react to cyanide
poisoning by excreting thiocyanate.' 64 Decades later, Wood and Cooley confirmed this
result by noting that rats fed methionine-3 5S prior to injection with cyanide produced
radiolabeled thiocyanate in their urine.1 65 Interestingly, when they repeated the same
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experiment using cystine-3 5S instead of methionine-3 5S, the major radioactive metabolite
upon isolation was determined to be 2-iminothiazolidine-4-carboxylic acid (II) which is
formed by cyclization of p-thiocyanoalanine (I) as shown below:' 66
N--C
S HN, S
CHL 012O
HN - C.
H2N---CH-C . OH
(I) (II)
These findings suggested the existence of an alternative (non-enzymatic) pathway for
cyanide detoxification involving endogenous cystines or protein disulfide bonds and
prompted a number of investigators to explore the reaction of cyanide with a variety of
different disulfide bond containing peptides and proteins in vitro.167-172 The collective
conclusion was that cyanide ion can be utilized as a specific chemical reagent for cleaving
proteins at the N-terminus of cysteines participating in disulfide bonds.' 73
The first step of the reaction (shown in Figure VI. 1) involves nucleophilic attack by
cyanide ion to open the disulfide bond resulting in the formation of thiocyanoalanine and
cysteine. In the second step, thiocyanoalanine cyclizes at alkaline pH to form an
iminothiazolidine ring with concomitant peptide backbone bond cleavage. In the ideal case,
each cysteine in any given disulfide has an equal probability of getting cyanylated in the
first step. Since cyanide does not react with free thiol groups the resulting peptides should
153
R' O
I ii
H2N-CH-C- . . .
CH 2 O01 II
-HN-CH-C- . . .
Step 1
R' O
I 
H2N-CH-C--
CH 2 O0I I I
. . . -HN-CH-C--
I
CH 2 O0I II
-HN-CH-C-
R"f O
II
. . . -HN-CH-C-OH
CN'-
S
CH 2 0I I I
S. . -HN-CH-C-
R" O
I 
-HN-CH-C-OH
R' O
I 
H2N-CH-C-
S
CH 2 0I II
. .. -HN-CH-C--
N=C
CH 2 O0I I I
. . -HN-CH-C-
R" O
II
. . -HN-CH-C-OH
Step 2
R'
I Ii
H2N-CH-C-OH
HN ,s0
+ HN -C-
CH 2 0S II
. .. -HN-CH--C-
R" 0
' IC
- HN-CH-C-OH
S
CH 2 O OIH2N-CH-C-. IIHNCHC OH
H 2 N-CH-C-... -HN-CH-C-. . .- C-OH
HN S R"
HN C IIN-CH-C-OH+ HN -C- . . -HN-CH-C--OH
Figure VI. 1. The reaction of cyanide with a protein containing a disulfide bond.
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1"1
contain overlapping sequence information as shown by the products of step 2 in Figure
VI. 1. Unfortunately, preservation of the overlapping sequence regions is hampered by the
tendency of free sulfhydryl groups to reoxidize to form new disulfide bonds under basic
conditions.' 74 Furthermore, a major problem lies in the reversibility of the S-cyanylation
step (requiring large excesses of cyanide ion) since free sulfhydryls can react with
thiocyanoalanine to release cyanide ion and form a new disulfide bond. The mechanism is
illustrated in Figure VI.2 and provides an explanation for the reversible nature of the first
step leading to the scrambling of disulfide bonds and eventually to the formation of
peptides lacking any overlap. For example, when ribonuclease, which contains four
disulfide bonds, was incubated with cyanide, nine peptides were detected (all
iminothiazolidine blocked except for the N-terminal peptide) covering the entire sequence
yet none of them contained overlapping regions.'"
Cyclization of the p-thiocyanoalanine and consequent cleavage of the peptide
backbone is induced by performing the reaction at alkaline pH. However, prolonged
incubation of the protein in alkaline solution can produce dehydroalanine via p-elimination
of the thiocyanoalanine releasing thiocyanate and preventing cyclization and hence,
backbone cleavage. In addition, other possible side products may complicate the analysis
of the reaction mixture but these seem not to have been investigated in any detail.
Electrophilic reagents, such as 2-nitro-5-thiocyanobenzoic acid (NTCB) which is a
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S S S S
I I
CN-)
S
N
C
S SI I
N
C
H2N2
C
S®
I S SI I O
-C-OHH 2
Figure VI.2. Non-native disulfide bond formation due to the reversibility of S-cyanylation
with cyanide.
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II
C-OH
C-OH
Y-----------~------------~--------------H2
m
source of CN', were developed to overcome some of these problems and were found to be
generally more reliable."751 77 The reaction of a peptide sulfhydryl group with NTCB to
form cyanylated cysteine is shown below:
0 0
O\\ ,OH O\ .OH
C CýN C
S NN S NOz
CH 2 0 + CH2 O +
..---HN -- CH--C ..... --- HN -- CH-C - ...
NTCB
The drawback to the use of electrophilic cyanide reagents is that three separate reaction
conditions are required for the disulfide reduction, sulfhydryl cyanylation, and backbone
cleavage steps in contrast to the single step nucleophilic cyanide method. Although the S-
cyanylated product predominates, NTCB has been observed to form a mixed disulfide (with
mercaptonitrobenzoate) preventing S-cyanylation and peptide bond cleavage."17 More
importantly, it is no longer possible to generate overlapping peptides since electrophilic
reagents do not react with disulfide bonds. In practice, neither method has gained
widespread acceptance because the iminothiazolidine peptides produced are N-terminally
blocked and thus not amenable to Edman degradation sequencing although the N-terminal
iminothiazolidine can be reduced to alanine using a nickel catalyst. 179 It has also been
suggested that a pyrrolidone carboxylyl peptidase may provide a future method for the
enzymatic removal of these N-terminal blocking groups.' 76 In contrast, N-terminally
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blocked peptides, regardless of type, are easily sequenced using mass spectrometry.' 23,180
For example, the primary sequence of the protease inhibitor from Sarcophaga bullata was
determined directly from the collision induced dissociation (CID) mass spectra of the
shorter, NTCB derived, N-terminally blocked iminothiazolidine peptides.181 The
nucleophilic cyanide ion method can in principle produce larger N-terminal
iminothiazolidine peptides containing internal cysteines. These larger peptides (containing
overlapping sequence regions) would be more easily ionized by MALDI than by FAB.
VI.3 A New Strategy for the Optimization of the Cyanide Cleavage Reaction
to Generate Overlapping Peptide Fragments
The simplicity of the nucleophilic cyanide reaction and its potential to generate
larger peptide fragments with overlapping sequence information prompted the
reexamination of this reaction using MALDI-TOF-MS-- a method particularly well suited
to the analysis of larger peptides and proteins. As mentioned in the previous section, the
main problem with using cyanide as a protein cleavage reagent is apparently due to the
reversibility of the first step of the reaction (Step 1 in Figure VI.1) and consequently, the
need for a large molar excess of cyanide in the reaction mixture. Based on this hypothesis,
a new strategy was developed in an attempt to shift the equilibrium of the S-cyanylation
reaction toward products. Thus, free sulfhydryl groups formed by cyanide disulfide bond
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scission were specifically targeted to prevent them from reoxidizing to form new disulfide
bonds. This was accomplished by the addition of an S-alkylation reagent to the reaction
mixture in order to "trap" the free sulfhydryls as they formed. Figure VI.3 illustrates this
concept with 4-vinylpyridine as the S-alkylation agent. Reaction of 4-vinylpyridine with a
free sulfhydryl group results in the formation of the S-ethylpyridylated derivative which is
denoted in Figure VI.3 with the symbol "EP". 4-Vinylpyridine was chosen as the preferred
S-alkylation reagent due to its unique specificity toward free sulfhydryl groups and rapid
reaction at alkaline pH.' 82 ,183
Formation of a stable covalent cysteine adduct should in principle drive the
equilibrium of the first step of the cyanide reaction to the product side. Therefore, the
amount of cyanide required should decrease and the overall reaction rate should increase.
The generated peptides would contain stable internal S-ethylpyridylated cysteines and thus
preserve overlapping sequence information. Again, MALDI-TOF-MS should provide the
ideal analysis method for these larger peptides. Finally, the effect of the addition of the S-
alkylation agent on the reaction as a whole, including the monitoring of dehydroalanine
production and any other side product formation, (should it occur), could all be
simultaneously accomplished by MALDI-TOF-MS.
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Figure VI.3. New strategy for optimization of the S-cyanylation step with cyanide by
concomitant formation of S-ethylpyridylated (EP) peptides.
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Step 1
VI.4 Experimental Procedures
Solutions containing cyanide ion (typically 0.1 M) were prepared separately by
dissolving solid NaCN or KCN in deionized water. The pH of the cyanide solution was
carefully lowered by dropwise addition of 5-10% acetic acid using constant stirring. Care
was exercised to not allow the pH of the cyanide solution to fall below pH 7 at any time
during the addition of the acetic acid to prevent formation and escape of hydrogen cyanide
at lower pH levels. Following pH adjustment, enough deionized water was added to
achieve the desired final concentration. The total volume of the cyanide solution was
intentionally rather large (usually 50 mL) to facilitate pH measurement.
Optimization of the cyanide cleavage reaction was performed empirically by
selectively varying individual variables in the reaction conditions until the best possible
result (as determined by MALDI-TOF-MS) was achieved. In general, the protein to be
cleaved was dissolved in aqueous solution containing a denaturant such as guanidine
hydrochloride and a buffer. An aliquot of the cyanide ion solution was then added with
nearly simultaneous addition of an S-alkylation agent (4-vinylpyridine was added as a 2 %
solution in n-propanol). The majority of the experiments were performed using 2 M
guanidine hydrochloride, a 102 -fold molar excess of 4-vinylpyridine, a 103-fold molar
excess of cyanide ion, and 100 mM Tris-HCl buffer (pH 8.5). The reaction mixtures (total
volumes ranged from 50 to 200 jtL) were normally incubated in a heating block at 60 OC for
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2 hours. The reaction was terminated by lowering the pH of the reaction mixture by adding
glacial acetic acid. In some cases, a portion of the reaction solution was injected onto a
reversed phase HPLC column. The chromatography methodology (RP-HPLC) has been
already described in detail in Section 111.2.
Aliquots from the reaction solutions were analyzed directly by MALDI-TOF-MS
without any prior purification. The MALDI matrix solution was usually 10 g/L ACCA
prepared in 50/50 (v/v) acetonitrile/water. A saturated solution of SA in 30/70 (v/v)
acetonitrile/water was also used for some of the experiments. The reaction mixtures, which
contained denaturants and buffers, were diluted with larger amounts of matrix solution to
give a final concentration (for the protein and peptides) between 1-10 pmol/PL. Although
MALDI is generally insensitive to contaminants such as buffers and denaturants, it is easier
to achieve higher resolution and hence, mass accuracy by minimizing the final
concentration of these contaminants. Consequently, the initial protein concentration of the
reaction mixtures was usually about 1 x (10-4 ) M which then allowed the dilution of the
aliquots (with matrix solution) by at least one to two orders of magnitude.
MALDI-TOF-MS experiments were performed using two different instruments.
The modified Vestec VT 2000 LD-TOF, (described previously in Section 1.3), was used to
acquire linear mode mass spectra with 30 kV accelerating voltage. Thirty laser shots were
averaged for each scan with the resolution generally between 1:100 and 1:300. The
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PerSeptive BioSystems Voyager Elite mass spectrometer was used to acquire linear,
reflector, and post-source-decay (PSD) mode mass spectra. A more detailed description of
this instrument can be found in Section 11.3. Most of the mass spectra generated by the
Voyager Elite were acquired in the linear mode with delayed extraction (DE) and 20 kV
accelerating voltage to take advantage of the enhanced resolution (between 1:2000 and
1:4000). At least 64 (up to a maximum of 256) laser shots were summed for each mass
spectrum. PSD spectra were acquired in the continuous (non-DE) mode using 25 kV
acceleration. Complete PSD spectra were generated as described in Section 111.3.
The sources for many of the reagents used for this work have already been described
in Sections 111.2 and IV.2. In addition, NaCN, KCN, and guanidine thiocyanate were
purchased from Fluka, an 8 M solution of guanidine hydrochloride from Pierce, all proteins
and peptides (except E. coli thioredoxin which was obtained from Calbiochem), buffers
from Sigma, and S-alkylation reagents including iodoacetate and N-ethylmaleimide from
Aldrich.
VI.5 Results and Discussion
Preliminary experiments were performed with disulfide bond containing peptides
and proteins using varying concentrations of reactants, denaturants, and different
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temperatures in an attempt to optimize the reaction conditions. The MALDI-TOF mass
spectra of the reaction of the protein aprotinin with cyanide after 2 h at 60 oC is shown in
Figures VI.4A and VI.4B. Reaction conditions were identical for both (2 M guanidine-HC1,
100 mM Tris-HCl, pH 8.5, and a 1000-fold molar excess of NaCN) except that a 100-fold
molar excess of 4-vinylpyridine was also added to the reaction mixture in Figure VI.4B.
Clearly, the addition of 4-vinylpyridine was successful in shifting the equilibrium of the
reaction to the right since Figure VI.4A contains many products while essentially no
products were detected for the reaction mixture containing only cyanide ion (Figure VI.4B).
After three hours, nearly all of the aprotinin had been digested using the NaCN and
4-vinylpyridine combination. The primary structure of native aprotinin, which contains
three disulfide bonds, 184 is shown in Figure VI.5. The MALDI-TOF mass spectrum in
Figure VI.6 is of the same reaction mixture as in Figure VI.4B after three hours and
displays only the relevant peptide region. Figure VI.7 is a graphical representation of the
peptides from this digest that shows the overlapping sequences. The numbered peptides in
the mass spectrum (Figure VI.6), their position and sequence in the aprotinin amino acid
sequence, and the calculated and observed m/z values are listed in Table VI. 1. The peptide
labels on the left of Figure VI.7 correspond to the peptide annotations in the mass spectrum
(Figure VI.6) and to the entries in the first column of Table VI. 1.
The MALDI-TOF mass spectrum in Figure VI.6 contains several interesting
164
O
O
C)
0o
o c
0o a
0
ozo
0 o
0
ct
H t
oouupunqv OArt!I O1
165
HH
03 0
03 0
H (9
166
00
(9
_r
-E
C) ct0 7
o c ,..
cto
a,
CO
o tO- z~
-a -a
aouupunqv 3A!Ijrj; )-
167
Q)
~d 6)
v; s
k a
Ocl
00
tn
v,
!
rPL
rL
a>
rd
'ij
C~ cC~ in \O t\
d)
P·r
!-
00 O0
ILw~•
0 1
ci
-
., o
o " a0 3a
U cn
$ )
4-ýz. '-C
>c) C
.2 2 v
LnC)) CvC,
~ 0l 0 -
~~~
r, ~~ * b
; d rn'f
0, d C)C
-4~E
bD, ,
04 -l~ ~ -
168
u
I I
p,
w
Table VI. 1. Peptides resulting from the digestion of aprotinin with NaCN and 4-
vinylpyridine.
Pep.' POS.b Calc. Obs.
z C  ZSeq u e n
c e
1 1-13 1597.8* 1597.9 ()RPDFCLEPPYTGP (C)
2 1-29 3554.2 3554 () RPDFCLEPPYTGPCKARIIRYFYNAKAGL (C)
3 1-37 4515.4 4514.7 ()RPDFCLEPPYTGPCKARIIRYFYNAKA-
GLCQTFVYGG (C)
4 5-29 2958.5 2958.7 (F) CLEPPYTGPCKARIIRYFYNAKAGL (C)
5 5-37 3919.6 3919.6** (F) CLEPPYTGPCKARIIRYFYNAKAGLCQTFV-
YGG (C)
6 14-29 1895.3 1895.3 (P) CKARIIRYFYNAKAGL (C)
7 14-37 2856.4 2856.6 (P) CKARIIRYFYNAKAGLCQTFVYGG (C)
8 30-50 2507.8 2508.2 (L) CQTFVYGGCRAKRNNFKS-AED (C)
9 30-58 3516.1* 3516.3 (L) CQTFVYGGCRAKRNNFKSAEDCM-
RTCGGA()
10 38-50 1546.7 1547 (G) CRAKRNNFKSAED (C)
11 38-54 2143.5 2144.1 (G) CRAKRNNFKSAEDCMRT (C)
12 38-58 2555.0* 2555.3 (G) CRAKRNNFKSAEDCMRTCGGA ()
13 51-58 929.1" 929.1** (D) CMRTCGGA()
apeptide annotations from Figures VI.6 and VI.7.
bThe position of the peptide in the amino acid sequence of aprotinin.
cThe calculated masses for the dehydration product, (M+H) ÷ -18, except for those
peptides marked with an asterisk where the calculation is for the (M+H) ÷ ion.
dPeptides marked with a double asterisk were used as internal calibrants.
eN-terminal cysteines are cyclized iminothiazolidine groups. Internal cysteines (in bold)
are S-ethylpyridylated. Amino acids in parentheses before and after the peptide sequence
correspond to the preceding and following residues, respectively.
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features. First of all, ions at calculated m/z values for (M+H) ÷ ions for most of the peptides
were either very weak or absent completely. Instead, the dehydration product, m/z =
(M+H)÷ - 18 was observed. Peptide #11 was an exception with significant intensities for
both the (M+H) ÷ and (M+H) ÷ - 18 ions as indicated in Figure VI.6. In addition, although
the observed m/z for peptide #1 was predominantly due to the (M+H) ÷ ion, the (M+H)÷ - 18
was also detected for this peptide. On the other hand, three of the peptides (#9, #12, and
#13) were detected solely as (M+H) ÷ ions. A quick glance at Figure VI.7 shows that
peptides #9, #12, and #13 are all C-terminal peptides, i.e., they contain the C-terminus of
aprotinin. Therefore, it would appear from this experiment that any peptide that is present
wholly or in part as the dehydration product cannot contain the C-terminus of the original
protein.
Only two (#6 and #10) of the thirteen peptides detected were the result of complete
cleavage and therefore did not contain internal cysteines. Although it is possible that the
remaining five possible complete cleavage products may have been too small in size to be
efficiently ionized by MALDI, peptides 5-13 and 30-37 (complete cleavages) should have
been large enough (calculated m/z 1002.1 and 900.0, respectively) to be easily detected by
MALDI-TOF mass spectrometry. Therefore, approximately 85% of the peptides generated
from digesting aprotinin with cyanide and 4-vinylpyridine contained overlapping
sequences.
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Peptides containing at least two internal S-ethylpyridylated cysteines were always
accompanied by a dehydroalanine analogue formed by elimination of the 4-(thioethyl)-
pyridine:
N$-CH2 -CH,
I
CH2  CHI II
- CH C
S-ethylpyridylated peptide Dehydroalanine peptide
(M+H) (M+H) -139
This was not problematic for two reasons. First of all, the dehydroalanine containing
peptide was never the major product as compared to the S-ethylpyridylated peptide and
secondly, dehydroalanine products (although arising from cyanylated cysteines rather than
S-ethylpyridylated ones) can easily be identified in the mass spectrum as (M+H) ÷ - 139 as
shown above. The dehydroalanine containing peptides, [(M+H)÷ - 139], in the mass
spectrum (Figure VI.6) are 139 Da lower in mass than the corresponding S-ethylpyridylated
peptide and are indicated by the arrows. It should be emphasized that these arrows
represent chemical cleavage products that are 139 Da lighter than the corresponding
expected peptides and therefore are not fragment ions. Apart from dehydration,
dehydroalanine formation was the major side product of the reaction with five of the
thirteen peptides exhibiting this derivative. Two of these five peptides also formed
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lanthionine analogues but are again minor products in comparison with the desired S-
ethylpyridylated derivative. The lanthionines are characterized by a mass difference of -244
Da from the fully S-ethylpyridylated derivative product as indicated in Figure VI.6.
Lanthionines form via the attack of a free sulfhydryl group on thiocyanoalanine with release
of thiocyanate as shown below:168,173
N C
CH 2  CH2
S2
CH CH
N-C -S +
S
CH2  CH2
I 2 2
- CH CH
Lanthionine
S-Ethylpyridylated peptide (M+H)+ -244
The (M+H) ÷ - 244 arrows indicating lanthionine containing peptides are similar to the
notation used for the (M+H) ÷ - 139 peaks discussed earlier in that they represent a chemical
cleavage product rather than fragment ions.
The high specificity of the cyanide/4-vinylpyridine cleavage reaction is
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demonstrated by the fact that only two peptides (marked with asterisks in Figure VI.6) are
due to non-specific cleavage. The first, at m/z 1443.8 corresponds to the peptide sequence
1-11 and the second (m/z 2201.7) to peptide sequence 37-54. The peak at m/z 1639.9
(labelled G) turned out to be the N-terminal peptide #1 (1-13) guanidylated by reaction with
guanidinium chloride. This side reaction occurs predominantly with unblocked, free N-
terminal peptides, and leads to the following product:
NH R 1 O R2 OII I II I II
H2N-C-NH-CH-C- -NH-CH-C-OH
guanidyl moiety Peptide
E. coli thioredoxin was one of the initial larger test proteins selected due to its
commercial availability and more importantly, because it contained only one disulfide
bond. Despite the unique reactivity of the thioredoxin cysteines (thioredoxin is a potent
protein disulfide reductasel 85,186), the protein resisted cyanylation under non-denaturing
conditions even after incubation with cyanide and 4-vinylpyridine for 24 hours at 60 oC.
This lack of reactivity in the absence of a denaturant was a consistent result for all of the
proteins tested. Urea, although an excellent denaturant, was found to carbamylate primary
amino groups very easily and was therefore not used. Heat, non-aqueous solvents, and
guanidine thiocyanate were also evaluated as potential denaturation agents, however,
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guanidine hydrochloride (2 M) proved to be the best overall reagent for this purpose.
Although some guanidylination products were observed, these occurred primarily with N-
terminal peptides of proteins and could be readily identified by the presence of the (M+H)+
+ 42 ion as already discussed above. An added benefit of using a denaturant such as
guanidine hydrochloride was its ability to solubilize proteins that ordinarily have poor
solubility in alkaline solution.
The primary sequence of E. coli thioredoxin'8 7 and the overlapping peptides
expected from a cyanide/4-vinylpyridine digest of this protein are illustrated in Figure VI.8.
As in Figure VI.7, the dots symbolize N-terminal iminothiazolidine groups and "S-EP"
denotes an S-ethylpyridylated cysteine. Figures VI.9A and VI.9B are MALDI-TOF mass
spectra of E. coli thioredoxin reaction mixtures after 1 hour at 60 OC containing a 10-fold
and 100-fold molar excess of 4-vinylpyridine, respectively. Both solutions are otherwise
identical, each containing 2 M guanidine hydrochloride and a 1000-fold molar excess of
cyanide ion at pH 8.5. Figure VI.9A is dominated by the singly and doubly charged peaks,
(M+H)+ at m/z 11,674 and (M+2H)"+ at m/z 5838, respectively, due to the native, unreacted
E. coli thioredoxin. In addition, the most prominent peaks are at m/z 3538 and 7925 which
correspond to the (M+H) + ions of peptides 1-31 and 35-108, respectively. However, at the
larger excess of 4-vinylpyridine, the reaction is more complete (Figure VI.9B). The ions at
m/z 3539 and 7925 are now abundant and there are additional peaks at m/z 3900 and 8288
which correspond to the (M+H)÷ ions of the overlapping peptides 1-34 and 32-108 as
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predicted in Figure VI.8. An artifact of this reaction with thioredoxin is the unspecific
cleavage of the protein between residues 33 and 34 giving rise to peptides marked with the
asterisks in Figure VI.9B at m/z 3426 and 8102 ((M+H)+ ions for peptides 1-33 and 34-108,
respectively). The unexpected formation of these peptides probably is due to the unusually
close proximity of the two cysteines (positions 32 and 35) in the primary structure and the
unique characteristics of that disulfide bond.' 86 The extent of this cleavage of a specific
bond not involving cysteine has not been found in similar experiments with other proteins
and peptides. On the other hand, in analogy with the aprotinin experiment, neither of the C-
terminal peptides generated from thioredoxin exhibited an (M+H)* - 18 ion. Conversely,
such dehydration products were detected for both the 1-31 and 1-34 peptides. No
dehydroalanine or lanthionine containing peptides were observed with thioredoxin. Finally,
repeating the same experiment with more 4-vinylpyridine (103-fold molar excess) did not
increase the rate of reaction and served only to complicate the mass spectrum by
introducing additional nonspecific ethylpyridylation adducts.
Catsimpoulas and Wood, who were among the first to investigate protein cleavage
with cyanide proposed that formation of iminothiazolidine increases with proton
concentration.'68 On the basis of their experiments with glutathione, they suggested that the
cyanylation reaction be performed with cyanide in the pH range 6-8 to increase the rate of
S-cyanylation and to retard the formation of p-elimination products. The conclusion that
lower pH favors S-cyanylation is surprising since one would expect a priori that the
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reaction rate should be slower because hydrogen cyanide is a poorer nucleophile than
cyanide ion. Catsimpoulas and Wood also hypothesized that thiocyanoalanine forms a
stable cyclic iminothiazolidine intermediate in this pH range without concomitant peptide
bond cleavage. Jacobson et al., however, were unable to detect an internal (i.e., uncleaved)
cyclic iminothiazolidine intermediate after S-cyanylation' 76 . Their conclusion was that
iminothiazolidine formation and peptide bond cleavage is a concerted process that is
catalyzed by hydroxide ion as shown below:
O
H H
N_~C
S
o\ H2 o HN S
-C-NH ----CH -C- -C
.OH HN---- C-
('OH
Both E. coli thioredoxin and ribonuclease A were reacted with cyanide and 4-
vinylpyridine at different pH values (6.5, 7.5, 8.5, and 9.5) to investigate the effect of pH on
the generation of overlapping peptides. For thioredoxin, all of the pH values resulted in the
production of the expected peptides (Figure VI.8), however, the reaction rate was much
slower at the lower pH values (6.5 and 7.5) with the majority of the thioredoxin still
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uncleaved after long incubation times at elevated temperatures. The effect of pH was more
noticeable with bovine ribonuclease A, a protein containing four disulfide bonds.'"8 Figure
VI. 10 compares the MALDI-TOF mass spectra of ribonuclease A digested with cyanide and
4-vinylpyridine at pH 6.5 (Figure VI. 10A) and pH 8.5 (Figure VI. 10B) after two hours at
60 'C. In each spectrum, the numbered peaks represent expected cleavage products and
correspond to the peptide labels column in Table VI.2. (Table VI.2 is a compilation of the
mass spectrometric data from cleavage of ribonuclease A at pH 8.5). The peptides listed in
Table VI.2 are also graphically represented in Figure VI. 11 to emphasize the overlapping
sequences produced. Similar to thioredoxin, the rate of the ribonuclease digest increased
with increasing pH. However, with ribonuclease A, eight of the nineteen peptides detected
at pH 8.5 were not observed when the identical reaction was performed at pH 6.5.
Although three contaminant or non-specific cleavage peaks (marked by asterisks) in Figure
VI. 10A are relatively easily ionized at pH 6.5 they are barely detectable at pH 8.5 (Figure
VI. 10B). This observation can be attributed to the higher product peptide concentration at
pH 8.5. Since more of the protein is digested at pH 8.5, the product peptide concentration is
also increased. A distinguishing feature of the mass spectrum in Figure VI. 10A is the
presence of the peaks with a mass difference of -80 mass units as denoted by the arrows.
Similar to the ones containing dehydroalanine, these peptides do not arise from the
fragmentation of the S-ethylpyridylated peptide but are related by having the same amino
acid sequence. At pH 6.5, (M+H) ÷ - 80 ions are observed that correspond to peptides with
an internal S-cyanylated rather than S-ethylpyridylated cysteine. Two of the fully S-
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ethylpyridylated peptides, at m/z 4736.4 and m/z 3407.9, were accompanied by
corresponding (M+H) ÷ - 80 ions as indicated by the arrows in Figure VI. 10A.
SN CH2  N = C
CH2  CH1
SCH - C
S-ethylpyridylated peptide (M+H) - 80
(M+H)+
Again, the arrows represent a cleavage product that is 80 Da lighter than the expected S-
ethylpyridylated peptide and are not meant to imply mass spectrometric fragmentation. The
p -elimination of thiocyanoalanine was successfully prevented at pH 6.5 since no (M+H)+ -
139 ions indicating dehydroalanine formation were detected. Despite the fact that
dehydroalanine formation was suppressed, there is no advantage to performing the reaction
at this lower pH since the reaction seems to be quite incomplete. Furthermore, the (M+H)+
ions due to the fully S-ethylpyridylated peptides were much more abundant in the mass
spectrum of the pH 8.5 reaction mixture. There were no (M+H)+ - 80 ions detected at pH
8.5 and the dehydroalanine products, although present, produced weak signals in
comparison to the S-ethylpyridylated peptide ions. The MALDI mass spectrum of the
ribonuclease A reaction at pH 9.5 was almost identical to the one at pH 8.5. Consequently,
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raising the pH to 9.5 was not particularly helpful since no additional peptides were observed
(data not shown). Furthermore, undesirable dehydroalanine formation was enhanced at pH
9.5 and the intensity of signals due to lanthionine containing peptides increased
significantly.
In summary, optimal conditions for cleavage and generation of overlapping peptides
were achieved by using a 103-fold molar excess of cyanide (NaCN), 102-fold molar excess
of 4-vinylpyridine, guanidine hydrochloride (2 M), 100 mM Tris-HCI at pH 8.5 and 60 'C
for 2-4 hours. For all proteins and peptides tested, the pH range between 8-9 was the best
compromise in that the reaction was rapid and produced easily identifiable products.
Lysozyme (from hen egg white)' 89 and trypsinogen (from bovine pancreas)' 90 were also
cleaved using the cyanide/4-vinylpyridine methodology. The data for the lysozyme
cleavage is tabulated in Table VI.3 and graphically represented in Figure VI.12. Similarly,
the data due to trypsinogen cleavage is shown in Table VI.4 and Figure VI. 13. In both
cases, peptides with overlapping sequences were successfully generated as illustrated by
Figures VI. 12 and VI. 13.
As mentioned at the beginning of this section, systematic experiments were also
performed with disulfide bond containing peptides including oxytocin, brain natriuretic
peptide, somatostatin, melanin concentrating hormone and urotensin II to provide simpler
models. Overlapping peptides were successfully generated for each of these peptides using
185
Table VI.3. Peptides resulting from the digestion of lysozyme with NaCN and 4-
vinylpyridine at pH 8.5 for 2 hours.
Pept.a Pos.b Sequencec
1 1-29 () KVFGRCELAAAMKRHGLDNYRGYSLGNWV (C)
(2 1-63 )KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKF-
ESNFNTQATNRNTDGSTDYGILQINSRWW (C)
3 6-29 (R) CELAAAMKRHGLDNYRGYSLGNWV (C)
4 6-63 (R) CELAAAMKRHGLDNYRGYSLGNWVCAAKF-
ESNFNTQATNRNTDGSTDYGILQINSRWW (C)
5 30-63 (R) CAAKFESNFNTQATNRNTDGSTDYGILQINSRWW (C)
6 64-75 (W) CNDGRTPGSRNL (C)
7 64-79 (W) CNDGRTPGSRNLCNIP (C)
8 64-93 (W) CNDGRTPGSRNLCNIPCSALLSSDITASVN (C)
9 76-93 (L) CNIPCSALLSSDITASVN (C)
10 76-114 (L) CNIPCSALLSSDITASVNCAKKIVSDGDGMNAWVAWRNR (C)
(P) CSALLSSDITASVNCAKKIVSDGDGMNAWVAWRNRCKGT-
DVQAWIRGCRL ()
12 94-114 (N) CAKKIVSDGDGMNAWVAWRNR (C)
13 94-126 (N) CAKKIVSDGDGMNAWVAWRNRCKGTDVQAWIRG (C)
14 94-129 (N) CAKKIVSDGDGMNAWVAWRNRCKGTDVQAWIRGCRL ()
15 115-126 (R) CKGTDVQAWIRG (C)
16 115-129 (R) CKGTDVQAWIRGCRL ()
aPeptide annotations from Figure VI.12.
bThe position of the peptide in the amino acid sequence of lysozyme.
cN-terminal cysteines are cyclized iminothiazolidine groups. Internal cysteines (in bold)
are S-ethylpyridylated. Amino acids in parentheses before and after the peptide sequence
correspond to the preceding and following amino acids, respectively.
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Table VI.4. Peptides resulting from the digestion of trypsinogen with NaCN and 4-
vinylpyridine at pH 8.5 for 2 hours.
Pept." Pos.b Sequencec
1 1-30 () VDDDDKIVGGYTCGANTVPYQVSLNSGYHF (C)
2 1-46 () VDDDDKIVGGYTCGAVT...YHFCGGSLINSQWVVSAAH (C)
3 13-30 (T) CGANTVPYQVSLNSGYHF (C)
4 13-46 (T) CGANTVPYQVSLNSGYHFCGGSLINSQWVVSAAH (C)
5 47-114 (H) CYKSGIQVRLGQ...ASLNSRVASISLPTS (C)
6 47-121 (H) CYKSGIQVRLGQ...ASLNSRVASISLPTSCASAGTQ (C)
7 115-142 (S) CASAGTQCLISGWGNTKSSGTSYPDVLK (C)
8 115-153 (S) CASAGTQCLISGWGNTKSSGTSYPDVLKCLKAPILSNSS (C)
9 122-142 (Q) CLISGWGNTKSSGTSYPDVLK (C)
10 143-167 (K) CLKAPILSNSSCKSAYPGQITSNMF (C)
11 143-178 (K) CLKAPILSNSSCKSAYPGQITSNMFCQGDSGGPVV (C)
12 154-167 (S) CKSAYPGQITSNMF (C)
13 154-178 (S) CKSAYPGQITSNMFCQGDSGGPVV (C)
14 179-202 (S) CQGDSGGPVVCSGKLQGIVSWGSG (C)
15 179-229 (S) CQGDSGGPVVCSGKLQGIVSWGSGCAQKNKPGVYTKV (C)
16 203-229 (G) CAQKNKPGVYTKVCNYVSWIKQTIASN ()
17 216-229 (V) CNYVSWIKQTIASN ()
apeptide annotations from Figure VI. 13.
bThe position of the peptide in the amino acid sequence of trypsinogen.
cN-terminal cysteines are cyclized iminothiazolidine groups. Internal cysteines (in bold)
are S-ethylpyridylated. Amino acids in parentheses before and after the peptide sequence
correspond to the preceding and following amino acids, respectively.
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the reaction conditions outlined in the preceding paragraph. For example, urotensin II has
the sequence AGTADCFWKYCV with a disulfide bond between Cys-5 and Cys-11.191
Although purification of the reaction mixture is not necessary for MALDI-TOF-MS (Figure
VI. 14A), an HPLC fractionation (Figure VI.14B) was performed to obtain an independent
quantitative estimate of the products. The peptides in each HPLC fraction were identified
by MALDI-TOF-MS and the data is summarized in Table VI.5. Four major HPLC peaks
were observed corresponding to fractions 1, 2, 4, and 5. The three fractions containing the
peaks with the highest absorbance, fractions 2, 4, and 5, corresponded to the expected
cleavage products with overlapping sequences. Unexpectedly, the fraction representing the
fourth largest HPLC peak (fraction 1) contained a peptide due to non-specific cleavage.
PSD mass spectra of the major products were obtained to confirm the assigned sequences in
Table VI.5. The PSD mass spectra of urotensin II peptides m/z 1267 [(M+H)÷] and m/z
1249 [(M+H) ÷ - H20] are shown in Figures VI. 15A and VI. 15B, respectively. The
nomenclature for the peptide fragmentation observed in PSD spectra has already been
discussed in detail in Section 11.3. The sequence of the peptide (M+H) ÷ = m/z 1267,
(AGTADCFWKY; Cys is S-ethylpyridylated) was confirmed by the nearly complete N-
terminal b ion series in Figure VI. 15A. The lower mass region contains expected
immonium ions denoted by the capital letter abbreviations for specific amino acids ("VP"
denotes the ion due to vinylpyridine). At slightly higher mass range, there are numerous
peaks (mostly left unlabeled for clarity) due to internal fragment ions that provide further
evidence for the assigned sequence. Finally, loss of ethylpyridine from the precursor ion is
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Table VI.5. HPLC fractionated peptides resulting from digestion of urotensin II with NaCN
and 4-vinylpyridine after 2 hours.a
HPLC .. Observed Calculated
Position SequenceFraction m/z m/z
1 1-11 1370.6 1370.6 ()AGTADCFWKYC (V)
2 1-10 1267.3 1267.5 () AGTADCFWKY (C)
3 6-10 771.7 771.9 (D) CFWKY (C)
4 1-12 1574.9 1574.9 () AGTADCFWKYCV()
5 6-12 1079.2 1079.3 (D) CFWKYCV ()
6 1-10 1249.4 1249.4 ()AGTADCFWKY (C) - H20
()AGTADCFWKYCV ()7 1-12 1435.6 1435.7 AGTADCFWKYCV() AGTADCFWKYCV()
8 1-10 1309.3 1309.5 () guanidyl.- AGTADCFWKY (C)
aThe amino acids in parentheses before and after the peptide sequences denote the
preceding and following amino acids, respectively. N-terminal cysteines are cyclized
iminothiazolidine groups. Underlined cysteines (fraction 7) correspond to the dehydroalanine
product while cysteines in bold are S-ethylpyridylated. Fractions 6 and 7 contain the dehydration
and guanidylated products, respectively.
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indicated by the "-EP". Most of the fragment ions in the PSD mass spectrum of the
dehydration product (Figure VI.15B) are the same as those of the normal peptide [i.e.,
(M+H)+ = m/z 1267] in Figure VI. 15A. However, the mass spectrum of the dehydration
product differs notably from that of the normal peptide in the large increase in the number
of internal fragment ions throughout the mass spectrum. Since the loss of H20 must occur
N-terminal to the peptide backbone cleavage (no dehydration products are observed
corresponding to peptides that contain the original C-terminus), a possible mechanism for
the formation of the dehydration product (M+H)4 = m/z 1249.5 is shown below:
OH
NH 2  N-C
(CH2) 4 O CH 2 O CH2 O
I II .. II
(AGTADCFW) -NH-CH-C-NH-CH-C-NH-CH-C-- (V)
H2N--(CH2)4  0
HN S(AGTADCFW) -N NN
/ CH2  OH HN- (V)
m/z 1249.5
The yn -18 ions (which are not usually observed in PSD spectra), a and b ions, and the
absence of the y2 ion together provide supporting evidence for the structure of the
dehydration product shown above.
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Finally, a discussion of this reaction is not complete without pointing out that the
sequence of shorter peptides containing N-terminal iminothiazolidine groups (such as those
derived from disulfide bond containing peptides) can be easily verified by obtaining a PSD
mass spectrum of the peptide. For example, the PSD mass spectrum of the urotensin II
peptide (M+H) ÷ = m/z 1079.3 (shown in Figure VI.16) confirms the sequence CFWKYCV
where Cys-l is the N-terminally blocked iminothiazolidine and Cys-6 is S-ethylpyridylated.
In contrast to the peptides in Figure VI. 15, the presence of the b, ion provides further
confirmation for the N-terminal iminothiazolidine group since peptides with a free N-
terminus generally do not produce b, ions.' 22 Furthermore, the sensitivity of the PSD
technique is illustrated by the fact that only approximately one picomole of peptide was
used to obtain the complete spectrum.
VI.6 Conclusion
Specific cleavage of proteins at cysteine via S-cyanylation is certainly not a new
reaction and has been studied since at least the early 1960's. As already mentioned in
Section VI.2, it failed to gain much use principally due to the production of N-terminally
blocked peptides that were not directly amenable to sequencing by Edman degradation. A
renewed interest in this reaction was sparked by the demonstration that the
iminothiazolidine N-terminally blocked peptides could easily be sequenced by mass
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spectrometry. '980." 8 On the other hand, the potential of the nucleophilic cyanide reaction to
produce peptides with overlapping sequences and thus identify native disulfide bond
linkages was never fully realized. This failure was attributed to the tendency of free
sulfhydryl groups to react with original disulfide bonds to form new disulfide bonds. 192 The
problem was exacerbated by the similar reaction of free sulfhydryls reacting with
cyanylated cysteines to release cyanide with consequent disulfide bond rearrangement.
Therefore, the next logical step was to attempt to block these unfavorable reactions.
Sequencing methods generally require at least two separate protein cleavage
experiments utilizing enzymes or chemical cleavage agents with different specificities in
order to obtain overlapping sequence information which then allows proper alignment of
the peptides. The reaction of cyanide with proteins is unique in that in that it can take place
in two different directions. Thus, for each disulfide bond, at least two different peptides can
be formed each overlapping with each other. The addition of 4-vinylpyridine as an S-
alkylation agent proved to be successful in blocking free sulfhydryl groups and preserving
peptides with overlapping sequences. As predicted, addition of the S-alkylation agent
served to shift the equilibrium of the reaction of the reaction toward products reducing the
reaction time and lowering the amount of cyanide required. The cyanide/4-vinylpyridine
reaction, despite being a chemical cleavage method, rivals some enzymatic methods in its
specificity. Although side reactions do occur, the products are easily identifiable and can
actually be informative. Dehydroalanine formation by p-elimination of thiocyanate is never
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the main product and is identified by its mass deficiency of 139 mass units as compared to
the fully S-ethylpyridylated product. Lanthionine containing product ions arising from the
expulsion of thiocyanate by a sulfide ion (see page 172) without formation of
dehydroalanine are considerably rarer and are observed only with larger peptides containing
multiple internal cysteines. Finally, dehydration products are fortuitously informative since
it has been observed that they only occur when the peptide does not contain the original C-
terminus of the original protein.
Earlier workers often had to rely on indirect methods such as calorimetry,
colorimetry, or amino acid analysis to establish and quantitate the components of the
cyanide/protein reaction mixtures. MALDI-TOF-MS with its tolerance for contaminants
such as buffers and salts and low detection limits (in the low picomole to femtomole range)
is especially well suited to the analysis of unpurified reaction mixtures containing proteins
and larger peptides. Since cysteines are generally not particularly abundant in proteins, the
peptides generated tend to be fewer and larger making cyanide digestion an ideal
application for MALDI-TOF-MS analysis. The low sample requirement due to the
sensitivity of MALDI coupled with the simplicity and rapidity of the cyanide/4-
vinylpyridine experiment makes this an easy experiment to perform without sacrificing
precious material. For example, it can provide a quick method for sequence confirmation of
proteins containing disulfide bonds. With unknowns, the newly emerging technique of
post-source-decay (PSD) is especially promising since sequence information can routinely
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be obtained from just a few picomoles of peptide although the use of this method, in this
case, is probably limited to the smaller peptides.
In conclusion, since overlapping peptides are generated by this method and MALDI-
TOF-MS provides accurate mass measurement of the peptides, it should be possible, in
principle, to align the peptides in their proper order (preferably using a computer program)
without any prior knowledge of the amino acid sequence.
199
Section VII
References
1. Biemann, K. "Amino Acid Sequence in Oligopeptides" In Biochemical Applications
of Mass Spectrometry, Waller, G.R. Ed., John Wiley & Sons, New York, (1972),
405-428; Biemann, K. "Amino Acid Sequence in Oligopeptides and Proteins" In
Biochemical Applications of Mass Spectrometry (first supplementary volume),
Waller, G.R., Dermer, O.C. Eds., John Wiley & Sons, New York, (1980), 469-525.
2. Carr, S.A., Herlihy, W.C., and Biemann, K. "Advances in Gas Chromatographic
Mass Spectrometric Protein Sequencing. 1. Optimization of the Derivitization
Chemistry" (1981) Biomed. Mass Spectrom. 8, 51-61.
3. Carr, S.A., Herlihy, W.C., and Biemann, K. "Advances in Gas Chromatographic
Mass Spectrometric Protein Sequencing. 2. Applications to Membrane Proteins"
(1981) Biomed. Mass Spectrom. 8, 62-69.
4. Rose, K., Bairoch, A., and Offord, R.E. "Amino Acid Sequence Determination by
Gas Chromatography-Mass Spectrometry of Permethylated Peptides" (1983) J.
Chrom. 268, 197-206.
5. Torgerson, D.F., Skowronski, R.P., and Macfarlane, R.D. "New Approach to the
Mass Spectrometry of Non-Volatile Compounds" (1974) Biochem. Biophys. Res.
Commun. 60, 616-621.
6. Winkler, H.U. and Beckey, H.D. "Field Desorption Mass Spectrometry of Peptides"
(1972) Biochem. Biophys. Res. Commun. 46, 391-398.
7. Barber, M., Bordoli, R.S., Sedgwick, R.D., and Tyler, A.N. "Fast Atom
Bombardment of Solids (F.A.B.): A New Ion Source for Mass Spectrometry" (1981)
J Chem. Soc. Chem. Comm. 7, 325-327.
8. Barber, M., Bordoli, R.S., Elliot, G.J., Sedgwick, R.D., Tyler, A.N., and Green,
B.N. "Fast Atom Bombardment Mass Spectrometry of Bovine Insulin and Other
Large Peptides" (1982) J. Chem. Soc. Chem. Comm. 8, 936-938.
9. Barber, M., Bordoli, R.S., Elliot, G.J., Tyler, A.N., Bill, J.C., and Green, B.N. "Fast
Atom Bombardment (FAB) Mass Spectrometry: A Mass Spectral Investigation of
Some of the Insulins" (1984) Biomed. Mass Spectrom. 11, 182-186.
200
10. Gibson, B.W. and Biemann, K. "Strategy for the Mass Spectrometric Verification
and Correction of the Primary Structure of Proteins Deduced from their DNA
Sequences" (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 1956-1960.
11. Bateman, A., Dell, A., and Morris, H. "Fast Atom Bombardment Mass
Spectrometry of Large Peptides" (1985) J Appl. Biochem. 7, 126-132.
12. Yamashita, M. and Fenn, J.B. "Electrospray Ion Source. Another Variation on the
Free-Jet Theme" (1984) J. Phys. Chem. 88, 4451-4459.
13. Meng, C.K., Mann, M., and Fenn, J.B. "Of Protons or Proteins" (1988) Z. Phys. D.
10, 361-368.
14. Fenn, J.B., Mann, M., Meng, C.K., Wong, S.F., and Whitehouse, C.M.
"Electrospray Ionization for Mass Spectrometry of Large Biomolecules" (1989)
Science. 246, 64-71.
15. Meng, C.K., McEwan, C.N., and Larsen, B.S. "Electrospray Ionization on a
High-Performance Magnetic Sector Mass Spectrometer" (1990) Rapid Commun.
Mass Spectrom. 4, 147-150.
16. Meng, C.K., McEwan, C.N., and Larsen, B.S. "Peptide Sequencing with
Electrospray Ionization on a Magnetic Mass Spectrometer" (1990) Rapid Commun.
Mass Spectrom. 4, 151-155.
17. Gallagher, R.T., Chapman, J.R., and Mann, M. "Design and Performance of an
Electrospray Ionization Source for a Doubly-focusing Magnetic Sector Mass
Spectrometer" (1990) Rapid Commun. Mass Spectrom. 4, 369-372.
18. Loo, J.A., Ogarzalek Loo, R.R., and Andrews, P.C. "Primary to Quaternary Protein
Structure Determination with Electrospray Ionization and Magnetic Sector Mass
Spectrometry" (1993) Org. Mass Spectrom. 28, 1640-1649.
19. Karas, M., Bachmann, D., Bahr, U., and Hillenkamp, F. "Matrix-Assisted
Ultraviolet Laser Desorption of Non-Volatile Compounds" (1987) Int. J. Mass
Spectrom. Ion. Proc. 78, 53-68.
20. Morris, H.R., Panico, M., and Haskins, N.J. "Comparison of Ionization Gases in
FAB Mass Spectra" (1983) Int. J. Mass Spectrom. Ion. Proc. 46, 363-366.
21. Aberth, W., Straub, K.M., and Burlingame, A.L. "Secondary Ion Mass Spectrometry
with Cesium Ion Primary Beam and Liquid Target Matrix of Bioorganic
201
Compounds" (1982) Anal. Chem. 54, 2029-2034.
22. Falick, A.M., Wang, G.H., and Walls, F.C. "Ion Source for Liquid Matrix
Secondary Ionization Mass Spectrometry" (1986) Anal. Chem. 58, 1308-1311.
23. Perel, J. "Fast Atom Bombardment Mass Spectrometric Techniques and Ion Guns"
(1985) ACS Symp. Ser. 291 (Desorption Mass Spectrom.), 125-144.
24. Martin, S.A. Ph.D. Dissertation, M.I.T. Cambridge, MA, 1984.
25. Gower, J.L. "Matrix Compounds for Fast Atom Bombardment Mass Spectrometry"
(1985) Biomed Mass Spectrom. 12, 191-196.
26. De Pauw, E. "Liquid Matrices for Secondary Ion Mass Spectrometry" (1986) Mass
Spectrom. Rev. 5, 191-212.
27. Cook, K.D., Todd, P.J., and Friar, D.H. "Physical Properties of Matrices Used for
Fast Atom Bombardment" (1989) Biomed. Env. Mass. Spec. 18, 492-497.
28. Witten, J.L., Schaffer, M.H., O'Shea, M., Cook, J.C., Hemling, M.E., and Rhinehart,
K.L. "Structures of Two Cockroach Neuropeptides Assigned by Fast Atom
Bombardment Mass Spectrometry" (1984) Biochem. Biophys. Res. Commun. 124,
350-358.
29. Naylor, S., Findeis, A.F., Gibson, B., and Williams, D.H. "An Approach Toward the
Complete FAB Analysis of Enzymic Digests of Peptides and Proteins" (1986) J.
Amer. Chem. Soc. 108, 6359-6363.
30. Conzemius, R.J. and Capellan, J.M. "A Review of the Applications to Solids of the
Laser Ion Source in Mass Spectrometry" (1980) J. Org. Chem. 34, 197-271.
31. Denoyer, E., Van Grieken, R., Adams, F., and Natusch, D.F.S. "Laser Microprobe
Mass Spectrometry. 1. Basic Principles and Performance Characteristics" (1982)
Anal. Chem. 54, 26A-41A.
32. Hercules, D.M., Day, R.J., Balasanmugan, K., Dang, T.A., and Li, C.P. "Laser
Microprobe Mass Spectrometry. 2. Applications to Structural Analysis" (1982)
Anal. Chem. 54, 280A-305A.
33. Posthumus, M.A., Kistemaker, P.G., Meuzelar, H.L.C., and ten Neuver de Braouw,
M.C. "Laser Desorption-Mass Spectrometry of Polar Non-Volatile Bio-Organic
Molecules" (1978) Anal. Chem. 50, 985-991.
202
34. Cotter, R.J. "Laser Desorption Chemical Ionization Mass Spectrometry" (1980)
Anal. Chem. 52, 1767-1770.
35. Hillenkamp, F., Karas, M., Beavis, R.C., and Chait, B.T. "Matrix-Assisted Laser
Desorption/Ionization Mass Spectrometry of Biopolymers" (1991) Anal. Chem. 63,
1193A-1202A.
36. Karas, M. and Hillenkamp, F. "Laser Desorption Ionization of Proteins with
Molecular Masses Exceeding 10,000 Daltons" (1988) Anal. Chem. 60, 2299-2301.
37. Guilhaus, M. "Principles and Instrumentation in Time-of-Flight Mass Spectrometry.
Physical and Instrumental Concepts" (1995) J. Mass Spectrom. 30, 1519-1532.
38. Spengler, B., Kirsch, D., Kaufmann, R., Karas, M., Hillenkamp, F., and Giessmann,
U. "The Detection of Large Molecules in Matrix-Assisted UV-Laser Desorption"
(1990) Rapid Commun. Mass Spectrom. 4, 301-305.
39. Bahr, U., Karas, M., and Hillenkamp, F. "Analysis of Biopolymers by
Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry" (1994)
Fresenius J. Anal. Chem. 348, 783-791.
40. Karas, M., Bahr, U., and Giesmann, U. "Matrix-Assisted Laser Desorption
Ionization Mass Spectrometry" (1992) Mass Spectrom. Rev. 10, 335-357.
41. Strupat, K., Karas, M., and Hillenkamp, F. "2,5-Dihydroxybenzoic Acid: A New
Matrix for Laser Desorption-Ionization Mass Spectrometry" (1991) Int. J. Mass
Spectrom. Ion. Proc. 111, 89-102.
42. Wu, K.J., Steding, A., and Becker, C.H. "Matrix-Assisted Laser Desorption
Time-of-Flight Mass Spectrometry of Oligonucleotides Using 3-Hydroxypicolinic
Acid as an Ultraviolet-Sensitive Matrix" (1993) Rapid. Commun. Mass. Spectrom.
7, 142-146.
43. Beavis, R.C. and Chait, B.T. "Cinnamic Acid Derivatives as Matrices for Ultraviolet
Laser Desorption of Proteins" (1989) Rapid Commun. Mass Spectrom. 3, 432-435.
44. Beavis, R.C. and Chait, B.T. "a-Cyano-4-hydroxycinnamic Acid as a Matrix for
Matrix Assisted Laser Desorption Mass Spectrometry" (1992) Org. Mass Spectrom.
27, 156-158.
45. Doktycz, S.J., Savickas, P.J., and Krueger, D.A. "Matrix/Sample Interactions in
Ultraviolet Laser-Desorption of Proteins" (1991) Rapid Commun. Mass Spectrom. 5,
203
145-148.
46. Vorm, O., Roepstorff, P., and Mann, M. "Improved Resolution and Very High
Sensitivity in MALDI-TOF of Matrix Surfaces Made by Fast Evaporation" (1994)
Anal. Chem. 66, 3281-3287.
47. Vorm, 0. and Mann, M. "Improved Mass Accuracy in Matrix-Assisted Laser
Desorption/Ionization Time-of-Flight Mass Spectrometry of Peptides" (1994) J.
Amer. Soc. Mass. Spectrom. 5, 955-958.
48. Perera, I.K., Perkins, J., and Kantartzoglou, S. "Spin-Coated Samples for High
Resolution Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass
Spectrometry of Large Proteins" (1995) Rapid Commun. Mass Spectrom. 9,
180-187.
49. Kichling, H.J. and Biemann, K. "Novel Sample Preparation for MALDI" (1995)
Proc. 43th Amer. Soc. Mass. Spec. Conf , p. 1225.
50. Ehring, H., Karas, M., and Hillenkamp, F. "Role of Photoionization and
Photochemistry in Ionization Processes of Organic Molecules and Relevance for
Matrix-Assisted Laser Desorption Ionization Mass Spectrometry" (1992) Org. Mass
Spectrom. 27, 472-480.
51. Juhasz, P., Papayannopoulos, I.A., Zeng, C.-H., Papov, V., and Biemann, K. "The
Utility of Matrix-Assisted Laser Desorption for the Direct Analysis of Enzymatic
Digests of Proteins" (1992) Proc. 40th Amer. Soc. Mass. Spec. Conf , 1913-1914.
52. Beavis, R.C. and Chait, B.T. "Factors Affecting the Ultraviolet Absorption of
Proteins" (1989) Rapid Commun. Mass Spectrom. 3, 233-237.
53. Vertes, A., Irinyi, G., and Gijbels, R. "Hydrodynamic Model of Matrix-Assisted
Laser Desorption Mass Spectrometry" (1993) Anal. Chem. 65, 2389-2393.
54. Beavis, R.C. and Chait, B.T. "Velocity Distributions of Intact High Mass
Polypeptide Molecule Ions Produced by Matrix Assisted Laser Desorption" (1991)
Chem. Phys. Lett. 181, 479-484.
55. Spengler, B. and Bokelmann, V. "Angular and Time Resolved Intensity
Distributions of Laser-Desorbed Matrix Ions" (1993) Nucl. Instrum. Meth. Phys.
Res. B. 82, 379-385.
56. Zhou, J., Ens, W., Standing, K., and Verentchikov, A. "Kinetic Energy
204
Measurements of Molecular Ions Ejected into an Electric Field by Matrix Assisted
Laser Desorption" (1992) Rapid Commun. Mass Spectrom. 6, 671-678.
57. Beavis, R.C. and Chait, B.T. "Matrix-Assisted Laser Desorption Mass Spectrometry
Using 355 nm Radiation" (1989) Rapid Commun. Mass Spectrom. 3, 436-439.
58. Juhasz, P., Biller, J.E., Costello, C.E., Papayannopoulos, I.A., and Biemann, K.
"Evaluation of Factors Contributing to the Accuracy and Reliability of the Mass
Assignments in Matrix-Assisted Laser Desorption Mass Spectrometry" (1991) Proc.
39th Amer. Soc. Mass. Spec. Conf , 344-345.
59. Beavis, R.C. and Chait, B.T. "High-Accuracy Molecular Mass Determination of
Proteins Using Matrix-Assisted Laser Desorption Mass Spectrometry" (1990) Anal.
Chem. 62, 1836-1840.
60. Overberg, A., Karas, M., Bahr, U., Kaufmann, R., and Hillenkamp, F.
"Matrix-Assisted Infrared-Laser (2.94 lim) Desorption/Ionization Mass
Spectrometry of Large Biomolecules" (1990) Rapid Commun. Mass Spectrom. 4,
293-296.
61. Overberg, A., Karas, M., and Hillenkamp, F. "Matrix-Assisted Laser Desorption of
Large Biomolecules with a TEA-CO2-Laser" (1991) Rapid Commun. Mass
Spectrom. 5, 128-131.
62. Eckerskorn, C., Strupat, K., Karas, M., Hillenkamp, F., and Lottspeich, F. "Mass
Spectrometric Analysis of Blotted Proteins After Gel Electrophoretic Separation by
Matrix-Assisted Laser Desorption Ionization" (1992) Electrophoresis. 13, 664-665.
63. Strupat, K., Karas, M., Hillenkamp, F., Eckerskorn, C., and Lottspeich, F.
"Matrix-Assisted Laser Desorption Ionization Mass Spectrometry of Proteins
Electroblotted After Polyacrylamide Gel Electrophoresis" (1994) Anal. Chem. 66,
464-470.
64. Biemann, K. "Peptides and Proteins: Overview and Strategy" (1990) Meth. Enzym.
193, 351-360.
65. Allen, G. "Enzymic Cleavage of Denatured Polypeptides" In Sequencing of Proteins
and Peptides, Burdon, R.H., van Knippenberg, P.H. Eds., Elsevier, Amsterdam,
(1989), 82-95.
66. Allen, G. "Specific Cleavage of Proteins by Chemical Methods" In Sequencing of
Proteins and Peptides, Burdon, R.H., van Knippenberg, P.H. Eds., Elsevier,
205
Amsterdam, (1989), 95-104.
67. Sato, K., Asada, T., Ishihara, M. et al. "High Performance Tandem Mass
Spectrometry: Calibration and Performance of Linked Scans of a Four-Sector
Instrument" (1987) Anal. Chem. 59, 1652-1659.
68. "Tandem Mass Spectrometry" McLafferty, F.W. Ed., John Wiley & Sons, (1983).
69. Cooks, R.G. and Glish, G.L. "Mass Spectrometry / Mass Spectrometry" (1981)
Chem. Eng. News. 59, 40-52.
70. Matsuo, T., Matsuda, H., Katakuse, I. et al. "Field Desorption-Collisional Activation
Mass Spectrometry with Accumulated Linked-Scan Technique for Peptide Structure
Elucidation" (1981) Anal. Chem. 53, 416-421.
71. Biemann, K. "Mass Spectrometry of Peptides and Proteins" (1992) Annu. Rev.
Biochem. 61, 977-1010.
72. Biemann, K. "Sequencing of Peptides by Tandem Mass Spectrometry and
High-Energy Collision-Induced Dissociation" (1990) Meth. Enzym. 193, 455-479.
73. Hunt, D.F., Yates III, J.R., Shabanowitz, J., Winston, S., and Hauer, C.R. "Protein
Sequencing by Tandem Mass Spectrometry" (1986) Proc. Natl. Acad. Sci. U. S. A.
83, 6233-6237.
74. Johnson, R.S., Martin, S.A., Biemann, K., Stults, J.T., and Watson, J.T. "Novel
Fragmentation Process of Peptides by Collision-Induced Decomposition in a
Tandem Mass Spectrometer: Differentiation of Leucine and Isoleucine" (1987)
Anal. Chem. 59, 2621-2625.
75. Johnson, R.S., Martin, S.A., and Biemann, K. "Collision-Induced Fragmentation of
(M + H)+ Ions of Peptides. Side Chain Specific Sequence Ions" (1988) Int. J. Mass
Spectrom. Ion. Proc. 86, 137-154.
76. Downard, K.M. and Biemann, K. "Amino Acid Sequence Prerequisites for the
Formation of c, Ions" (1993) J. Amer. Soc. Mass. Spectrom. 4, 874-881.
77. Downard, K.M. and Biemann, K. "Methionine Specific Sequence Ions Formed by
the Dissociation of Protonated Peptides at High Collision Energies" (1995) J. Mass
Spectrom. 30, 25-32.
78. Chien, B.M., Michael, S.M., and Lubman, D.M. "Enhancement of Resolution in
206
Matrix-Assisted Laser Desorption Using an Ion-Trap Storage/Reflectron
Time-of-Flight Mass Spectrometer" (1993) Rapid Commun. Mass Spectrom. 7,
837-843.
79. Colby, S.'M., King, T.B., and Reilly, J.P. "Improving the Resolution of
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry by
Exploiting the Correlation between Ion Position and Velocity" (1994) Rapid
Commun. AMass Spectrom. 8, 865-868.
80. Whittal, R.M. and Li, L. "High Resolution Matrix-Assisted Laser
Desorption/lonization in a Linear Time-of-Flight Mass Spectrometer" (1995) Anal.
Chem. 67, 1950-1954.
81. Brown, R.S. and Lenon, J.J. "Mass Resolution Improvement by Incorporation of
Pulsed Ion Extraction in a Matrix-Assisted Laser Desorption/Ionization Linear
Time-of-Flight Mass Spectrometer" (1995) Anal. Chem. 67, 1998-2003.
82. Vestal, M.L., Juhasz, P., and Martin, S.A. "Delayed Extraction Matrix-Assisted
Laser Desorption Time-of-Flight Mass Spectrometry" (1995) Rapid Commun. Mass
Spectrom. 9, 1044-1050.
83. Spengler, B., Kirsch, D., and Kaufmann, R. "Metastable Decay of Peptides and
Proteins in Matrix-Assisted Laser-Desorption Mass Spectrometry" (1991) Rapid
Commun. Mass Spectrom. 5, 198-202.
84. Spengler, B., Kirsch, D., Kaufmann, R., and Jaeger, E. "Peptide Sequencing by
Matrix-Assisted Laser Desorption Mass Spectrometry" (1992) Rapid Commun.
Mass Spectrom. 6, 105-108.
85. Kaufmann, R., Kirsch, D., and Spengler, B. "Sequencing of Peptides in a
Time-of-Flight Mass Spectrometer: Evaluation of Postsource Decay Following
Matrix-Assisted Laser Desorption lonisation (MALDI)" (1994) Int. J. Mass
Spectrom.. Ion. Proc. 131, 355-385.
86. Rouse, J.C., Yu, W., and Martin, S.A. "A Comparison of the Peptide Fragmentation
Obtained from a Reflector Matrix-Assisted Laser Desorption-Ionization
Time-of-Flight and a Tandem Four Sector Mass Spectrometer" (1995) J. Amer. Soc.
Mass. Spectrom. 6, 822-835.
87. Biemann, K. "Appendix 5. Nomenclature for Peptide Fragment Ions (Positive Ions)"
(1993) Meth. Enzym. 193, 886-887.
207
88. Carr, S.A., Roberts, G., Annan, R.S., Hemling, M.E., and Hoyes, J. "Evaluation of
PSD-MALDI and CID-MALDI for Structural Analysis" (1995) Proc. 43th Amer.
Soc. Mass. Spec. Conf., p. 620.
89. Cordero, M.M., Cornish, T.J., and Cotter, R.J. "Sequencing Peptides: Post-Source
Decay MS Without Scanning the Reflectron" (1995) Proc. 43th Amer. Soc. Mass.
Spec. Conf , p. 619.
90. Hayashi, R., Moore, S., and Stein, W.H. "Carboxypeptidase from Yeast" (1973) J.
Biol. Chem. 248, 2296-2302.
91. Hayashi, R. "Carboxypeptidase Y in Sequence Determination of Peptides" (1977)
Meth. Enzym. 47, 84-93.
92. Bradley, C.V., Williams, D.H., and Hanley, M.R. "Peptide Sequencing Using the
Combination of Edman Degradation, Carboxypeptidase Digestion, and Fast Atom
Bombardment Mass Spectrometry" (1982) Biochem. Biophys. Res. Commun. 104,
1223-1230.
93. Ambler, R.P. "Carboxypeptidases A and B" (1972) Meth. Enzym. 25B, 262-271.
94. Schlir, M., Btrnsen, K.O., and Gassman, E. "Fast Protein Sequence Determination
with Matrix-Assisted Laser Desorption and Ionization Mass Spectrometry" (1991)
Rapid Commun. Mass Spectrom. 5, 319-326.
95. "Mammalian Proteases. A Glossary and Bibliography" McDonald, J.K. and Barrett,
A.J. Eds., Academic Press, (1986).
96. "Proteolytic Enzymes. A Practical Approach" Beynon, R.J. and Bond, J.S. Eds., IRL
Press, (1989).
97. Yokoyama, S., Miyabe, T., Oobayashi, A., Tanabe, 0., and Ichishima, E. "Effect of
Citric Acid on the Stabilization of Crystalline Acid Carboxypeptidase from
Penicilliumjanthinellum" (1981) Agric. Biol. Chem. 45, 311-312.
98. Pfleiderer, G. "Particle-Bound Aminopeptidase from Pig Kidney" (1970) Meth.
Enzym. 19, 514-521.
99. Light, A. "Leucine Aminopeptidase in Sequence Determination of Peptides" (1972)
Meth. Enzym. 25B, 253-261.
100. Stark, G.R. "Sequential Degradation of Peptides from Their Carboxyl Termini with
208
Ammonium Thiocyanate and Acetic Anhydride" (1968) Biochemistry. 7,
1796-1807.
101. Shively, J.E. and Bailey, J.M. "Carboxy-Terminal Sequencing: Formation and
Hydrolysis of C-Terminal Peptidylthiohydantoins" (1990) Biochemistry. 29,
3145-3156.
102. Boyd, V.L., Bozzini, M., Zon, G., Noble, R.L., and Mattaliano, R.J. "Sequencing of
Peptides and Proteins from the Carboxy Terminus" (1992) Analyt. Biochem. 206,
344-352.
103. Chait, B.T., Wang, R., Beavis, R.C., and Kent, S.B.H. "Protein Ladder Sequencing"
(1993) Science. 262, 89-92.
104. Bartlet-Jones, M., Jeffery, W.A., Hansen, H.F., and Pappin, D.J.C. "Peptide Ladder
Sequencing by Mass Spectrometry Using a Novel, Volatile Degradation Reagent"
(1994) Rapid Commun. Mass Spectrom. 8, 737-742.
105. Wang, R. and Chait, B.T. "Carboxyl-Terminal Ladder Sequencing of Peptides and
Proteins" (1995) Proc. 43th Amer. Soc. Mass. Spec. Conf , p. 921.
106. Mannervik, B., Carlberg, I., Larson, K. "Gluthathione: General Review of
Mechanism of Action" In Coenzymes and Cofactors, Vol III, Part A, Dolphin, D.,
Paulson, R., Amramovic, O. Eds., John Wiley and Sons, New York, (1989),
475-516.
107. Bushweller, J.H., Aslund, F., Wiithrich, K., and Holmgren, A. "Structural and
Functional Characterization of the Mutant Escherichia coli Glutaredoxin (C14 -> S)
and Its Mixed Disulfide with Glutathione" (1992) Biochemistry. 31, 9288-9293.
108. Holmgren, A. "Thioredoxin and Glutaredoxin Systems" (1989) J. Biol. Chem. 264,
13963-13966.
109. Holmgren, A. "Thioredoxin" (1985) Annu. Rev. Biochem. 54, 237-271.
110. Holmgren, A., Ohlsson, I., and Grankvist, M.-L. "Thioredoxin from Escherichia
coli" (1978) J. Biol. Chem. 253, 430-436.
111. Holmgren, A. "Hydrogen Donor System for Escherichia coli
Ribonucleoside-Diphosphate Reductase Dependent upon Glutathione" (1976) Proc.
Natl. Acad Sci. U. S. A. 73, 2275-2279.
209
112. Mark, D.F. and Richardson, C.C. "Eschrichia coli Thioredoxin: A Subunit of
Bacteriophage T7 DNA Polymerase" (1976) Proc. Natl. Acad. Sci. U. S. A. 73,
780-784.
113. Ziegler, D.M. "Role of Reversible Oxidation-Reduction of Enzyme
Thiols-Disulfides in Metabolic Regulation" (1985) Annu. Rev. Biochem. 54,
305-329.
114. Mieyal, J.J., Stark, D.W., Gravina, S.A., Dothey, C., and Chung, J.S.
"Thioltransferase in Human Red Blood Cells: Purification and Properties" (1991)
Biochemistry. 30, 6088-6097.
115. Makino, N. and Sugita, Y. "The Structure of Partially Oxygenated Hemoglobin. A
Highly Reactive Intermediate Toward a Sulfhydryl Titrant" (1982) J. Biol. Chem.
257, 163-168.
116. Craescu, C.T., Poyart, C., Schaeffer, C., Garel, M.C., Kister, J.C., and Beuzard, Y.
"Covalent Binding of Glutathione to Hemoglobin. II. Functional Consequences and
Structural Changes Reflected in NMR Spectra" (1986) J. Biol. Chem. 261,
14710-14716.
117. Valentine, W., Toohey, J., Paglia, D., Nakatani, M., and Brockway, A.
"Modification of Erythrocyte Enzyme Activities by Persulfides and Methanethiol:
Possible Regulatory Role" (1987) Proc. Natl. Acad Sci. U. S. A. 84, 1394-1398.
118. Mieyal, J.J., Stark, D.W., Gravina, S.A., Dothey, C., and Hocevar, B.A.
"Thioltransferase in Human Red Blood Cells: Kinetics and Equilibrium" (1991)
Biochemistry. 30, 8883-8891.
119. Terada, T., Oshida, T., Nishimura, M. et al. "Study on Human Erythrocyte
Thioltransferase: Comparative Characterization with Bovine Enzyme and Its
Physiological Role Under Oxidative Stress" (1992) J. Biochem. 111, 688-692.
120. Papayannopoulos, I.A., Gan, Z.-R., Wells, W.W., and Biemann, K. "A Revised
Sequence of Calf Thymus Glutaredoxin" (1989) Biochem. Biophys. Res. Commun.
159, 1448-1454.
121. Yang, Y., Gan, Z.-R., and Wells, W.W. "Cloning and Sequencing the cDNA
Encoding Pig Liver Thioltransferase" (1989) Gene Amst. 83, 339-346.
122. Hopper, S., Johnson, R.S., Vath, J.E., and Biemann, K. "Glutaredoxin from Rabbit
Bone Marrow" (1989) J Biol. Chem. 264, 20438-20447.
210
123. Biemann, K. "Contributions of Mass Spectrometry to Peptide and Protein Structure"
(1988) Biomed. Env. Mass. Spec. 16, 99-111.
124. Rtigg, U.T. and Rudinger, J. "Reductive Cleavage of Cystine Disulfides with
Tributylphosphine" (1977) Meth. Enzym. 47, 111-116.
125. Johnson, R.S. and Biemann, K. "The Primary Structure of Thioredoxin from
Chromatium vinosum Determined by High-Performance Tandem Mass
Spectrometry" (1987) Biochemistry. 26, 1209-1214.
126. Papov, V.V., Gravina, S.A., Mieyal, J.J., and Biemann, K. "The Primary Structure
and Properties of Thioltransferase (Glutaredoxin) from Human Red Blood Cells"
(1994) Protein Sci. 3, 428-434.
127. Padilla, C.A., Martinez-Galisteo, E., Barc6na, J.A., Spyrou, G., and Holmgren, A.
"Purification from Placenta, Amino Acid Sequence, Structure Comparisons, and
cDNA Cloning of Human Glutaredoxin" (1995) Eur. J. Biochem. 227, 27-34.
128. Fernando, M.R., Sumimoto, H., Nanri, H. et al. "Cloning and Sequencing of the
cDNA Encoding Human Glutaredoxin" (1995) Biochim. Biophys. Acta. 1218,
229-231.
129. Baldwin, M.A., Falick, A.M., Gibson, B.W., Prusiner, S.B., Stahl, N., and
Burlingame, A.L. "Tandem Mass Spectrometry of Peptides with N-terminal
Glutamine - Studies on a Prion Protein Peptide" (1990) J Amer. Soc. Mass.
Spectrom. 1, 258-264.
130. Larson, K., Eriksson, V., and Mannervik, B. "Thioltransferase from Human
Placenta" (1985) Meth. Enzym. 113, 520-524.
131. Mann, M. Personal Communication. (1993).
132. Wollman, E.E., d'Auriol, L., Rimsky, L. et al. "Cloning and Expression of a cDNA
for Human Thioredoxin" (1988) J. Biol. Chem. 263, 15506-15512.
133. Benedict, C.V. and Waite, J.H. "Composition and Ultrastructure of the byssus of
Mytilus edulis" (1986) J. Morphol. 189, 261-270.
134. Diamond, T.V. Master's Thesis, University of Delaware, Newark, DE, 1993.
135. Waite, J.H. and Tanzer, M.L. "Polyphenolic protein of Mytilus edulis: Novel
Adhesive Containing L-Dopa and Hydroxyproline" (1983) Science. 212, 1038-1040.
211
136. Waite, J.H. "Evidence for a Repeating 3,4-Dihydroxyphenylalanine- and
Hydroxyproline-Containing Decapeptide in the Adhesive Protein of the Mussel,
Mytilus edulis L." (1983) J. Biol. Chem. 258, 2911-2915.
137. Waite, J.H., Housley, T.J., and Tanzer, M.L. "Peptide Repeats in a Mussel Glue
Protein: Theme and Variations" (1985) Biochemistry. 24, 5010-5014.
138. Taylor, S.W., Waite, J.H., Ross, M.M., Shabanowitz, J., and Hunt, D.F.
"trans-2,3-cis-3,4-Dihydroxyproline, a New Naturally Occurring Amino Acid, is the
Sixth Residue in the Tandemly Repeated Consensus Decapeptides of an Adhesive
Protein from Mytilus edulis" (1994) J Am. Chem. Soc. 116, 10803-10804.
139. Rzepecki, L.M., Hansen, K.M., and Waite, J.H. "Characterization of a Cystine-Rich
Polyphenolic Protein Family from the Blue Mussel Mytilus edulis L" (1992) Biol.
Bull. 183, 123-137.
140. Papov, V., Diamond, T.V., Biemann, K., and Waite, J.H. "Hydroxyarginine-
Containing Polyphenolic Proteins in the Adhesive Plaques of the Marine Mussel
Mytilus edulis" (1995) J. Biol. Chem. 34, 20138-20192.
141. Waite, J.H. "The Phylogeny and Chemical Diversity of Quinone-Tanned Glues and
Varnishes" (1990) Comp. Biochem. Physiol. 97B, 19-29.
142. Weber, G. "Biochemical Strategy of Cancer Cells and the Design of Chemotherapy:
G.H.A. Clowes Memorial Lecture" (1983) Cancer Res. 43, 3466-3492.
143. Jackson, R., Weber, G., and Morris, H.P. "IMP Dehydrogenase, an Enzyme Linked
with Proliferation and Malignancy" (1975) Nature. 256, 331-333.
144. Nagai, M., Natsumeda, Y., Konno, Y., Hoffman, R., Irino, S., and Weber, G.
"Selective Up-Regulation of Type II Inosine 5'-Monophosphate Dehydrogenase
Messenger RNA Expression in Human Leukemias" (1991) Cancer Res. 51,
3886-3890.
145. Antonino, L.C. and Wu, J.C. "Human IMP Dehydrogenase Catalyzes the
Dehalogenation of 2-Fluoro- and 2-Chloroinosine 5'-Monophosphate in the Absence
of NAD" (1994) Biochemistry. 33, 1753-1759.
146. Jayaram, H.N., Pillwein, K., Nichols, C.R., Hoffman, C.R., and Weber, G.
"Selective Sensitivity to Tiazofurin of Human Leukemic Cells" (1986) Biochem.
Pharmacol. 35, 2029-2032.
212
147. Nelson, P., Eugui, E., Wang, C., and Allison, A. "Synthesis and Immunosuppressive
Activity of Some Side-Chain Variants of Mycophenolic Acid" (1990) J. Med.
Chem. 33, 833-838.
148. Robins, R. "Nucleoside and Nucleotide Inhibitors of Inosine Monophosphate (IMP)
Dehydrogenase as Potential Tumor Inhibitors" (1982) Nucleosides & Nucleotides. 1,
35-44.
149. Malinoski, F. and Stollar, V. "Inhibitors of IMP Dehydrogenase Prevent Sindbis
Virus Replication and Reduce GTP Levels in Aedes albopictus Cells" (1981) Virol.
110, 281-291.
150. Mizuno, K., Tsujino, M., Takada, M. et al. "Studies on Bredinin. I. Isolation,
Characterization, and Biological Properties" (1974) J Antibiot. 27, 775-782.
151. Streeter, D.G., Witkowski, J.T., Khare, G.P. et al. "Mechanism of Action of
1-p -D-Ribofuranosyl- 1,2,4-Triazole-3-Carboxamide (Virazole), A New
Broad-Spectrum Antiviral Agent" (1973) Proc. Natl. Acad. Sci. U. S. A. 70,
1174-1178.
152. Matsuda, A., Minakawa, N., Sasaki, T., and Ueda, T. "The Design, Synthesis and
Antileukemic Activity of 5-Alkynyl-l-p -D-Ribofuranolylimidazole-4-
Carboxamides" (1988) Chem. Pharm. Bull. 36, 2730-2733.
153. Minakawa, N., Matsuda, A., and Ueda, T. "Nucleosides and Nucleotides. 98.
Synthesis and Antitumor Activities of 5-Ethynylimidazole-4-Carboxamide and
-Carbonitrile Derivatives" (1990) Nucleosides & Nucleotides. 9, 1067-1078.
154. De Clercq, E., Cools, M., Balzarini, J. et al. "Antiviral Activities of
5-Ethynyl-l-p-D-Ribofuranosylimidazole-4-carboxamide and Related Compounds"
(1991) Antimicrob. Agents Chemother. 35, 679-684.
155. Minakawa, N., Takeda, T., Sasaki, T., Matsuda, A., and Ueda, T. "Nucleosides and
Nucleotides. 96. Synthesis and Antitumor Activity of 5-Ethynyl-l -Beta-D-
Ribofuranosylimidazole-4-carboxamide (Eicar) and Its Derivatives" (1991) J. Med.
Chem. 34, 778-786.
156. Balzarini, J., Karlsson, A., Wang, L. et al. "Eicar (5-Ethynyl-l-p-D-
ribofuranosylimidazole-4-carboxamide). A Novel Potent Inhibitor of Inosinate
Dehydrogenase Activity and Guanylate Biosynthesis" (1993) J. Biol. Chem. 268,
24591-24598.
213
157. Wang, W., Papov, V.V., Minakawa, N., Matsuda, A., Biemann, K., and Hedstrom,
L. "Inactivation of Inosine 5'-Monophosphate Dehydrogenase by the Antiviral
Agent 5-Ethynyl-1-p-D-Ribofuranosylimidazole-4-Carboxamide 5'-
Monophosphate" Biochemistry. [In Press].
158. Hedstrom, L. and Wang, C.C. "Mycophenolic Acid and Thiazole Adenine
Dinucleotide Inhibition of Tritrichomonasfoetus Inosine 5'-Monophosphate
Dehydrogenase: Implications on Enzyme Mechanism" (1990) Biochemistry. 29,
849-854.
159. Teideman, A.A. and Smith, J.M. "Nucleotide Sequence of the guaB Locus Encoding
IMP Dehydrogenase of Escherichia coli K12" (1985) Nuc. Acids Res. 13,
1303-1316.
160. Gilbert, H. and Drabble, W. "Active-Site Modification of Native and Mutant Forms
of Inosine 5'-Monophosphate Dehydrogenase from Escherichia coli K12" (1980)
Biochem. J. 191, 533-541.
161. Antonino, L.C., Straub, K., and Wu, J.C. "Probing the Active Site of Human IMP
Dehydrogenase Using Halogenated Purine Riboside 5'-Monophosphates and
Covalent Modification Reagents" (1994) Biochemistry. 33, 1760-1765.
162. Collart, F.R. and Huberman, E. "Cloning and Sequence Analysis of the Human and
Chinese Hamster Inosine-5'-Monophosphate Dehydrogenase cDNAs" (1988) J.
Biol. Chem. 263, 15769-15772.
163. Allen, G. "Cleavage with Cyanogen Bromide" In Sequencing of Proteins and
Peptides, Elsevier, Amsterdam, (1989), 95-99.
164. Lang, S. "Studien tiber Entgiftungstherapie. I. Ueber Entgiftung der Blausdiure"
(1895) Arch. exptl. Pathol. Pharmakol. 36, 75-99.
165. Wood, J.L. and Cooley, S.L. "Detoxification of Cyanide by Cystine" (1956) J. Biol.
Chem. 218, 449-457.
166. Schoberl, A., Kawohl, M., and Hamm, R. "Die Umsetzung von Cystin und
Cystamin mit Kalliumcyanid, ein neuer Weg in die Thiazolinchemie" (1951) Chem.
Ber. 84, 571-576.
167. Gawron, 0. and Fernando, J. "Kinetics of the Cyanide-Cystine Reaction" (1961) J
Amer. Chem. Soc. 83, 2906-2908.
214
168. Catsimpoolas, N. and Wood, J.L. "The Reaction of Cyanide with Bovine Serum
Albumin" (1964) J. Biol. Chem. 239, 4132-4137.
169. Gawron, O., Mahboob, S., and Fernando, J. "pH Effects on the Kinetics of the
Cystine-Cyanide Reaction" (1964) J. Amer. Chem. Soc. 86, 2283-2286.
170. Catsimpoolas, N. and Wood, J.L. "Specific Cleavage of Cystine Peptides by
Cyanide" (1966) J. Biol. Chem. 241, 1790-1796.
171. Wiegand, G.H. and Tremelling, M. "On the Mechanism of Reaction of Cyanide Ion
with Cystine" (1966) Tetrahedron Lett. 50, 6241-6245.
172. Kajiyama, K., Iwata, M., Sakamoto, M., and Tonami, H. "Reaction of Wool with
Potassium Cyanide" (1978) Sen'i Gakkaishi. 34, T259-T267.
173. Spande, T.F., Witkop, B., Degani, Y., and Patchomik, A. "Cleavage of Cystine
Peptides by Cyanide" (1970) Adv. Prot. Chem. 24, 122-125.
174. Lundblad, R.L., Noyes, C.M. "The Modification of Cystine - Cleavage of Disulfide
Bonds" In Chemical Reagents for Protein Modification, CRC Press, Boca Raton,
(1984), p. 95.
175. Degani, Y. and Patchornik, A. "Selective Cyanylation of Sulfhydryl Groups. II. On
the Synthesis of 2-Nitro-5-thiocyanatobenzoic Acid" (1971) J. Org. Chem. 36,
2727-2728.
176. Jacobson, G.R., Schaffer, M.H., Stark, G.R., and Vanaman, T.C. "Specific Chemical
Cleavage in High Yield at the Amino Peptide Bonds of Cysteine and Cystine
Residues" (1973) J. Biol. Chem. 248, 6583-6591.
177. Degani, Y. and Patchornik, A. "Cyanylation of Sulfhydryl Groups by
2-Nitro-5-thiocyanobenzoic Acid. High-Yield Modification and Cleavag of Peptides
at Cysteine Residues" (1974) Biochemistry. 13, 1-11.
178. Degani, Y. and Degani, C. "Subunit-Selective Chemical Modifications of Creatine
Kinase. Evidence for Asymmetrical Association of the Subunits" (1979)
Biochemistry. 18, 5917-5923.
179. Schaffer, M.H. and Stark, G.R. "Ring Cleavage of 2-Iminothiazolidine-4-
Carboxylates by Catalytic Reduction. A Potential Method for Unblocking Peptides
Formed by Specific Chemical Cleavage at Half-Cystine Residues" (1976) Biochem.
Biophys. Res. Commun. 71, 1040-1047.
215
180. Zaia, J., Papayannopoulos, I.A., and Biemann, K. "Utility of a Cysteine-Specific
Cleavage Reaction in the Structure Determination of Proteins by Laser Desorption
Time-of-Flight and Tandem Mass Spectrometry" (1991) Proc. 39th Amer. Soc.
Mass. Spec. Conf, 1414-1415.
181. Papayannopoulos, I.A. and Biemann, K. "Amino Acid Sequence of a Protease
Inhibitor Isolated from Sarcophaga bullata determined by Mass Spectrometry"
(1992) Protein Science. 1, 278-288.
182. Friedman, M., Krull, L.H., and Cavins, J.F. "The Chromatographic Determination of
Cystine and Cysteine Residues in Proteins as S-p-(4-Pyridylethyl) cysteine" (1970)
J. Biol. Chem. 245, 3868-3871.
183. Mak, A.S. and Jones, B.L. "Application of S-ethylpyridylation of Cysteine to the
Sequence Analysis of Proteins" (1978) Analyt. Biochem. 84, 432-440.
184. Kassell, B., Radicevic, M., Ansfield, M.J., and Laskowski, Sr. "The Basic Trypsin
Inhibitor of Bovine Pancreas. IV. The Linear Sequence of 58 Amino Acids" (1965)
Biochem. Biophys. Res. Commun. 18, 255-258.
185. Laurent, T.C., Moore, E.C., and Reichard, P. "Enzymatic Synthesis of
Deoxyribonucleotides. IV. Isolation and Characterization of Thioredoxin, the
Hydrogen Donor from Escherichia coli B" (1964) J. Biol. Chem. 239, 3436-3444.
186. Holmgren, A., Siderberg, B.-O., Eklund, H., and Brtinden, C.I. "Three Dimensional
Structure of Escherichia coli Thioredoxin-S2 to 2.8 A Resolution" (1975) Proc.
Natl. Acad. Sci. U. S. A. 72, 2305-2309.
187. Holmgren, A. "Thioredoxin. 6. The Amino Acid Sequence of the Protein from
Escherichia coli B" (1964) Eur. J. Biochem. 6, 475-484.
188. Kartha, G., Bello, J., and Harker, D. "Tertiary Structure of Ribonuclease" (1967)
Nature. 213, 862-865.
189. Canfield, R.E. and Liu, A.K. "The Disulfide Bonds of Egg White Lysozyme
(Muramidase)" (1965) J Biol. Chem. 240, 1997-2002.
190. Mikes, O., Holeysovsky, V., Tomasek, V., and Sorm, V. "Covalent Structure of
Bovine Trypsinogen. The Position of the Remaining Amides" (1966) Biochem.
Biophys. Res. Commun. 24, 346-352.
191. Pearson, D., Shively, J.E., Clark, B.R. et al. "Urotensin II: A Somatostatin-Like
216
Peptide in the Caudal Neurosecretory System of Fishes" (1980) Proc. Natl. Acad.
Sci. U. S. A. 77, 5021-5024.
192. Papayannopoulos, I.A. Ph.D. Dissertation, M.I.T. Cambridge, MA, 1981.
217
Section VIII
Appendices
Appendix I.
Structures and nomenclature for fragment ions in high energy CID and PSD a
RN-H
H2N-CH
a, b,
y3
-2H
INH
R
-CH.
+2H
"NHi
a2 b2
R3i3
.CH
C2 a3 b3
YI
+2H
NH"
+2H
RO 0
i4  11
-CH-C-OH
H2N=CHR
Immonium Ion
RaO Rb
H2N-CH-C -. . .- NH-CH-C=O
Internal (Acyl) Fragment Ion
aThe "R" refers to the amino acid side chain. Ra and Rb in the structure of the internal
fragment ion are not the N-terminal residue and C-terminal residue side chains, respectively.
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Appendix II.
Additional fragment ions formed via high energy CID
H+ R
Rn-1 CHR'
H- (NH- CH- CO)n- I -NH- CH
an + I
-4-
R H+
(HR' Rn-1
CH- CO-- (NH-- CH- CO)n-1-OH
zn + 1
Rn- 1 CHR'
I I I
H- (NH- CH- CO)n- I - NH- CH
dn
H +
CHR' Rn-
I I
CH- CO- (NH- CH- CO)n- 1- OH
Wn
H +
Rn- 1
HN CH- CO- (NH- CH- CO)n- 1- OH
Vn
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Appendix III.
Additional fragment ions commonly found in PSD spectraa
H+
Rn-1 RnI I I I
(CH-CO)n- 1-NH-CH
Rn-1 Rn
or II I(CH-CO)n-1-NH= CH
an - 17
Rn-1 Rn ®
(CH- CO)n- 1-NH-CH- C O
bn - 17
H
+
Rn- Rn O(CH- IIH-CH-(CH--CO)n. I-NH- CH- C- OH
bn + H20
H+
Ra O RbI II II
H2N-CH-C-. . -NH-CH
Internal fragment ion - 28 (-CO)
aThe above ions are more prevalent in PSD than in high energy CID mass spectra. In
addition, dehydration occurs with certain residues to form a, -18 and bn -18 ions.
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Appendix IV.
Amino acid codes, nominal mass of residuea, corresponding immonium ionsb
and side chain (R) lossc.
Amino 3-letter 1-letter Residue Immonium R-Group
Acid Code Code Mass Ion Mass Loss
Alanine Ala A 71 44 -15
Arginine Arg R 156 129 -100
Asparagine Asn N 114 87 -58
Aspartic Acid Asp D 115 88 -59
Cysteine Cys C 103 76 -47
Glutamine Gin Q 128 101 -72
Glutamic Acid Glu E 129 102 -73
Glycine Gly G 57 30 -1
Histidine His H 137 110 -81
Isoleucine Ile I 113 86 -57
Leucine Leu L 113 86 -57
Lysine Lys K 128 84 -72
Methionine Met M 131 104 -75
Phenylalanine Phe F 147 102 -91
Proline Pro P 97 70 -41
Serine Ser S 87 60 -31
Threonine Thr T 101 74 -45
Tryptophan Trp W 186 204 -130
Tyrosine Tyr Y 163 107 -107
Valine Val V 99 72 -43
aResidue structure NHCH(R)CO where R is the amino acid side chain.
bMass of H2N'=CHR where R is the amino acid side chain.
cThe loss in mass from the precursor ion due to side chain cleavage between the p-y
carbons. (The resultant high mass ions are observed only in high energy CID mass spectra).
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